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General introduction 
Our immune system represents a highly complex system to effectively fight 
a vast array of pathogens and, at the same time, tolerate 'self-antigens'. In general. 
multiple combined signals define whether or not an immune response is generated. 
The involved signals can be either activation signals or inhibitory signals, which 
are derived from pathogen associated molecular patterns (PAMPs), immune cells 
or synthetically derived compounds. The repertoire of signals being present 
ultimate determines whether tolerance or immunity will be induced. Two key players 
in regulating the immune balance are the regulatory T cells (Tregs) and the dendritic 
cells (DCs). Tregs are known to be important for immune inhibition, and the DCs are 
crucial for immune activation and homeostasis. For a long period of time researchers 
have been focussing on the activation of immune cells, though the importance 
of understanding suppression of immune cells is now being recognized to be just 
as important. 
The Immune System 
In daily life, the body is constantly challenged to fight bacteria, viruses, fungi, 
etc. Our immune system has evolved into an effective system that minimizes 
the damage that invaders can cause. The immune system can be divided into two 
components, the innate and adaptive immune system. Both systems have their own 
specificity and different cells are involved. The innate immune system, together 
with the physical barriers, represents the first line of cellular defence and leads 
to an immediate maximal response upon pathogen encounter. This response 
is largely non-specific, and no immunological memory or lasting protective immunity 
will develop. Within minutes or hours the pathogen can be eliminated. Cells that are 
involved in the innate immune responses are mast cells, macrophages, neutrophils, 
dendritic cells, basophils, eosinophils, and natural killer cells [1-3]. Innate immunity 
is able to recognize pathogens via several molecules, like the so-called pattern 
recognition receptors (PRRs). Furthermore, the innate system is responsible for 
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recruiting immune cells to the infection site, and activating the adaptive immunity 
and the complement system. The adaptive immune system is the second barrier 
that exists in mammalians, is pathogen- and antigen-specific, and leads to 
immunological memory. This means that the adaptive cells are able to recognize 
pathogens, and can accumulate a stronger and faster defence for each consecutive 
encounter with the same pathogen, although the maximal response is not as fast 
as for the innate responses. The cells of the adaptive immune system consist of the 
B lymphocytes and T lymphocytes, including CD4+ helper T cells, CD8+ cytotoxic 
T cells, and y6T cells [1,2]. Considering that these cells are antigen-specific, 
they respond in a pathogen-specific manner, i.e. each cell is specialized to respond 
to one specific pathogen. Their antigen specificity is accomplished by the T cell 
receptor (TCR) or B cell receptor (BCR). The genes that encode for these receptors 
undergo somatic recombination, which is responsible for an unlimited variation 
of TCRs or BCRs which in turn recognize the broad range of peptides. 
Immune activation 
One of the important cells in activating the adaptive immune response, is the 
dendritic cell (DQ [4]. From all cells of the innate immune system, the DCs 
are the most potent antigen presenting cells (APCs). In the last decades, several 
different subtypes of DCs were discovered; Langerhans cells, intestinal DC, the mDC 
(myeloid DC) and the pDC (plasmacytoid DC), some of which even can be subdivided 
further based on the different markers and functions [S-7]. The DCs are located 
at specific sites in the periphery, especially at places where they can come in contact 
with the external environment, like the skin, gastrointestinal tract or lungs. Depending 
on the DC subtype and the microorganisms they encounter, different adaptive 
immune responses can be induced. 
DCs originate from haematopoietic bone marrow precursor cells and are subjected 
to a specific maturation process. From the bone marrow, the precursor DC 
migrates into the peripheral tissues, where they initially become immature DCs. 
In this immature state the DC is highly capable in constant surveillance of the 
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surrounding peripheral tissues. When encountering a pathogen, the immature DC 
take up the unknown material, thereby activating its maturation. During the 
maturation process the DCs degrade the engulfed material into presentable antigenic 
fragments. These mature DCs effectively migrate to the secondary lymphoid organs 
(like lymph nodes, Peyer's patches, and spleen), where they present the antigens 
in the context of the major histocompatibility complex (MHC) to the T- or B-cells. 
During the maturation process, multiple receptors become expressed on the surface 
of the DC, like CDBO, CD86 and CD40, which act as eo-stimulatory signals to the T-
and B-cells. It can be said that the DC is the communicator between the innate and 
adaptive immune system. Next to interacting with the M HC molecules through this cell 
surface contact and other receptors, DCs are capable of communicating via cytokine 
production, like for example IL -1, IL -6, IL -12, TNF and IFNa. In some situations, antigen 
presentation or antigen uptake is not as it should be, for example within a tumor 
settings. Our laboratory has examined potential ways to improve the availability 
of antigen source, DC vaccination strategies, and to enhance DC maturation. 
In situ tumor destruction by cryo ablation can efficiently increase antigen-
loading of the DCs [8]. In combination with immune modulation a possible 'in situ 
DC-vaccine' can becreated.lmmunestimulation can beachievedviatheadministration 
of Toll-like Receptor (TLR) ligands, that improve DC maturation if administered at the 
right time schedule [9]. Once the DC interacts with the T- or B-cell that recognizes 
the presented antigen, it will activate this specific T-or B-cell. 
T cells also play an important role in cell-mediated immunity besides the DCs. 
T cells originate from haematopoietic bone marrow precursor cells, and are further 
matured in the thymus, where immature thymocytes undergo positive and negative 
selection. During positive selection, the thymocytes are selected for their capability 
to interact with MHC molecules. The cells with adequate affinity receive a survival 
signal; other cells will go into apoptosis. Secondly, the remaining cells will be 
subjected to negative selection. This means that the cells that interact too strong 
to self-antigen are also deleted from the population. In addition, within the thymus, 
the thymocytes become either CD4 or CDB positive. When the naive T cells leave 
the thymus, they migrate mainly to the T cell areas of secondary lymph nodes. 
The CD4 T cells are also known as helper T cells (Th cells) and CDB T cells are known 
as cytotoxic T lymphocytes (CTLs). The CTLs are able to kill target cells that present 
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MHCclassl bound peptides [10]. MHCclassimoleculesareexpressed by all nucleated 
cells, and present peptides of pathogens that replicate inside host cells. Th cells 
recognize peptides presented by MHC class D molecules [11]. After activation, they 
help B cells to produce antibodies and undergo class switching. Furthermore, they 
are responsible for recruiting and activating COB T cells, macrophages, neutrophils, 
and many other cells. Until now eight different Th cell subsets have been identified, 
of which four cell subsets are recognized as exclusive lineages; namely Thl, Th2, 
Thl7 and iTreg (induced Treg) [12-15]. During priming, the cytokine environment 
as well as the consequent activation of specific transcription factors, controls the 
differentiation of the naive CD4 T cell into any of the four mentioned Th cell lineages 
(Figure 1). 
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Figure 1. Peripheral CD4 
T c:eU differentiation. 
After leaving the thymus, 
the naive CD4- T cell can 
differentiate into four well 
defined T cell subsets. 
Depending on the c:ytnkine 
signals that are received 
by the naive T cell, the 
T cell will become Thl, 
Th2, Th17 or iTreg. For 
each subset different 
transcription factors 
are important for their 
development and function. 
Also each subset ofTh cell 
is able to secrete different 
kinds of cytokines. More 
subsets are known, 
however it is not clear 
if they represent a new 
functional lineage within 
the T helper types. 
Eventually, the subtypes can be identified by the expressed transcription factor and 
the produced cytokines. Thl cells are important for the activation of macrophages 
and the clearance of intracellular pathogens, and Th2 cells are critical for IgE 
production, eosinophil recruitment and clearance of extracellular parasites [16,17]. 
The recently discovered Th17 cells have shown to be involved in autoimmune 
diseases [13], and play a crucial role in both mucosal host defences, and in the 
immune responses against extracellular bacteria and fungi [18]. The Tregs will be 
discussed in more detail later in this Chapter and in Chapter 2. All of the Th cells have 
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specific involvements in pathogen clearance. On the other hand, they also have been 
associated with many (auto)immune diseases. Th2 cells are shown to be involved in 
allergies, and Th17 cells play a role in inflammatory bowel disease (Crohn's disease), 
rheumatoid arthritis, psoriasis and multiple sclerosis. For the other four discovered 
Th cell subtypes (Th9, Tfh, Trl and Th3) it is not yet clear whether they represent new 
individual lineages, since their cytokine profile and transcription factor expressions 
do not seem to be unique [15]. 
Pattern recognition receptors 
Pathogens are detected by the immune cells via Pattern Recognition Receptors 
(PRRs). To this family of receptors belong the NOD-like receptors (NLRs), RIG-like 
helicases, C-type lectins, and the Toll-like Receptors (TLRs). NLRs are soluble proteins 
located in the cytoplasm. where they may recognize endogenous and microbial 
proteins. RIG-like helicases are important for the recognition of cytoplasmic viral RNA, 
and C-type lectins especially recognize carbohydrate structures at the cell surface. 
The TLR family of evolutionary highly conserved transmembrane receptors are 
the most extensively studied PRRs. The first discovered Toll protein was found 
in the Drosophila melanogaster (fruit fly), where it plays an important role in the 
antifungal response ofthe adult fly [19,20]. It was found that in mammals homologues 
of the Toll protein exist with similar functions [21], for which until now about 
13 different TLRs are found. TLRs have been shown to be type I integral membrane 
receptors, with three domains; an extracellular N-terminalligand-binding leucin-rich 
repeat (LRR) domain, a single transmembrane domain, and a C-terminal cytoplasmic 
signaling domain. This last cytoplasmic signal-transducing domain shows great 
homology with the well known signaling domains of the IL-l receptor family 
members, and is therefore referred to as Toll IL-l receptor (TIR) domain [22]. 
Structurally, the extracellular domain of the TLRs forms a solenoid, horseshoe-like 
shape (Figure 2), and the TLRs function as dimers. Most TLRs form homodimers, only 
TLR2 forms heterodimers together with TLRl or TLR6. In general, the intracellular 
TIR domains become activated upon ligand binding. The TIR domains are able to use 
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two different signaling pathways, one via the adaptor protein myeloid differentiation 
factor 88 (MyD88) and the other via adaptor protein TRIF. 
Adapted frum Jia et al. Cell 2007, 130:1071·1082. 
Figure 2. Crystal structare 
of Toll-like receptor 1/2 
heterodlmer. TI.Rs need 
to fonu dlmers to sfgna1 
intracellularly. MostTLRs form 
homodlmers, only TLR2 forms 
heterodimerswith eitherTLRt 
or TI.R6. This figure shows 
the crystal structure of TLR1 
and TLR2, represented by the 
blue and green horse-shoe like 
shapes. This hewrodimer is 
binding the Hgand Pam3Cys 
(shown in red) in the middle, 
where 2 of lt's chains bind 
in the TLR2 pocket, and the 
third one In the TLR1 pocket. 
Intracellular signaliug of the 
two parts of TLR1 and TI.R2, 
leads to the acti:vation of the 
MyD88 signalling pathway. 
All TLRs except for TLR3 signal through MyD88. TLR3 signals totally via TRIF 
and TLR4 signals partially via TRIF. MyD88 and TRIF activate several pathways, 
which eventually activate transcription factors like NFt<B and IRF-3. TLR pathway 
activation results in the production of pro-inflammatory cytokines and chemolcines, 
including IL-l, IL-6, IL-8, IL-12, IFNa/~, TNF, IP-10 and RANTES. Additionally, 
TLR activation induces up-regulation of MHC class II molecules, and costimulatory 
molecules like CD86 and CD80 on APCs. 
TLRs are expressed on all different immune cells, like macrophages, DCs, monocytes, 
B cells and T cells, and also on some non-immune cells, like epithelial cells 
and fibroblasts [23]. In addition, the TLRs can be divided into 2 groups, 
the cell surface-expressed and endosomal-expressed TLRs. TLRl, 2, 4, 5, and TLR6 
are expressed on the cell surface and recognize lipid-based ligands [23]. In contrast 
TLR3, 7, 8, and TLR9 are mainly expressed intracellularly where they recognize 
nucleic-acid ligands [23]. All ligands are highly conserved in evolution 
and thus present on many pathogens. Furthermore, it is reported that TLRs are able 
to recognize endogenous ligands, in particular the damage-associated molecular 
patterns (DAMPs). More details on the specific ligands detected by the TLRs 
are discussed in Chapter 2. 
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Immune inhibition/regulation 
Immunological tolerance can be described as the process by which the immune 
cells do not trigger an immune response to a specific antigen against which 
normally a response would be triggered. Tolerance can be divided into three parts; 
the central tolerance, acquired tolerance and the peripheral tolerance. 
Central tolerance is referred to as the processes that take place in the thymus, 
namely the positive and negative selection mentioned before in the section on 
T cells. Acquired tolerance indicates the flexibility of the immune system to adapt 
itself in certain circumstances to a specific non-reactivity, to antigens that normally 
would elicit a response. This is for instance the case during pregnancy, in which the 
fetus and placenta need to be tolerated, and also during induced oral tolerance, 
which prevents hypersensitivity to food and the mucosal flora. Acquired tolerance 
is also the case at the side of the intestine. The gut flora consists of a wide range 
of commensale bacteria and probiotics, and to these bacteria tolerance is 
developed during life. Peripheral tolerance is referred to as the tolerance induced 
in the active process by antigen encounter. Several cells are involved in this peripheral 
tolerance. 
Dendritic cells are well known immune activators, however they also play an equally 
important role in peripheral tolerance. As described before, DCs are able to provoke 
an immune response by activating the adaptive and innate immune system when 
they encounter a pathogen. To function properly DCs need to undergo the total 
process of differentiation and maturation. Recent studies analysed the possibility 
of DCs to present antigens without the administration of maturation stimuli [24]. 
These DCs are in a steady state and still able to capture soluble proteins. The low dose 
of antigen presentation by these DCs leads to the deletion of the corresponding T cell 
population. This means that they are not immunologically quiescent but play a role 
in peripheral tolerance. Tolerogenic DCs seem to express less major histocompatibility 
complexes, less activatory receptors and more inhibitory receptors. The encounter 
of ILlO by immature DCs can induce a tolerogenic phenotype, which are able 
to induce regulatory T cells that inhibit activated CD4+ and CDS+ T cells [25]. 
Tolerogenic DCs are able to reduce immune responses in multiple ways, depending 
on how they are generated. The importance is that DCs are not only activating 
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the immune system, but also have important roles in inducing peripheral tolerance. 
Since the early 1970's it is already known that there should also be 'suppressor' 
T cells. However;. it was not until 1995 these cells could be isolated and (re-)defined 
as regulatory T cells. Regulatory T cells (Tregs) are the most important subset 
of T cells that mediates peripheral tolerance, by which the immune system limits 
inappropriate or excessive immune responses. All Tregs require TCR triggering 
to become activated. Once activated by a specific antigen, Treg suppress responder 
T cells in an antigen-nonspecific 'bystander' manner [26]. A cardinal feature of natural 
Treg is their expression of the transcription factor forkhead box P3 (FoxP3) [27]. 
This transcription factor controls genes that encode proteins capable of mediating 
Treg suppressive function [28,29]. Two different CD4• Treg subtypes have been 
identified; the naturally occurring Tregs (nTregs) and the induced Tregs OTregs), 
though no reliable marker is 
known to distinguish between 
both of them. n Tregs originate 
from the thymus (Figure 3), 
where they experience the 
positive and negative thymic 
selection protocol. The exact 
procedure of how nTregs 
are generated in the thymus 
remains unclear. In the thymus, 
the autoimmune regulator 
gene (Aire) promotes the 
Thymocyte precursor cell 
nTreg cell 
TCR 
CD4 
CD25 
expression of tissue-specific 1t3s crLA-4 
OX40 
Figure 3. Nabu'ally 
occ:urriDg T:rep. 
Naturally occurring 
1\'egs haw their own 
thymocytic prewr:sor. 
Ttegs express 
several phenotyplcal 
markers, like PoxP3, 
CD2S, CTI.A-4, GITR 
and OX40. They are 
able to suppress other 
immune cells, which 
is cell-cell contact 
dependent Depletion 
of nTregs from the 
periphery leads to 
the Induction of 
autolmmune diseases 
in mice and hwnans. 
self-antigens by thymic medullary epithelial cells. Several reports suggest that in 
addition to deletion of self-reactive conventional T cells, Aite-expressing stromal cells 
may also enhance FoxP3expression inthymocytes, which will becomethe nTregs [30].In 
the periphery, the nTregs representabout 5-15%ofthe normal CD4•T cell population. 
Important signals for nTreg development are also important for their maintenance 
in the periphery. Initially the most important signals for this maintenance is TGFp. 
TGF~ signaling in peripheral nTregs is critical for maintaining FoxP3 expression which 
preserves the stability of nTreg features [31]. 
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Furthermore, IL2 is important for nTreg survival, nTreg generation and function 
in the thymus and periphery [32,33]. In addition to FoxP3, nTregs can be further 
characterized by the expression of, CD25, CD127 {for human Tregs), CTLA-4, LAG-3, 
CD39, CD73, and costimulatory molecules such as CD28, CD80/86, CD40, OX40 
and 4-lBB [34-36]. More detailed information about phenotypic characteristics, 
suppression mechanisms and expression/involvement of TLRs on Tregs is discussed 
in Chapter 2. 
The other subtypes of Tregs, the iTregs, are induced in the periphery in a variety 
of ways. ILlO and antigenic stimulation of naive T cells causes the development 
of type 1 regulatory T cells {Trl cells). Immature DCs, tolerogenic myeloid DCs 
and pDCs are able to induce the generation of Trl cells in transplant settings, and 
against certain allergens, pathogens, and tumor antigens in mice and humans. 
These Trl cells have the ability to produce high amounts of ILlO and TGF~, 
which are therefore able to suppress from a 'distance' [33,37]. However; Trl cells 
additionally seem to produce ILS and IFNy, depending on the experimental 
conditions. In general, Trl cells are poorly proliferating cells that require the 
presence of IL2 and IllS. The Trl cells normally express the known surface 
markers like CD25, CTLA4 and GITR. but no intracellular FoxP3 could be found [33]. 
Another stimulus that can induce iTregs in the periphery together with antigen 
stimulation is the cytokine TGF~. These induced iTregs are called Th3 cells, 
and subsequently produce TGF~ as their major immune suppressive mechanism 
[33,37]. The presence of TGF~ is correlated to FoxP3 expression. The other markers 
ofTh3 cells are comparable to the markers ofTrl cells. Th3 cells are mainly important 
in a variety of disease settings, such as cancer or multiple sclerosis [38], and 
in maintaining tolerance to antigens expressed in the intestinal tissue, as is seen 
in inflammatory bowel disease (IBD) [39]. 
Next to the nTregs and iTregs, several other T cell subsets with suppressive function 
have been identified. These include CD8+FoxP3+ Tregs, double-negative (CD4-CD8-) 
Tregs and y.STregs, although more research is needed to determine their influence 
and function. In Summary, both nTregs and iTregs are crucial to sustain the balance 
between maintaining peripheral tolerance and controlling responses to infections. 
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The immune system in health and disease 
Failure to appropriately induce either immunity or tolerance will result 
in a pathological condition. For example, in transplantation settings, the immune 
system can cause unwanted inflammations to the grafted tissue eventually causing 
transplant rejection. Understanding how the immune system acts in regulating 
tolerance, should allow guiding every immune response to the right direction that 
is needed at that moment. 
Microorganisms 
As mentioned above, Tregs are one of the most important cells for keeping 
the balance in our immune system. Tregs are known to be involved in several 
pathologies. In Mycobacterium tuberculosis infections Tregs proliferate and 
accumulate at sites of infection, and prevent clearance of the bacteria in mice 
[40]. In line with these findings, patients with tuberculosis have higher amounts of 
Tregs which inhibit IFNy production by peripheral blood mononuclear cells (PBMCs). 
Depleting these Tregs causes increased IFNy producing M. tuberculosis-specific 
cells. 
Besides the pathogenic bacteria, the human body also comes in contact with 
commensal bacteria. These microbiotics are important for the digestive system, 
and do not need to be eliminated. Although the intestinal flora contains hundreds 
of bacterial species which are beneficial to the human body, the immune system 
also needs to control these enteric pathogens to avoid harmful infections. How the 
immune system keeps this balance in the intestinal flora is still puzzling. 
The intestinal flora comprises of a very large amount of intestinal bacteria. 
Interesting microorganisms which are alleged to have effects on the intestinal 
flora are the probiotics. The name probiotics was first used by Werner Kollath 
in 1953 as supplements necessary to restore health to patients {ref). Nowadays 
the definition of probiotics adopted by the FAO/WHO is "Live microorganisms 
which, when administered in adequate amounts confer a health benefit on the 
host". Although the definition states that the probiotics can have beneficial effects, 
this has not been proven yet. Specific effects of these probiotics in health 
and disease are still being investigated, and until now the European 
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Food Safety Authority has rejected most claims made about probiotics. 
Most claims indicate that probiotics are able to act directly and indirectly 
to the gut flora and can affect gastrointestinal function and modulate immune 
function. As an example, it has been shown that L acidophilus and B. (ragilis 
can inhibit the immunosuppressive effect of Tregs on enterobacterial stimulated 
effector T cells or on Th17 responses [41]. Another probiotic strain, L. salivarius, 
is not able to have a significant effect on Tregs [41]. Thus, distinct probiotic strains 
might have different effects on the immune system. 
Tumors 
The main strategies used in treating cancer focused on decreasing tumor 
size using surgery, radiotherapy and chemo-/hormonal therapy. In case 
of tumors, the immune system has failed to induce a successful immune response 
capable of eliminating the tumor. Cancer immunotherapy aims to induce 
an effective immune responses targeted at the tumor. Tumor cells express 
(mutated) antigens that are recognized as non-self or foreign, due to genetic 
and epigenetic changes that are associated with carcinogenesis. Successful induction 
of anti-tumor immune reactivity is however no guarantee for elimination 
of the tu mar. In part, this is caused by the ability of tu mars to escape or suppress 
immunity. These escape mechanisms include for instance impaired antigen 
presentation, up-regulation of negative costimulatory molecules and elaboration 
of immunosuppressive factors. 
Intriguingly, recent studies have implicated Tregs as important factors in inducing 
tumor tolerance. Our group and many others have shown that Tregs infiltrate 
in human and mouse brain turners [42,43]. Depletion of these Tregs from the 
tumor site enhance anti-tumor immune responses, and decreases the turner size 
[44-46]. On the contrary, adoptive transfer of Tregs into a murine model could inhibit 
CD8+ T cell specific immune responses against turners [47,48]. Furthermore, 
the number of tumor infiltrating Tregs can be applied as a prognostic factor 
for patient survival for at least some tumor types [49,50]. High levels of Tregs were 
found in high-grade brain tumors and brain metastases, whereas no accumulation 
of Tregs was found in benign tumors. These infiltrated Tregs were found in close 
proximity with effector T cells, potentially suppressing the local effector cells. 
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Multiple mechanisms may be responsible for Treg accumulation in tumors. 
Turners are also capable of up-regulating the production of indoleamine 2,3-
dioxygenase (IDO) by the infiltrated DCs. IDO is known to suppress T cell responses 
and to promote tolerance to tumors. Sharma et al. showed that plasmacytoid 
DCs isolated from turner-draining lymph nodes produced IDO, which activated 
Tregs in an MHC restricted and CTLA-4 dependent manner. These activated Tregs 
up-regulated PD-Ll and PD-L2 expression on DCs, which can lead to inhibition 
of the effector T cell responses via the PD-1 receptor [51]. Our laboratory has also 
reported that PD-Ll/PD-1 pathway can be expressed by tumor cells themselves. 
This pathway is thereby also an important immunomodulating mechanism 
of the turner cells [49]. In conclusion, the turner microenvironment has multiple 
mechanisms to influence immune cells and to prevent/inhibit antitumor immune 
responses. Investigations aiming to unravel the activation and inhibition 
of regulatory T cells may be rewarding to develop novel therapies in both cancer 
and transplantation or autoimmunity. 
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Aim and outline of this thesis 
More knowledge on influencing Treg suppression mechanisms will clearly improve 
the now used immunotherapies. The research described in this thesis has been 
performed to gain further insight into the effect of different stimuli on the balance 
between immune inhibition and immune activation, focussing on Treg cells and TLR 
stimuli in different immunological conditions. 
Chapter 2 of this thesis gives a brief overview of the current knowledge of naturally 
occurring Tregs and the influence TLRs have on their function. The chapter also 
emphasizes the role that Tregs have in cancer settings. In Chapter 3 we analysed 
the influence of the location of tumor antigens within tumor cells, including 
in association of secreted vesicles called exosomes, on the immunogenicity 
of the tumor. The balance between immune activation and inhibition was studied 
by analyzing the amount and activation status of DCs, effector T cells and Tregs. 
In Chapter 4, the immunogenicity and type ofT cell response induced by different 
probiotic bacteria was investigated. We compared Lactobacillus Rhamnosus, 
Lactobacillus Casei and Bi(ldobacterium Breve for their capacity to induce 
an inflammatory response, and the importance that TLR stimuli have in their 
recognition by the immune cells. Chapter 5 focuses on the importance of TLR2 
triggering on Treg function. Purified TLR2 ligand has a major effect on Tregs, 
that can be mimicked by using TLR21igand containing infectious agents. Furthermore, 
the data show that TLR2 is broadly expressed by immune cells and that TLR2 ligand 
effect not only Treg but also T effector cells and Dendritic cells. To determine 
the effect TLR2 triggering has on the gene expression profile of Tregs and effector 
T helper cells micro-array analysis was performed as described in Chapter 6. 
This chapter describes a newly found gene called CRISPl that is preferentially 
expressed by Treg, reports the characteristics of its expression and possible function. 
In Chapter 7, the results described in this thesis will be summarized and discussed. 
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Abstract 
To balance self-tolerance and immunity against pathogens or tumors the immune 
system depends on both activation mechanisms and down regulatory mechanisms. 
Immunologists have long been focusing on the activation mechanisms and a major 
breakthrough was the identification of the Toll-like receptor (TLRs) family of proteins. 
TLRs recognize conserved molecular patterns present on pathogens, including 
bacteria, viruses, fungi and protozoa. Pathogen recognition via TLRs activates 
the innate as well as the adaptive immune response. The discovery of a suppressive 
T cell subset, that constitutively expresses the IL-2 receptor a-chain (CD25), 
has boosted studies investigating negative regulation of immune responses. It is now 
well appreciated that these regulatoryT cells (Tregs), play a pivotal role in controlling 
immune function. Interestingly, recent studies revealed that TLR2 signaling affects 
Treg expansion and function. This review will focus on the presence and influence 
of different TLRs on T-lymphocytes, including Tregs, and their role in cancer. 
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Introduction 
Induction of protective T cell responses requires naive T cells to receive signals 
via their T -cell receptor (TCR), eo-stimulatory molecules and cytokine receptors. 
These signals can be provided by professional antigen presenting cells, like activated 
dendritic cells (DCs). DCs are stimulated when they encounter pathogen associated 
molecular patterns (PAMPs) that are recognized by pathogen recognition receptors, 
such as Toll-like receptors (TLRs). TLR engagement alerts the immune system 
for danger and leads to the activation of innate immune cells [1,2] e.g. production 
of pro-inflammatory cytokines, induction of phagocytosis and other innate 
effector mechanisms. Furthermore, TLR triggering induces DC maturation which 
is essential for the induction of adaptive immune responses [1]. DC maturation leads 
to the upregulation of eo-stimulatory molecules and MHC molecules, secretion 
of immune modulatory cytokines (i.e. IL-12, IL-23) and chemokines, and enhanced 
migration from the periphery to draining lymph nodes [2-4]. Within mice and humans 
thirteen TLRs have now been identified that recognize distinct conserved PAMPs [3,5]. 
For example, TLR4 and TLRS recognize the gram-negative bacterial component 
LPS and the bacterial flagellin protein respectively [4-6]. TLR2 can interact with 
either TLR1 or TLR6 [4,5]. The heterodimer TLR1/2 recognizes bacterial triacyl 
lipopeptides, while TLR2/6 recognizes bacterial diacyllipopeptides. Recently, profilin 
on uropathogenic E.coli and T.gondii was identified as the ligand for TLRll [7,8]. 
These bacteria sensing TLRs are largely located on the cell surface of immune cells. 
In contrast, TLR3, TLR7, TLR8 and TLR9 are present inside immune cells and can 
recognize nucleic acids like RNA and DNA or derivates thereof [4-6]. They sense 
the presence of intracellular pathogens or virally infected cells following 
phagocytosis. The ligands for TLR10, TLR12 and TLR13 are as yet unknown. Besides 
pathogen derived exogenous ligands, some TLRs can also become activated by 
recognition of so-called endogenous ligands. TLR2 and TLR4 have both been 
reported to interact with heat shock proteins [9-11] and necrotic cells, TLR3 with 
mRNA [12]. TLR4 has also been proposed to interact with fibronectin, fibrinogen, 
and murine ~-defensin 2 [6,13,14]. Finally, TLR9 has been shown to become 
activated by chromatin-IgG complexes found in the autoimmune disease SLE [15]. 
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The finding that TLRs can recognize endogenous ligands, especially ligands that are 
released following tissue destruction/pathology, as well as PAMPs indicates they 
are not only key molecules in immunity against micro-organisms but also may play 
a role in autoimmune diseases and cancer [6]. 
Immune suppression: Regulatory T cell subsets 
To prevent extensive immune-mediated tissue damage or auto-immune diseases, 
the initiation, expansion and retraction of effector T cell (Teff) responses need to 
be closely controlled. Here for, multiple feedback control mechanisms are in place 
within the Teff itself, like induction of suppressor of cytokine signaling (SOCS) genes 
and activation induced cell death following T cell activation [16,17]. In addition, 
Teff immune responses are highly regulated by immune suppressive regulatory 
T cell subsets. The significance of regulatory T cells (Tregs) in maintaining immune 
homeostasis is illustrated by the development of autoimmune symptoms in 
individuals lacking functional Tregs [18]. Furthermore, theoccurrenceof autoimmunity 
in spontaneous autoimmune models in mice could be prevented upon transfer of 
Tregs [19,20], while temporal depletion of Tregs improved cancer vaccine efficiency 
by enhancing Teff responses [21]. 
Several distinct immunosuppressive Treg subsets have been described, which can 
be broadly subdivided into two groups, 1) cells that originate from the thymus 
[22], referred to as 'naturally occurring Tregs', and 2) Tregs that have been induced 
in the periphery, also called 'adaptive Tregs'. The best characterized Tregs are the 
naturally occurring CD4+CD25+ Tregs that constitute 5 to 15% of the total CD4+ 
T cell population [22]. Once activated, the CD4+CD25+ Tregs are able to suppress 
T cell proliferation and cytokine production as well as antigen presenting cell function 
[23]. The suppressive activity of these cells requires TCR triggering by MHC class 
11 molecules presenting either self or non-self peptide epitopes. CD4+CD25+ Treg 
mediated suppression is known to be antigen non-specific and involves cell-contact 
dependent mechanisms [24]. Naturally occurring Tregs express the transcription 
factor forkhead box protein (FoxP3) [25,26], which has been shown to be induced 
by the cytokine TGF-~ [27,28]. Recently, the AKT signaling pathway has been 
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identified as a strong repressor of Treg differentiation in the thymus by diminishing 
TGF-P-induced FoxP3 expression. AKT mediated signals thus represent a major 
determinant with broad impact on the onset of Treg specification [29]. Recently 
Ono et al. found that FoxP3 physically interacts with the transcription factor 
AML1/Runx1, thereby preventing IL-2 and IFNy production by Tregs while 
inducing Treg-cell-associated molecules and suppressive activity [30]. 
The importance of FoxP3 in Treg development and function was further 
demonstrated in FoxP3 knockout mice as well as scurfy mice that carry a natural 
mutation in the FoxP3 gene. Interestingly, both mice show autoimmune symptoms 
resembling the human immunodysregulation, polyendocrinopathy, enteropathy, 
X-linked (IPEX) syndrome that is caused by a mutation in the human FoxP3 
gene [18]. Furthermore, transduction of FoxP3 into na"ive CD4+ T cells resulted in a 
suppressive phenotype in mice [26,31]. Although several other markers have been 
identified in human and/or murine CD4+CD25+ Tregs, like cytotoxic T-lymphocyte 
activation antigen (CTLA-4) [32], Glucocorticoid-induced TNFR family-related gene 
(GITR) [33], integrin aEp7 (CD103) [34], CCR8 and the absence of CD127 [35], FoxP3 
represents the most specific marker for naturally occurring Tregs available to date. 
CD4+ regulatory T cells that develop in the periphery are referred to as adaptive 
Tregs. At least two types of adaptive Tregs have been characterized. Type 1 
regulatory T cells (Tr1) arise after repeated TCR stimulation in the presence of IL-10 
[36,37]. More recently, IL-27 produced DC upon interaction with FoxP3 expressing 
Tregs was shown to be a key factor in the generation of Tr1 cells which could be 
further enhanced by TGF-p [38]. Tr1 cells have been identified in humans and 
in mice, and are able to inhibit T cell responses in vitro and in vivo [36]. Tr1 cells 
do not express FoxP3 and mediate suppression by secreting high amounts of IL-10 
[36]. Altered Tr1 function has been reported for patients with multiple sclerosis [39], 
and adoptive transfer of Trl cells inhibited the development of murine experimental 
allergic encephalomyelitis in vivo [40]. Th3 cells represent the second subset 
of adaptive Tregs. They differentiate from naive CD4 T cell precursors by repeated TCR 
stimulation in combination with high amounts ofTGF-P [41,42]. Th3 cells also secrete 
high amounts of TGF-P themselves, thereby suppressing immune responses [41,42]. 
Ag-specific TGF-P producing Th3 cells have recently been shown to be important 
in inducing and maintaining peripheral tolerance by driving the differentiation 
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of adaptive Ag-specific FoxP3+ regulatory cells in the periphery in mice [43,44]. 
We note that also human CD4+CD25+ Tregs expressing a4~7 integrin or a4~1+ have 
been shown to induce Trl-like and Th3-like T suppressor cells from na·ive CD4+ 
T cells respectively [45]. 
Aside the CD4+ regulatory T cell subsets expressing the a~ TCR, recent studies 
showed that CD8+CD122+ regulatory T cells [46], and T cells carrying the yo TCR can 
also have immune suppressive functions. T cells expressing they and o TCR chains 
are divided into two different subsets, namely Vol (yol T cell or intraepithelial 
lymphocytes) and Vo2 (residing in peripheral blood) [47]. yol T cells isolated from 
breast tumor tissue were shown to be highly suppressive in a trans-well system, 
but the soluble factor causing the suppression remains to be identified [47]. 
These tumor-infiltrating yol T cells do not express CD25, GITR, or FoxP3. 
In conclusion, the field of regulatory T cells is still expanding, and new regulatory 
subsets are likely to be discovered in the coming years. The existence of multiple 
Treg subsets underscores the importance of immune suppressive cells within 
the immune system, and addressing their role in tolerance and immunity will be 
an intense area of future research. 
Suppressive mechanisms of naturally occurring Tregs 
Tr1, Th3 and yoT cells are known to suppress via secretion of soluble factors, 
like anti-inflammatory cytokines. Naturally occurring CD4+CD25+ Tregs suppress 
via contact-dependent mechanisms. In the past few years, multiple cell contact-
dependent mechanisms exploited by these Tregs have been reported (figure 1). 
Cell contact-dependent suppression was shown to involve CTLA-4 and membrane-
bound TGF-P (mTGF-P) expressed on the cell surface of CD4+CD25+ Tregs [35,48], 
in vitro secretion of granzyme B [49] or perforin [50], and through modulation ofll-2 
responsiveness [35,51]. In line with the finding that neither of the aforementioned 
suppressive mechanisms could entirely explain Treg suppression, several new 
suppression mechanisms have recently been defined. In mice, CD4+CD25+FoxP3+ 
Tregs preferentially express the ectonucleotidases CD39 and CD73 on their 
cell-surface and their expression is amplified and stabilized by FoxP3 [52,53]. CD39 
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degrades nucleoside tri- and diphosphates likeATP into adenosine monophosphates 
(AMP) and CD73 catabolizes the conversion of AMP into adenosine. The presence 
of extracellular ATP is regarded as an indicator for tissue damage and can function 
as a natural immune adjuvant and danger signal by binding to the purinergic 
receptors. In contrast, adenosine is known to exert an immunosuppressive 
effect on immune cells, like inhibition of proliferation and TNF or IFNy synthesis 
by Thl cells [52-54], upon binding to adenosine receptors. Thus, CD39 
mediated removal of the pro-inflammatory ATP and its conversion into 
immunosuppressive AMP by CD73 represents another mechanism by which 
CD4+CD25+FoxP3+CD39+CD73+ Tregs can suppress immune responses [52,53]. 
ATP 
+ (pminflammatory) 
~! 
I CD4+CD25+ Treg I 
• • 
In vitro and in vivo activation of the TRAIL/DRS pathway 
is a known mechanism to induce apoptosis. Recently, 
TRAIL, or TNF-related apoptosis inducing ligand, 
Target T cell 
Immune 
Inhibition 
Figure 1. Schematic 
representadon of the 
different suppressive 
mechanisms employed by 
naturally occurring Tregs. 
ATP, adenosine triphoshpate; 
AMP, adenosine 
monophosphate;TRAIL. TNF-
related apoptosis inducing 
ligand; GZB, granzyme B; IL-
35, Interleukln-35. 
was found to be upregulated upon Treg activation, while activated Teffs express 
increasing levels of DRS [SS]. Addition of DRS-blocking antibodies significantly 
reduced the suppressive capacity of the Tregs in vitro and in vivo [55]. 
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Proteomic analysis of human CD4+CD25+ regulatory T cells revealed galectin-10 
to be a specific intracellular marker of CD4+CD25+ Tregs [56]. Further analysis 
revealed that siRNA mediated downregulation of galectin-10 abrogated Treg 
suppressive capacity, but further characterization is necessary to elucidate the exact 
physiological role in suppression. 
Another mechanism became apparent following the discovery that the cAMP-
cleaving enzyme phosphodiesterase 3B (PDE3B) is strongly reduced in Tregs 
as compared to conventional CD4+ T cells. As a consequence Tregs contain 
elevated levels of cAMP, a second messenger known to regulate a wide variety 
of cellular functions in a large group of cell types [57]. In T lymphocytes increased 
levels of endogenous cAMP inhibit cell activation, cytokine production, and cell 
proliferation by interfering with the activation of Ras and Rapl [57]. Bopp et al. now 
demonstrated that contact-dependent suppression by naturally occurring Tregs 
can occur via a well-known mechanism, namely the intercellular transport of cAMP 
via gap junctions [58]. Upon Treg interaction with a target cell, cAMP levels within 
the target cell increased resulting in immune suppression, which could be blocked 
by addition of a gap junction inhibitor [58]. These two examples link the previously 
described role of nucleotide catabolites in immune regulation to the cell-contact 
dependent suppressive activity of Tregs. 
Functional genomics analysis comparing CD4+CD25+FoxP3+ Tregs with CD4+CD2s-
Teff also led to the discovery of the inhibitory cytokine IL-35, a novel member of the 
IL-12 heterodimeric cytokine family [59]. Epstein-Barr-virus-induced gene 3 (Ebi3}, 
was shown to be preferentially expressed in the Treg subset along with IL-12a chain 
(or p35) to form the heterodimer IL-35. Subsequent in vitro experiments showed 
that Tregs from Ebi3 knockout or IL-12a knockout have a significantly reduced 
suppressive capacity [59]. Teffs retrovirallytransduced with IL-35 gained suppressive 
activity and also recombinant IL-35 inhibited Teff proliferation. Subpopulations 
of yo T cells and CD8+ T cells may also express small amounts of IL-35, suggesting 
that IL-35 may be involved in their regulatory potential as well. Whether or not IL-35 
can be induced in FoxP3+ Th3 cells is not known. The discovery of IL-35 secretion 
as an additional factor required for maximal Treg mediated immune suppression 
is intriguing, but also raises questions regarding contact dependency of Treg 
mediated suppression and the target cells expressing the putative IL-35 receptor. 
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The presence of multiple different suppressive mechanisms exploited by Tregs 
further raises the question which suppressive mechanism(s) are most important for 
inhibition of a particular function in a given target cell or pathological condition. 
Modulation of the Treg function 
Tregs play a central role in the suppression of immune reactions and prevention 
of autoimmune responses harmful to the host. However, during acute infection, 
Tregs might hinder effector T cell activity directed towards the elimination of the 
pathogenic challenge. Therefore, Treg mediated suppression needs to be tightly 
controlled. Control of Treg function is known to occur through cytokines like 
IL-l, IL-6 and IL-12, and multiple eo-stimulatory molecules expressed by antigen 
presenting cells [60,61]. These cytokines and eo-stimulatory molecules are efficiently 
induced upon TLR stimulation of APC and act either by direct stimulation of Treg 
proliferation and/or inhibition ofTreg suppression or indirectly by rescuing Teffs from 
Treg mediated suppression. Another key cytokine that supports Treg development 
and maintenance is IL-2. Furthermore, IL-2 plays a dominant role in regulating 
Treg mediated suppression [61,62]. IL-15, which signals through the common 
IL-2 receptor ~and y chain, is able to substitute IL-2 as a growth factor in vitro, while 
IL-4 and IL-7 can act as growth and survival factors, respectively [60]. 
More recent TLR expression profiling studies revealed that multiple TLRs 
are expressed in CD4+ T cells as well as CD4+CD25+ Tregs [6,60,63-65]. Interestingly, 
murine and human CD4+CD25+ Tregs express higher levels of TLR4, TLR5, TLR7, 
and TLR8 in comparison with CD4+ Teffs [6,60,63,64]. Several independent studies 
have now highlighted the importance of TLRs on CD4+CD25+ Tregs (figure 2). 
TLR5 is expressed on both CD4+ Teffs and CD4+CD25+ Tregs [66]. Interaction 
offlagellin with its receptor TLR5 on Teffs increased their proliferation and production 
of IL-2 while on Tregs flagellin/TLR5 increased their suppressive capacity [63,66]. 
The influence of TLR4 on Tregs is not yet clear. Initially, it was reported that LPS 
could enhance murine Treg mediated suppression by binding to TLR4 on Tregs 
[64], but this direct effect of LPS on purified Tregs could not be confirmed 
by others [65,66,67]. Nevertheless, the confined expression of TLR4 on 
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Tregs, warrants further examination of the effects of TLR4 ligands, including 
endogenous TLR4 ligands, on Tregs. We reported an important role for TLR2 in 
regulating murine Treg mediated suppression [67]. TLR2 activation on Tregs 
using the synthetic ligand PAM3Cys, in combination with IL-2 and TCR triggering, 
Suppression Proliferation 
Enhanced proliferation 
Figure Z. Effec:l5 of TLR·ligands proposed to directly modulate the function 
of naturally oa:un1ng Tregs upon direct interaction of the TLR·ligand with the 
Treg. Pre-treatment of Tregs with either endogenous HSP60 (TLR2), LPS (TLR4) 
or Flagellin (TLRS) has been reported to enhance the Treg suppressive capacity.ln 
contrast, PAM3Cys (TLRl/2) and ssRNA (TLR8) abrogate the suppressive capacity. 
The exposure ofTregs to PAM3Cys Induces Treg proliferation and Is mediated via 
TLRl/2. The effect of signaling via TLR6,-7 or the effect of combinations of TLR· 
ligands on Tregs is not known. CpG, guanosine-containing DNA oligonudeotides; 
HSP60, endogenous 60kDa heat shock protein; LPS, lipopolysaccharide; ssRNA, 
single stranded RNA. 
can induce Treg proliferation and results in temporal loss of suppression [67]. 
Upon removal of the TLR2 ligand, the Tregs regained their suppressive function 
[67]. Applying TLR2 knockout and MyD88 knockout mice showed that these effects 
on Treg function were indeed TLR2 and MyD88 dependent [67]. Similar findings 
were reported by Liu et oL [68]. They further suggested downregulation of FoxP3 
as a putative mechanism for the abrogation of Treg suppression. Surprisingly, 
using the endogenous TLR2 ligand hsp60, opposite effects of TLR2 triggering 
on Tregs were observed by Zanini-Zhorov et al. [9]. Hsp60 activated Tregs enhanced 
their suppressive capacity by both cell-contact dependent mechanisms and TGF-~ 
and IL-10 production [9.] This discrepancy could possibly be explained by the nature 
of the TLR-Iigands used, PAM3Cys being a TLRl/2-ligand and hsp60 a TLR2/? ligand, 
the concentrations of the ligands used or differences in the way endogenous and 
exogenous ligands interact with TLR2. TLR8 is strongly and preferentially expressed 
on human Tregs as compared to human Teffs [69]. Triggering ofTLRB on Tregs resulted 
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in the specific abrogation of suppression without affecting Treg proliferation, while 
no effects on human Teffs were observed. Applying short interfering RNA technology 
to knock-down TLR8 in Tregs completely blocked the effect demonstrating a crucial 
role for TLR8 [69]. 
The positive and negative effects of TLR-Iigands on Tregs themselves are intruiging, 
but further research is required to fully decipher the role of TLR triggering on Tregs. 
Crucial questions regarding the dynamics of TLR expression on immune suppressive 
Treg subsets upon inflammation or in relation to the type of pathogen encountered 
are largely unexplored. Aside pathogen-derived TLR-Iigands, it will also be 
important to elucidate the impact of endogenous TLR-Iigands on Tregs to shed light 
on the multifactorial regulation of Treg homeostasis in health and disease. 
Tregs, TLRs and cancer 
Multiple studies have shown that immune suppressive T cells can infiltrate turners 
and dampen anti-tumor immune response in mice [70,71]. Increased levels of Tregs 
have been documented in the peripheral blood of cancer patients and especially 
in the local tumor microenvironment [72]. Naturally occurring CD4 .. CD25 .. Tregs 
as well as adaptive CD25 .. FoxP3 .. Tregs, Trl- and Th3 cells, have all been detected 
in tumors [51]. Next to these CD4 .. suppressor T cells, other suppressive cell types 
reported to be involved in turner-immune escape are IL-10 secreting CD8+ cells 
[73], invariant NKT cells [74,75] and yS T cells [47]. Wang et aL succeeded to isolate 
human tumor infiltrating Tregs and identified LAGE-1 and ARTCl as the first natural 
tumor ligands for these Tregs [76,77]. Collectively, these findings could possibly 
explain why even in turners found to be infiltrated with leukocytes [78-80], turner 
progression is seemingly unhindered. 
The detrimental effect of Tregs in anti-turner immunity is emphasized by murine 
cancer models showing that Treg depletion with monoclonal antibodies against 
CD25 lead to significantly increased anti-cancer immunity [81-85]. Moreover, Treg 
depletion improves the efficacy of anti-cancer vaccines. As TLRs provide an important 
link between innate and adaptive immunity, TLR-Iigands are increasingly applied 
in cancervaccines [86]. However, besides innate immune cells and nowT lymphocytes, 
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also non-immune cells like epithelial cells and keratinocytes have been shown 
to express TLRs. Moreover, recent reports indicate that TLRs can also be 
expressed on tumor cells [87-90]. It might be especially rewarding to investigate 
the effects of TLR-Iigands on the function of different inhibitory T cell subsets. 
So far, application of TLR8-Iigands have been shown to enhance immune function 
of DC and at the same time reduce the suppressive capacity of human Tregs 
[69]. In contrast, the immune stimulatory potential of LPS and flagellin, might 
be counteracted by the direct enhancement of the suppressive function of murine 
Tregs via TLR4 and TLRS, respectively [63,64,66]. TLR2 plays a crucial role in both 
Treg expansion [67] and the suppressive capacity of Tregs [68]. Hence, stimulation 
via this receptor may lead to temporal immune stimulation but also a profound 
increase in the number of Tregs. Selecting the optimal combination of TLR-
Iigands for a given vaccine may turn out to be a crucial component in maximizing 
the anti-tumor immune response. 
In summary, understanding the functional control of immune suppressive 
T cells, including the role of TLR signaling, may offer new opportunities to shift 
the balance between immunity and tolerance. This, and the identification of specific 
targets on immune suppressive T cells that allow their elimination from the tumor 
microenviron ment, represent some of the major challenges towards the development 
of effective cancer immunotherapy. 
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Abstract 
The immune response against turners is complex and leads to either immunity 
or tolerance. Effective anti-tumor immunotherapy requires the identification 
of suitable target antigens. Interestingly, many of the turner antigens used 
in clinical trials are present in preparations of tumor vesicles (exosomes). In this 
study we compared T cell responses elicited by murine MCA101 fibrosarcoma 
turners expressing a model antigen at different localizations within the turner cell: 
a) in association with secreted vesicles (exosomes) b) as a non-secreted 
cell-associated protein or c) as secreted soluble protein. Remarkably, 
we demonstrate that only the turner secreting vesicle-bound antigen elicits: 
1) a strong antigen-specific CD8+ T cell response, 2) CD4+ T cell help, 
3) antigen-specific antibodies and 4) a decrease in the percentage of 
immunosuppressive regulatory T cells in the tumor. Moreover, in a therapeutic tumor 
model of cryoablation, only in turners secreting vesicle-bound antigen antigen-
specific CD8+ T cells could still be detected up to 16 days after therapy. Together, 
we conclude that the localization of an antigen within the tumor codetermines 
whether a strong immunostimulatory response is elicited. In vivo, vesicle-bound 
antigen clearly skews towards a more immunogenic phenotype, whereas soluble 
or cell-associated antigen expression cannot overcome turner tolerance. This 
may explain why in particular immunotherapies based on these vesicle-bound 
turner antigens are potentially successful. Therefore, we conclude that this 
study may have significant implications in the discovery of new turner antigens 
suitable for immunotherapy and that their location should be taken into account 
to ensure a strong anti-tumor immune response. 
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Introduction 
The immune system has to protect the host against foreign pathogens and avoid 
damage to normal tissues. Since turners are derived from these normal cells, 
the anti-turner immune response is not always effective and sometimes results 
in tolerance [1]. Immunotherapy against cancer aims to activate the immune system 
to destroy the tumor cells [2-4]. For example specific tu m or-associated antigens can 
be loaded onto professional antigen-presenting cells, dendritic cells, which are then 
activated and reinjected back into the patients. Many well-known antigens used for 
these clinical studies, such as Her2/Neu, Martl, TRP and gplOO have been found 
in vesicles secreted by turner cells, called exosomes [5]. Therefore, we wondered 
whether the localization of the antigen was important for the anti-turner immune 
response. 
Antigen-presenting cells can capture antigen from turners using various sources 
of material: ape ptotic or necrotic turner cells, heat-shock protein-peptide complexes, 
plasma membrane fragments, soluble proteins or vesicles secreted by live turner 
cells, called exosomes [6-10]. The actual source of antigen in vivo however, is 
probably a combination of all of the above. It is known that antigen-presenting 
cells can direct soluble antigens into lysosomes resulting in presentation on MHC-
n molecules or target them to early endosomes, leading to MHC-1-restricted 
presentation [11]. Particulate antigens are phagocytosed and result in presentation 
on both MHC-1 and MHC-11. Particulate antigen in a cell-associated form has 
been shown to result in increased T cell activation compared to soluble antigen 
[12,13]. Also virus-like particles, which contain antigens, have been shown 
to result in a stronger T cell response compared to soluble proteins [14]. Since tumors 
continuously secrete membrane vesicles, such as exosomes, providing another 
source of particulate antigen, we wondered whether this source of antigen in vivo 
leads to a more profound T cell mediated immune response compared to secreted 
soluble or non-secreted cell-associated antigens. 
Previously, we reported that a turner expressing the model antigen ovalbumin (OVA) 
coupled to the factor Vlll-like C1C2-domain of milk fat globule EGF factor vm (MFG-
E8)/Iactadherin, secreted OVA in association with vesicles, whereas the sOVA turner 
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secreted OVA only in a soluble form and not associated with vesicles ([15], Fig. lA). 
In addition, we constructed a fusion protein of FcyRD and the antigen OVA (FcROVA 
tumor, Fig. lA), since FcyRII is present on the plasma membrane and has been 
shown to be excluded from exosomes [16]. The FcROVA tumor expresses OVA only 
in a cell-associated membrane-bound form and does not secrete OVA in a soluble 
form nor in association with vesicles (Fig. lA). 
To obtain a strong T cell response, na"ive CDB+ T cells first need to encounter 
the antigen on MHC-I molecules. Since most tumors, including the murine 
fibrosarcoma MCAlOl used in this study, do not express sufficient levels of MHC-I 
to induce cytotoxic T cells (CTL) from na"ive T cells, the T cells need to be activated 
by professional antigen-presenting cells [17]. The naturally occurring T cell response 
in tumor-bearing mice does not always lead to tumor eradication and can 
even result in tolerance [1,18]. Because of their specific killing capacities, CDB+ 
T cells have the capacity to eliminate malignant cells. For the rejection of a tumor 
it is important that the cytotoxic T cells (CTLs) reach and deeply infiltrate the tumor, 
which is dependent on the presence of the antigen in the tumor [19]. However, 
help from CD4+ T cells is needed for maximal proliferation and effector function 
of CDB+ T cells [20]. CD4+ T cells are also necessary to provide help to B cells 
to start proliferation, induce antibody class switching and antibody production 
leading to antibody-dependent cell-mediated cytotoxicity [21]. By contrast, CD4+ 
regulatory T cells (Tregs) can inhibit or weaken the immune response and limit 
the efficacy [22,23]. Naturally occurring Tregs originate from the thymus and adaptive 
Tregs are induced in the periphery from conventional CD4+ T cells [24] . Tregs exert 
a strong, suppressive activity on multiple components of the immune system. 
Depending on the model, they can suppress priming or proliferation of the T cells, 
inhibit proliferation or even kill dendritic cells in an antigen-specific manner [23,25]. 
In general, the influx of CD8+ T cells is assumed to be beneficial for the patient 
whereas a higher Treg number in the tumor implies a worse prognosis [26]. 
The attribution of these diverse T cell responses in respect to differently localized 
antigen in tumors has not been investigated, yet. 
In this study we compared the potential of differently localized antigens to induce 
T cell mediated tumor immunity. We investigated the endogenous CDS+ as well as 
the CD4+ T cell response in mice bearing tumors with these differently localized 
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antigens. To determine the impact of the localization of antigens in a more 
therapeutical setting, we analyzed the antigen-specific COS+ T cell response after 
cryoablation, a turner destruction technique using a thermal energy source used 
to treat solid tumors [27]. We showed that only turners secreting vesicle-bound 
antigen induce a strong anti-tumor immune response, which is prolonged after 
therapy, whereas tumors secreting soluble antigen or containing non-secreted 
cell-associated antigen show a weak immune reponse, leading to tumor tolerance 
and thus outgrowth of the tumor. 
Materials and methods 
Mice 
C57BI/6J mice were obtained from Charles River and maintained under specific 
pathogen-free barrier conditions at the Central Animal Laboratory {Nijmegen, 
the Netherlands). OT -D mice were bred at the Central Animal Laboratory {Nijmegen, 
the Netherlands). Drinking water and standard laboratory food pellets were provided 
ad libitum. The experiments were performed in accordance to the guidelines 
for animal care of the Nijmegen Animal Experiments Committee. 
Plasmids 
The pcDNA3-hygromycin expression plasmids were from Invitrogen. The OVAC1C2 
and sOVA constructs were made as described previously [15]. The FcyRIIb receptor 
was amplified by PCR from mouse cDNA and the cytosolic part containing the ITIM 
sequence was deleted and replaced with OVA and inserted into the pcDNA3 vector 
(for FcROVA). 
Cells 
The MCA101 fibrosarcoma was cultured in DMEM supplemented with 10% bovine 
calf serum (Greiner Bio-One) and antibiotic-antimycotic {Gibco). Stable cell lines 
were obtained by electroporation, followed by selection with 1 mg/ml hygromycin 
(Roche) and cloning by limiting dilution as described before [15]. 
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Exosome purification 
Exosome production, purification and characterization were done as previously 
described [28]. Briefly, transfected MCA cells were cultured for 48h in medium 
depleted from serum-derived exosomes by overnight centrifugation at 100,000g. 
Exosomes were purified by successive centrifugations. Concentrations were 
quantified by micro protein BCA assay kit (Pierce) and routine characterization was 
done by western blotting and FACS analysis after coating on 4~m aldehyde-sulfate 
latex beads (lnvitrogen Molecular Probes). 
EUSA 
For detection of OVA in supernatant, cells and purified exosomes by EUSA, goat 
anti-OVA (MP Biomedicals) was coated on MaxiSorp 96-well plates (NUNC). Washes 
were done in PBS supplemented with 0.05% Tween20, blocking in PBS/5% milk. 
After incubation with the samples bound OVA was revealed by polyclonal rabbit 
anti-OVA serum (Sigma Aldrich) followed by horseradish peroxidase 
(HRP)-conjugated anti-rabbit antibody and 3,3',5,5'-tetramethylbenzidine (TMB) 
substrate reagent (Sigma). Reaction was stopped with 0,8 M H2S04 and absorbance 
was read at 450 nm. For detection of OVA-specific antibodies OVA was coated 
on MaxiSorp 96-well plates. EUSA was performed as described above, except that 
wells were blocked with PBS with 0.05% Tween and 1% BSA before diluted serum 
(as stated in the legends) was added to the plates. Biotinylated anti-mouse IgG1 
antibody (The Binding Site) was followed by HRP-conjugated streptavidin (lnvitrogen). 
A monoclonal mouse anti-OVA antibody was used as a positive control to obtain 
a standard curve from which the concentrations were calculated. 
355 Metabolic Labeling and Pulse-Chase Immunoprecipitation 
Transfected MCA cells were starved in methionine and cysteine-free DMEM medium, 
supplemented with dialyzed fetal bovine serum, for 2 h. Cells were labeled with 100 
~Ci/ml of 355 Tran-label for 15 min, washed, and then incubated in chase medium 
(complete DMEM) for 0, 30 or 120 min. Subsequently, cells were lysed in 50 mmoi/L 
Tris (pH 7.5), 0.3 moi!L NaCI, 0.5% Triton X-100, containing a mixture of protease 
inhibitors. Lysates and supernatants were then incubated with Protein G-agarose 
beads prebound with rabbit anti-OVA antibody 0/N at 4°C. After extensive washings, 
57Antigen localization controls immunity 
the samples were then boiled with non-reducing sample buffer and separated 
on SDS/10% PAGE gels. The gels were fixed, washed with DMSO and treated with 
PPO before drying and exposure to film at -sooc. 
B3Z T -cell activation assay 
Transfected MCA cells were incubated overnight at 3rc with 10 ng/ml IFNy 
to enhance MHC-1 expression. After washing, 5*1()4 MCA cells were coincubated 
for 16h with 1 *105 B3Z T cells, which carry a lacZ (~-galactosidase) construct driven 
by nuclear factor of activated T -cell elements from the IL-2 promoter and recognize 
the OVA peptide (257-264) SDNFEKL in the context of Kb MHC class I molecules. 
Cell pellets were lysed with PBS containing 0.125% NP40, 9 mM MgCI2, 100 mM 
~-mercapto-ethanol and 0,15 mM chlorophenolred-~-D-Galactopyranoside 
(Calbiochem). After 3h at 37°C the plate was read at 595 nm using a 96-well plate 
reader. 
In vivo tumor growth 
Transfected MCA cells (4 x 105) obtained from subconfluent studies were injected 
s.c. in the shaved flank and tumor size was measured every 3-4 days with a caliper. 
Tumor volume was calculated as length x width x ((length +width) I 2). Mice were 
killed at day 20 for Treg analysis. 
Intracellular cytokine staining 
Blood was drawn from the tail vein of animals at multiple time points. Erythrocytes 
were lysed using ACK lysisbuffer before cells were divided in 96-wells plates 
and incubated for Sh with 5 iJg/ml BrefeldinA with either no peptide, irrelevant 
peptide, COS+ OVA SIINFEKL peptide or a combination of PMA with ionomycin 
as a positive control. After stimulation, cells were stained with fluorophore-
coupled antibodies to mouse CD4 and CD8 (BD Pharmingen), followed by fixation, 
permeabilization and subsequent intracellular cytokine staining with anti-IFNy 
antibody according to manufacturer's protocol (BD Pharmingen). Cells were 
analyzed by flowcytometry on a FACSCalibur (Becton Dickinson) or a CyAn (Beckman 
Coulter). 
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In vivo T cell stimulation assay 
OT-n mice were sacrificed, lymph node suspensions were made and their CD4+ 
CD2S- T cells were sorted using the CD4+ T cell isolation kit combined with CD2S-
PE and PE-beads (Miltenyi Biotech). These sorted OT -n T cells were labeled with 
carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen Molecular Probes) 
before i.v. injection in C57BI/6J mice bearing 8-day old tumors. Three days later cells 
from the draining and non-draining lymph nodes were analyzed by flowcytometry 
after staining with fluorophore-coupled antibodies to CD4 and the TCRVa2 
(BD Pharmingen). 
T cell analysis 
Draining lymph nodes and tumors were excised and mashed using needles 
or scissors, respectively and digested in collagenase type m (Worthington 
Biochemical Corporation) and DNase {Roche) for 20 min. After addition of EDTA and 
resuspending, cells were applied to a filter to remove debris. Cells were stained with 
antibodies against CD4, CD8 and CD25. Intracellular staining for FoxP3 was performed 
according to the manufacturer's protocol (FoxP3-staining kit, eBiosciences). 
Suppression assay 
Draining lymph nodes of 5 tumor-bearing animals were pooled and Tregs 
were sorted using the regulatory T cell kit or a CD4+ isolation kit followed 
by anti-CD25-FITC and FITC-beads (Miltenyi Biotec). Conventional T cells were 
sorted from spleens of na'ive animals using anti-CD4-microbeads (Miltenyi 
Biotec) and labelled with carboxyfluorescein diacetate succinimidyl ester (CFSE; 
Invitrogen Molecular Probes). Conventional T cells were incubated with Tregs from 
thedifferenttumor-bearing animalstogetherwith anti-CD3 and feeders (T cell depleted 
splenocytes) for 3-4 days. Proliferation of the conventional T cells was assessed 
by CFSE-dilution as analyzed by flowcytometry. 
Cryoablation 
Tumor cells (4 x 105} were resuspended in a mixture of PBS and Matrigel (2:1) 
and injected s.c. at the right femur. At day 10, when all tumors were of similar size 
(-500 mm3), cryoablation was performed under isoflurane anaesthesia using a liquid 
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nitrogen cryoablation system (CS76, Frigitronics) as described before [29]. During 
2 treatment cycles of freezing and thawing the tumor was macroscopically frozen, 
while leaving surrounding healthy tissue intact. Blood was drawn one day before 
cryoablation and 7 and 16 days after cryoablation. Intracellular cytokine staining 
was performed as described above. 
Statistical analysis 
The data were analyzed with a one-way (bars) or two-way (curves) ANOVA, 
followed by a Bonferroni post-test. Statistical significance is shown in the graphs 
only if it is significant compared to all other groups using the following symbols: 
* p<O,OS, ** p<O,Ol, *** p<O,OOl 
Results 
Characterization of MCA tumor cells expressing diHerentially 
localized antigens 
To study the effect ofthe localization of antigens in the anti-tumor immune response, 
we compared murine MCAlOl fibrosarcoma tumors transfected with three different 
constructs. Previously, we coupled the model antigen OVA to the factorVlll-like ClC2-
domain of milk fat globule EGF factor VDI (MFG-E8)/Iactadherin, which resulted in 
secretion associated with vesicles (exosomes)[15]. The fibrosarcoma tumor MCA101 
expressing this OVAC1C2 construct grew much slower in immunocompetent (but 
not in immunodeficient) mice than the tumor secreting soluble OVA (sOVA tumor) 
(Fig. 2A and [15]). We could not discriminate whether this was due to a vesicle-bound 
or membrane-bound form of the antigen. Therefore, in this study we also included 
a membrane-bound, but only cell-associated form of the antigen OVA, FcROVA (Fig. 
lA). The supernatant, purified exosomes and cellular fraction of the FcROVA tumor 
were thoroughly characterized like the sOVA and the OVAC1C2 tumor and OVA was 
indeed only expressed in a cellular form and not on exosomes (Fig.lB and [15]). 
For the recognition and subsequent killing of tumors by cytotoxic T cells, it is 
very important that the MHC-peptide complexes on the cell surface are similar. 
Therefore, we checked the capability of the OVA-specific T cell line B3Z to recognize 
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the OVA-peptide (257-264) SDNFEKL in the context of Kb MHC class l The expressed 
~-galactosidase was measured and as shown in Fig.lC, indeed all cell lines showed 
equal amounts of MHC/OVA-peptide complexes. 
It has been suggested by Shen et al. that for cross-presentation the stability 
of the protein is an important factor. Thus, we performed a :~ss pulse-chase assay 
with the different transfected OVA tumor cell lines. As shown in Fig. 10, comparing 
the 30min pulse with the 120min pulse all proteins degraded at a similar rate. 
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The sOVA and FcROVA seem to be synthesized faster than the OVAC1C2 protein, 
but the degradation pattern is similar: In the supernatant only the sOVA tumor 
shows a strong secretion of the protein and to a lesser extent the OVAC1C2 tumor. 
As already verified by EUSA, the FcROVA tumor did not secrete protein at all. Overall, 
this figure shows that all proteins are equally stable. 
Vesicle-bound antigen induces profound antigen-specific 
CDB• T cell responses 
As shown in Fig. 2A we confirmed that only the OVAC1C2 tumors secreting vesicle-
bound OVA showed reduced growth. Remarkably, even the FcROVA tumor grew 
similar to the mock-transfected tumor, showing that the presence of only a cell-
associated membrane-bound, but not secreted form of OVA did not inhibitthe growth 
of tumors. Previously, we have shown that adoptively transferred OVA-specific COS• 
OT -I T cells injected at day 6 proliferated more in the OVAC1C2 tumor expressing 
vesicle-bound OVA compared to the sOVA tumor secreting soluble OVA Here, 
we followed the endogenous CD8• T cell response in the blood of mice bearing 
the different OVA-expressing turners in time. As shown in Fig. 28, the tumors 
bearing the various forms of OVA showed different kinetics of the endogenous 
OVA-specific COS• T cell response. The OVAC1C2 tumor showed the strongest 
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immune response, which peaked around 
day 12-15 and dropped around day 
20 in accordance with the contraction 
phase of the CTL response [30]. 
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slower In lmmune-compebmt hosts and Induces 
a strouger endogenous OVA-spedllc CD8+ T cell 
response in Yivo. 
A. Growth of the mode:, sOVA, OVAC1C2 and FcROVA 
tumor after s.c. lnjecdon In Immunocompetent 
C57BI/6J mice. 
B. The kinetics of the endogenous immune response 
in mice bearing different OVA·conl2ining tumors. 
Blood was collected from naYve mice or mice bearing 
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time poiDt:s. After restimulation fur Sh with OVA-
spedflc peptldes and brefeldlnA, the percentage of 
IFNy·produclng CDS+ T cells was measured by FACS 
analySis. Data are averages :tSBM of 10 mice from 
2 independent experiments. *:p<O,OS; -= p<0,001 
as demrmfned by a two·way ANOVA followed by a 
Bonferronl post· test agatnst all groups. 
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The sOVA tumor showed weaker, but similar kinetics compared to the OVAC1C2 
tumor. Interestingly, the FcROVA tumor, which has a membrane-bound form 
of OVA similar to the OVAC1C2 tumor, although only non-secreted cell-associated 
and not bound to secreted vesicles, exhibits a much weaker and earlier OVA-specific 
cos• T cell response. We conclude from these data that membrane-bound antigen 
must be associated with secreted vesicles in order to induce a strong antigen-
specific COB• T cell immune response in vivo. 
Only vesicle-bound antigen induces proliferation of 
OVA-specific CD4+ OT-D cells 
For a strong COB+ CTL response, C04+ T cell help has been shown to be essential 
[20]. Thus, we investigated the C04• helper T cell response. Less than 0,5% of the 
total CD4+ T cells in blood of the mice bearing the different turners were able to 
produce T-helper specific cytokines, such as IFNy IL-4 and IL-17, after incubation 
with PMA and ionomycin (data not shown). Since the detection level of OVA-
specific CD4• T cells in blood appeared too low, we took a different approach. 
We adoptively transferred OVA-specific C04+ OT -11 cells at day 8. Three days later the 
mice were sacrificed and the draining and non-draining lymph nodes were analyzed 
for proliferation of OT-II cells. Only in the draining lymph nodes of mice bearing 
the OVAC1C2 tu m or secreting vesicle-
bound OVA significant proliferation 
of the OT -II cells was observed (Fig. 
3A). As expected, no proliferation 
was found in the non-draining lymph 
nodes (Fig. 3B). 
Figure 3. Only vesicle-bound antigen induces 
efficient proliferation of OVA-specific CD4• 
T cells in vivo. CFSE-labeled OVA-specific 
CD4• OT-II T cells were injected i.v. in hosts 
bearing B-day old mock. sOVA. OVAC1C2 or 
FcROVA tumors. Mice were killed at day 11 and 
division of the OT-11 cells in the draining lymph 
node (A) and in the non-draining lymph node 
(B) was assessed by FACS analysis. Data are 
averages ±SEM of 4 mice from 2 independent 
experiments. ***: p<0,001 as determined by a 
one-way AN OVA followed by a Bonferroni post-
test against all groups. 
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Vesicle-bound antigen results in an OVA-specific IgGl antibody response 
Subsequently, we studied the capacity of CD4+ T cells to provide help to B cells 
to induce antibody class switching and produce antigen-specific antibodies. 
Therefore, we measured the amount of antibodies against the antigen OVA in the 
serum of mice bearing the turners with the differently localized antigens in time. 
Already early in the immune response at day 15 the mice with the OVAC1C2 turners 
secreting vesicle-bound OVA showed a significant OVA-specific IgGl response 
(Fig. 4A). At day 25 1 ~g/ml OVA-specific IgGl antibodies were detected in the 
OVAC1C2 turner bearing mice (Fig. 48). As a control we measured the amount 
of total IgGl antibodies and no significant differences were observed. In serum of 
the mice bearing the sOVA turners, secreting soluble OVA and FcROVA turners, 
containing non-secreted cell-
associated OVA, we detected only 
small amounts of OVA-specific IgG2b 
and IgG2c antibodies at day 25 ( < 50 
ng/ml, data not shown). We conclude 
from these data that the antigen needs 
to be secreted in a vesicle-bound 
form in order to induce production 
of OVA-specific antibodies of the 
IgG1 isotype. 
Cell-associated or soluble antigen 
does not decrease the percentage 
ofTregs 
To study whether antigen localization 
has an effect on the induction 
of turner tolerance, we investigated 
the influx of Tregs in the turners, since 
this has been demonstrated to be 
a negative prognostic factor [26]. 
We analyzed the percentage of Tregs 
in the draining lymph nodes and 
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Figure 4. Vesicle-bound antigen induces 
an OVA-specific lgG1 response. Blood was 
collected from naive mice or mice bearing 
mock, sOVA, OVAC1C2 or FcROVA tumors at 4 
different time points. OVA-specific IgG1 was 
measured by ELISA: for kinetics serum was 
diluted 1:50 (A), for concentration at day 25 
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in the turners expressing the different forms of antigen. No difference 
was seen in the draining lymph nodes of all turners comparing 
the percentage of Tregs of the total CD4+ T cell pool (Fig. SA). 
Also the functionality of the Tregs in the draining lymph nodes was not affected, 
as demonstrated in their ability to suppress the proliferation of conventional CD4+ 
T cells as shown in Fig. SB. When focusing on the turners, we found that 
the sOVA turner secreting soluble OVA as well as the FcROVA turner with 
cell-associated OVA contained equal percentages of Tregs compared to the 
mock tumor (Fig. SC). The presence of the immunodominant antigen OVA 
in itself proved not sufficient to skew the balance from turner tolerance towards 
immunity. However, when the antigen was secreted in a vesicle-bound form 
as in the OVAC1C2 turner the percentage of Tregs among CD4+ T cells 
in the tumor was significantly less. Since the ratio of Tregs and conventional 
T cells in the draining lymph nodes and the turner is important to skew 
the balance from immunity to tolerance, we also analyzed the percentages 
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of total CD4+ and CD8+ T cells in the 
draining lymph nodes and turners 
(sup pi. Fig. 1). The percentages 
of CD4+ and CD8+ T cells was equal 
in all tumors, confirming that the 
decrease in percentage of Tregs 
observed in the OVAC1C2 tumor 
Figure S. No reduction of Tregs in the sOVA 
and FcROVA tumor. Mice bearing different OVA-
containing tumors were killed at day 20 and the 
percentage of Tregs (FoxP3•CD25•) of the total 
pool of CD4• T cells in the draining lymph node 
(A.) or the tumor (C.) was measured by FACS 
analysis. Data are averages ±SEM of at least 17 
mice from 4 independent experiments. B. Cells 
from the draining lymph nodes were pooled 
according to turn or type and Tregs were sorted as 
described in materials and methods. Sorted Tregs 
were incubated for 3-4 days with CFSE-labeled 
CD4• conventional T cells together with sub-
optimal concentrations of anti-CD3 and feeders. 
The proliferation of the conventional T cells was 
measured by FACS analysis and averages ±SEM of 
4 independent experiments are shown. *: p<O,OS 
as determined by a one-way AN OVA followed by a 
Bonferroni post-test against all groups. 
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is indeed a decrease in the ratio of Tregs and conventional CD4+ 
T cells. The presence of a secreted soluble OVA or non-secreted cell-associated 
OVA was not sufficient to decrease the Tregs in the tumor, which could result in 
a strong immune response, which could counteract tumor tolerance. 
The vesicle-bound form of the antigen induces a prolonged 
OVA-specific COS+ T cell response after cryoablation 
The secreted vesicle-bound form of the antigen clearly skews the immune system 
towards anti-tumor immunity, whereas a secreted soluble form or a non-secreted 
cell-associated form of the antigen does not. We wanted to investigate whether 
this effect was still visible after therapeutic interference, such as cryoablation [27]. 
This is a tumor destruction technique using a thermal energy source to freeze the 
tumor. It is known that following tumor ablation in situ, large amounts of tumor 
debris are released that could be taken up by the immune system and induce 
a strong tumor specific immune response [29,31]. We wondered whether the antigen 
localization within the turn or cells in this particular therapeutical setting, where large 
amounts of antigens are released upon cryoablation, is important for the skewing 
of the immune response. The turners with differentially localized antigens were 
grown in immunocompetent mice as in Fig. 2A and at day 10 when all tumors 
were still of similar sizes, we performed cryoablation as described previously 
[29]. The tumors were completely destructed and no recurrence was observed. 
Without cryoablation the contraction phase of the CTL response has started at day 
19 as shown in Fig. 2B and hardly any OVA-specific T cells are present in blood. 
However, after cryoablation, when the tumor has completely disappeared a strong 
OVA-specific COB+ T cell response is still present at day 19 and even at day 26 only 
in the mice bearing OVAC1C2 tumors secreting vesicle-bound OVA (Fig. 5). 
By contrast, cryoablation of the other turners could not result in strong anti-tumor 
immunity, despite the release of all antigens, including the strong immunogenic 
protein OVA. in a tumor debris. Taken together these results demonstrate that only 
vesicle-bound antigens can lead to a boost in the immune response after therapeutic 
intervention and result in tumor immunity. 
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Discussion 
Whether the immune system is geared towards tolerance or immunity is of crucial 
importance for many diseases including cancer. Here, we show for the first time 
that in vivo secretion of vesicle-bound antigen is of eminent importance to obtain 
strong immunity against malignant tumors. It not only results in a stronger CDB+ 
T cell response, but also in proliferation of OVA-specific CD4+ T cells and more OVA-
specific antibodies. By contrast, transfection of a soluble antigen or a cell-associated 
antigen resulted in a similar tolerogenic immune response as the mock-transfected 
tumor not expressing the immunogenic protein OVA. 
At first sight our findings may seem in contrast with observations from 
Shen et al. who showed that in vivo membrane-bound forms of OVA induce higher 
levels of CTL activity than OVA expressed in the cytosol [13]. However, in that study 
fibroblasts were transfected with a fusion protein of the transferrin receptor and 
OVA as a cell-associated membrane-bound form of OVA. Most likely this fusion 
protein will not be excluded from exosomes, since the transferrin receptor is present 
in exosomes secreted by different cell types (reticulocytes, oligodendroglia! cells, and 
dendritic cells) [32-34] . Therefore, all preclinical mouse studies where fusion proteins 
of OVA and the transferrin-receptor are used, cannot be regarded as exclusively 
non-secreted cell-associated forms of OVA, as the chance that they will be secreted 
through exosom es is high. By contrast, our constructs a re either secreted in association 
with vesicles (OVAC1C2) or remain non-secreted cell-associated (FcROVA). This may 
explain the apparent differences between both studies. Furthermore, considering 
the stability of the protein. Shen et al. showed clear differences in the stability of the 
protein, whereas this was not the case in our different OVA-containing constructs 
(Fig. 10). 
CD8+ cytotoxic T cells are essential for the rejection of tumors [35,36]. In this study 
a significant endogenous OVA-specific CD8+ T cell response was only observed 
in the blood of the mice bearing the OVAC1C2 tumor, secreting vesicle-bound OVA. 
The sOVA tumor secreting soluble OVA showed only a minor COB+ T cell response. 
Our conclusion is that this is due to the localization of the antigen, i.e. soluble, 
vesicle-bound versus cell-associated. However, immune responses can also be 
influenced by the form of the antigen, the presentation ofthe peptide on MHC class 
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I and the stability of the protein. Previously, we have shown that when purified sOVA 
and OVAC1C2 proteins were bound to beads equal immune responses were elicited 
in vitro and in vivo, suggesting that the mere forms of the antigen did not alter the 
immune response. Also no differences were found in the amount of MHCI/OVA-
peptide complexes formed on the surface of the different transfectants. Last, the 
stability of the protein was also equal in all MCA transfectants as shown in Fig. lD. 
C04+ T cells provide essential help to COS+ T cells via the production of cytokines in 
order to induce and maintain a strong effector response [20]. Indeed, we showed by 
adoptive transfer of OVA-specific CD4+ OT-ll T cells, that only in the mice bearing 
the OVAC1C2 tumor, these CD4+ T cells proliferated and could therefore provide 
the necessary help to acquire a strong OVA-specific COS+ T cell response. It has 
been shown that CD4+ T cells are programmed to undergo only a limited number of 
divisions, whereas COS+ T cells undergo extensive proliferation [37]. Considering the 
low percentage of endogenous OVA-specific CDS+ T cells, it was not surprising that 
we didn't detect endogenous OVA-specific C04+ T cells in blood. 
In our study we observed a significant OVA-specific IgGl response in the OVAC1C2 
tumor, secreting vesicle-bound OVA and hardly any response in the sOVA and the 
FcROVA tumor. Since also for a functional B cell response C04+ T cells are necessary 
[21], this result is consistent with the observation that OVA-specific CD4+ T cells 
are only proliferating in the OVAC1C2 tumor. A few earlier in vivo studies compare 
membrane-bound antigen with soluble antigen in their ability to provoke antibody 
responses [38, 39]. These DNA vaccination studies reported a strong IgGl response 
after vaccination with the soluble form of OVA, but not with the membrane-bound 
form of OVA. Again as discussed above the transferrin receptor-OVA fusion protein 
was used as a membrane-bound form of OVA. This construct will also be present on 
exosomes as explained above, but on the inside of the vesicle and thereby limiting 
the availability for the B-cell receptor to internalize. By contrast, the OVAC1C2 
protein used in our study is detected on the outside of exosomes, rendering it more 
accessible for the B cells and can therefore explain the lgGl antibody production. 
The lack of a strong antibody response in the mice with the sOVA and FcROVA 
tumor can be explained by the absence of proliferation of the CD4+ T cells, which 
are necessary to provide help for class switching, resulting in the observed impaired 
IgG responses. 
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A higher Treg number in the tumor is often associated with a worse prognosis 
in patients [26,40-43]. The percentage of Tregs in the sOVA tumor, secreting 
soluble OVA and the FcROVA tumor, containing the non-secreted cell-associated 
OVA was comparable to the percentage Tregs in the mock-transfected tumor, 
whereas only in the OVAC1C2 tumor we saw a reduction of Tregs in the tumor. 
It could be suggested that this reduction of Tregs is not relevant since the sOVA and 
the FcROVA tumor already have less OVA-specific COS+ T cells (Fig. 2B). However, 
we showed previously that the addition of more OVA-specific na"ive CD8+ OT -1 T cells, 
could not increase the immunogenicity of the tumors, resulting in outgrowth of the 
sOVA tumor [15]. Indeed, only when the Tregs were depleted in the sOVA tumor, 
this could lead to regression of the tumor showing that the Tregs are important in 
this tumor model [25]. It is of note that the Tregs suppress in an antigen independent 
manner (Fig. 5B) and that the "tolerance" we observe is against the whole tumor 
and not antigen-specific tolerance. In immunogenic tumor cell lines such as 
the thymoma EL4 and the melanoma B16, the mere introduction of the immunogenic 
protein OVA is sufficient to overcome tolerance and induce a strong immune 
response. In the non-immunogenic MCA tumor that we use, clearly Tregs play 
an important role and tumor tolerance cannot be broken just by the introduction of 
an immunogenic protein, only when this protein is vesicle-bound. Moreover, Tregs 
in this same MCA model secreting sOVA have been shown to kill dendritic cells 
in an OVA-specific manner, thus in addition to direct suppression, blocking also 
indirectly the formation of a strong OVA-specific T cell mediated immune response 
[25]. Here, we did not find differences in the percentage of total dendritic cells 
(unpublished observation) nor Tregs (Fig. 4A) in the tumor-draining lymph nodes, 
but Tregs were significantly decreased in the OVAC1C2 tumor itself, which could 
explain the decreased immunosuppression observed in this tumor. Whether antigen-
specific killing of DCs by Tregs occurs differently in the draining lymph nodes of the 
different tumors will require further investigations. 
Accumulation of Tregs in the tumor is a result of either increased migration, 
conversion from FoxP3- conventional T cells, increased survival or increased 
proliferation. In ovarian cancer, marcrophages within the tumor have been shown 
to secrete CCL22, which can attract Tregs via CCR4 [41]. Therefore, we analyzed the 
amount of macrophages in the tumor and observed that the OVAC1C2 tumor did 
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not have a reduced number of macrophages (unpublished observation), suggesting 
that the decrease in Tregs is not because of less migration. It is well known that TGF~ 
secreted by the tumor can contribute to the induction of Tregs [44]. In vitro all four 
tumor cell lines secreted equal amounts of TGF~ (unpublished data), indicating that 
this alone cannot explain our findings. However, the amount of TGF~ in the tumor 
in vivo can be quite different due to the presence of other TGF~-secreting cells, such 
as the Tregs themselves, or an increase in secretion by the tumors. We were not 
able to analyze the survival and proliferation of the Tregs in the tumor. Probably, 
the decrease of Tregs as seen in the OVAC1C2 tumor is a combination of all factors 
described above. 
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Figure 6. Prolonged antigen-specific COB• T 
cell response in OVAClCZ tumor. Mice bearing 
different OVA-containing tumors were subjected 
to cryoablation at day 10 when all tumors were of 
similar sizes (Fig. 18). Blood was collected from the 
mice just before cryoablation, 9 and 16 days after 
cryoablation. After restimulation for Sh with OVA-
specific peptides and brefeldinA, the percentage 
of IFNy-producing CDB• T cells was measured by 
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Cryoablation is a technique that destroys the tumor without excising it and thereby 
leaves the tumor debris in situ for uptake by immune cells, resulting in weak but 
turner-specific immunity [29,31]. Using this type of treatment, we expected that 
differences between the three differently localized antigens would be neglected, 
since all tumors create a similar mass of tumor debris containing a similar amount 
of antigen, which could increase the immunogenicity and thus break tumor 
tolerance. Remarkably, we only observed an increase in OVA-specific CD8• T cells 
in the OVAC1C2 tumor and not in the sOVA tumor nor the FcROVA tumor after 
cryoablation (Fig.6). Whether this prolonged T cell response is due to a delay 
in T cell contraction, changes in the peak of the T cell response or a booster response 
cannot be concluded from these time points. However, when comparing the time 
points in Fig. 2B and Fig.6 it is unlikely that this is due to changes in the peak of the 
response or a delay in T cell contraction, since at day 19 we have never observed 
any OVA-specific immune response without cryoablation, whereas a week later 
a strong OVA-specific response was still visible after cryoablation when 
70 Chapter 3 
the tumor and the debris were completely gone. This suggests that this therapeutic 
intervention is not enough to increase the immune response when the immune 
response before cryoablation is already too low to counteract the growth of the 
tumor. Thus, the initial immune response elicited by vesicle-bound antigen is of 
essential importance for the outcome of the immune response after therapeutic 
intervention, such as cyroablation. 
We conclude from our study that location of antigen is of eminent importance 
for the immune system to induce tumor immunity. Vesicle-bound antigen clearly 
skews towards a more immunogenic phenotype whereas soluble or a non-secreted 
membrane-bound form of the antigen results in tumor tolerance. This has important 
implications for tumor therapies such as cryoablation, since the additional advantage 
of a prolonged antigen-specific CD8+ T cell immune response is only visible in the 
OVAC1C2 tumor secreting vesicle-bound antigen. The model antigen OVA used 
here is relevant to non-self tumor antigens arising from mutations of endogenous 
proteins but not to other tumor antigens, such as differentiation or testis tumor 
antigens. Although these studies were performed with the model antigen 
OVA, it is of interest to note that many of the tumor antigens already exploited 
in immunotherapies are found in preparations of tumor exosomes, such as 
Her2/Neu, Martl, TRP, gplOO [5]. This may explain why in particular immunotherapies 
based on these tumor antigens are potentially successful. Furthermore, certain 
forms of cancer therapy, such as irradiation, have been shown to increase exosome 
secretion [45], which might also lead to an increase in the immunogenicity 
of tumors that secrete vesicle-bound antigen. Therefore, we conclude that this study 
may have significant implications in the discovery of new tumor antigens suitable 
for immunotherapy and that their location should be taken into account to ensure 
a strong anti-tumor immune response. 
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Abstract 
The use of probiotics as food supplement has gained tremendous interest in the 
last few years as beneficial effects were reported in gut homeostasis and nutrient 
absorption, but also in immunocompromised patients to support protection from 
colonization or infection with pathogenic bacteria or fungi. As treatment approach 
to inflammatory bowel diseases, a suitable probiotic strain would ideally be one with 
a low immunogenic potential. Insight into the immunogenicity and type ofT-cell 
responses induced by potentially probiotic strains allows for a more rational selection 
of a particular strain. In the present study, the bacterial strains Bi{idobaeterium breve 
(NumRes 204), Lactobacillus rhamnosus (NumResl) and Lactobacillus casei (DN-114 
001) were compared concerning their capacity to induce inflammatory responses 
in terms of cytokine production by human and mouse primary immune cells. 
It could be demonstrated that the B. breve strain induced lower levels of the 
pro-inflammatory cytokine IFNy than the tested L. rhamnosus and L. casei strains. 
Both B. breve and Lactobacilli induced cytokines in a TLR9 dependent manner, while 
the lower inflammatory profile of B. breve was due to inhibitory effects of TLR2. 
No role for TLR4, NOD2 and C-type lectin receptors was apparent. In conclusion, 
TLR signalling is involved in the differentiation of inflammatory responses between 
probiotic strains used as food supplements. 
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Introduction 
In recent years probiotic supplements have been suggested to provide health 
benefits. Subsequently, the use of specific probiotic strains as safe supplements for 
human consumption has been approved. Probiotic strains are classified as being live 
microorganisms which, when administered in sufficient amounts, confer a health 
benefit to the host [11]. This health benefit could comprise more efficient digestion, 
nutrient absorption, or higher resistance to pathogenic bacteria in the gut. 
Microorganisms from the genera Lactobacillus and Bifidobacterium are often 
considered as probiotic candidates. All these bacteria are Gram-positive, 
(facultative) anaerobe microorganisms, that are common commensals in the 
human gastrointestinal tract. These bacteria are currently used in probiotic dietary 
products and several lines of evidence have demonstrated their beneficial effects on 
gut homeostasis [6,16,20,38,44]. In addition, mouse studies have been conducted 
to investigate the immunomodulatory capacity of these potential probiotics, 
with similar findings [18,23,43,46]. These effects range from downregulating cytokine 
responses in immune cells to induction of apoptosis in T cells and vaccine improving 
properties [4,7,8,10,13]. 
Previous studies indicate that the ability of probiotics to induce the secretion 
of various cytokinesis mediated to a large extent by cell wall components [13,25,40]. 
Cell wall components elicit these responses through recognition by pattern 
recognition receptors (PRRs), germ-line encoded receptors expressed on innate 
immune cells that are specialized to bind these bacterial substances. Examples 
of these receptors, either membrane-bound or localized intracellularly, are the 
Toll-like receptors (TLRs), C-type lectin receptors (CLRs, such as dectin-1, mannose 
receptor or DC-SIGN) and nucleotide-binding oligomerization domain (NOD) like 
receptors (NLRs, such as the peptidoglycan receptor NOD2). For the triggering 
of intracellular receptors the process of phagocytosis is required, whereas membrane-
bound receptors detect their ligand on the cell surface and in some cases facilitate 
phagocytosis [2]. Subsequently, downstream intracellular signalling from these 
receptors results in the modulation of cytokine responses [30]. 
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The PRRs that are responsible for the recognition of these strains resulting 
in induction of cytokine responses and activation of the immune system remain 
elusive. Therefore, in the present study the capacity of the bacterial strains 
Blfidobacterium breve (NumRes204) and Lactobacillus rhamnosus (NumResl) and 
L. casei (DN-114 001) to induce immune responses in peripheral blood mononuclear 
cells (PBMCs) has been examined in both healthy volunteers and NOD2 deficient 
Crohn's disease patients. Furthermore, the role of several PRRs of the innate immune 
system that could mediate these immune responses, including TLRs, CLRs and NLRs, 
has been investigated both in human and mouse cells. 
Material and methods 
Subjects 
Healthy volunteers and Crohn's disease patients were recruited at the Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands. The study was 
approved by the Ethical Committee of the Radboud University, and the volunteers 
have given informed consent. At the time of donation, Crohn's disease patients 
homozygous for the NOD2 frameshift mutation were in a quiescent phase, 
i.e. a prolonged period of at least three months of mild disease without relapses 
or exacerbations in the absence of immunomodulatory therapy. Also, they were 
receiving no immunomodulatory or anti-inflammatory medications for the last 
three months. 
Mice 
Wild-type C57BLJ6 mice were obtained from Charles River WIGA (Sulzfeld, Germany) 
GmbH. TLR2 knockout mice and TLR4 knockout mice, with CS7BL/6 background, 
were kindly provided by Dr. S. Akira (Osaka University, Osaka, Japan) [42]. All animal 
experiments were approved by the Animal Experimental Committee of Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands and were performed 
in accordance with institutional and national guidelines. 
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Reagents 
Blocking monoclonal antibodies of the innate immune receptors TLR2 (clone T2.5} 
and DC-SIGN (clone AZND1) including IgG1 isotype control were purchased from 
eBioscience, Coulter Beckman and R&D Systems, respectively, and were all used 
in a concentration of 10 IJg/ml. Blocking reagents of the receptors TLR4 (B. quintana 
lipopolysaccharide, [31], 1 1Jg/ml}, TLR9 (CpG ODN TTAGGG, Invivogen, 25 1Jg/ 
ml}, mannose receptor (mannan, Sigma, 100 IJg/ml), dectin-1 {laminarin, Sigma, 
100 !Jg/ml} and of phagocytosis (cytochalasin B, BIOMOL International, 1 !Jg/ml} 
were used. 
Bacterial fermentation and enumeration 
Two Lactobacillus strains (NumRes1 and DN-114 001) and a Bifidobocterium breve 
strain (NumRes204} were grown at 37°C in a 400 ml reactor containing MRS 
supplemented with 0.5 g/1 L-cysteine for Bifidobocterio. The pH was maintained 
at 6.5 by addition of NaOH. To ensure anaerobic conditions the headspace was 
flushed with N2 or a gas mixture consisting of 5% H:zt 5% C02 and 90% N2 for 
Blfidobacterio. Bacteria were harvested in the early stationary phase, washed in PBS 
and stored with glycerol 20% (w/v), in aliquots at -80°C. Cell counts were determined 
by plating serial dilutions (CFU) and fluorescent microscopy by staining with DAPI. 
PBMC stimulation experiments 
Venous blood was drawn from the cubital vein of healthy volunteers into 10 ml 
EDTA tubes (Monoject). The mononuclear cell fraction was obtained by density 
centrifugation of blood diluted 1:1 in pyrogen-free saline over Ficoii-Paque 
(Pharmacia Biotech, PA, USA). Cells were washed twice in saline and suspended 
in culture medium (DMEM, Invitrogen, CA, USA} supplemented with gentamicin 50 
IJg/ml, L-glutamine 10 mM and pyruvate 10 mM. Cells were counted in a Coulter 
counter (Coulter Electronics) and the number was adjusted to 5 x 106 cells/m I. A total 
of 5 x 105 MNCs in a 100 111 volume were added to round-bottom 96-wells plates 
(Greiner} and incubated with either 100 111 of culture medium (negative control), 
or with B. breve, L. rhomnosus or L. casei (all 107 microorganisms/Well} 
at a ratio of 20:1 (bacterial cells: MNCs) for 24 hours, 48 hours or seven days, alone 
or in combination with one of the above mentioned receptor blockers or inhibitors. 
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Splenocyte stimulation experiments 
Wild-type, TLR2KO and TLR4KO C57BI/6 mice were sacrificed and spleens were 
collected. From each total spleen a cell suspension was made in culture medium 
(IMDM, Invitrogen, CA, USA) supplemented with gentamicin 10 llg/ml, ultraglutamine 
1mM and 9% Foetal Calf Serum. A total of 2 x 106 splenocytes/100 Ill volume were 
added to round-bottom 96-well plates (Greiner) and incubated with either 100 
Ill of culture medium (negative control), or the various bacterial strains: 8. breve, 
L. rhamnosus and L. casei, all in a concentration of 4 x 106 microorganisms/Well 
(bacterial cell : MNCs "' 2:1). After 48 hours of incubation at 3rC, supernatants were 
collected and IFNy detection was performed. A limited amount of cell death was 
observed (but with total viability higher than 90%), and no significant differences 
were seen in cell death between the different bacterial strains 
Transfection and stimulation of TLR2 expressing HEK293 cells 
Stable TLR2 expressing HEK293 cells (Invivogen, CA, USA), containing a NFKB 
luciferase reporter construct (pNIFTY, Invitrogen, CA, USA) were maintained in DMEM 
+ 10% FCS and the appropriate antibiotics. Cells were seeded in 96-wells plates 
and overnight incubated with bacteria at different ratios of cells: bacteria. Luciferase 
activity present in celllysates was determined by detecting chemiluminesence after 
incubation with BriteLite (Perkin Elmer, MA, USA). 
Generation and stimulation of mouse bone marrow derived dendritic cells 
(BMDCs} 
Femurs and tibiae of female 6-12 weeks old C57BL/6 mice were removed and 
purified from surrounding muscle tissue. The protocol used for cell isolation 
and BMDC culture with only GM-CSF was adapted from previous publications 
[21,22]. Modifications were the following. At day 0 cells were plated in Petri dishes 
(Greiner, 10 cm) at 4 x 106 cells per well. The medium contained 20 ng/ml of mouse 
GM-CSF (Peprotech). At day 3, 4 ml of medium was added containing 37.2 ng/ml 
GM-CSF. At day 6 again 1 ml of medium was added, now containing 158 ng/ml 
GM-CSF. Immature DCs were harvested at day 7 and used in the cytokine assay. 
A cell suspension was made (1 x 106 cells/ml) and the cells were plated into 96-well 
plates. To the BMDCs either probiotics (bacterial cell : BMDC = 1:1) or Pam3Cys 
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(41Jg/ml) was added. DCs were incubated with these stimuli either 24 hours 
or 48 hours depending on the cytokine to be measured. 
Cytokine measurements 
Cytokine production capacity was measured by EUSAaccording to the manufacturer's 
protocol. EUSA kits were purchased from R&D Systems (MN, USA) for TNFa.. 
IL-1~ and IL-17, and from Sanquin (Amsterdam, The Netherlands) for IL-6, IL-10 and 
IFNy. Mouse IFNy cytokine production capacity was measured by EUSA according 
to the protocol as reported previously [45]. In brief, MaxiSorp 96-wells plates (Nunc, 
Roskilde, Denmark) were coated with 11Jg/ml purified rat anti-mouse IFNy (capture 
Ab, BD Pharmingen) overnight at 4°C in O.lM carbonate buffer. Plates were washed 
with 0.05% Tween/PBS, blocked with 1% BSA, 1% FCS in PBS for 1 hour at room 
temperature (Rn. Plates were washed and the samples and standards were incubated 
for 1 hour at 3]0C. Subsequently, wells were washed and incubated with 0.5 1Jg/ 
ml biotin-conjugated rat anti-mouse IFNy (Biolegend, clone XMG1.2) in 0.1% BSA, 
0.1%FCS in PBS for 1 hour at RT followed by streptavidin-horseradish peroxidase 
(lnvitrogen) and tetramethylbenzidine substrate (SFRI Laboratories, Berganton, 
France). The reaction was stopped with 2M H2S04, and adsorption was measured 
at 450 nm using a Bio-Rad Multiplate Reader (Bio-Rad Laboratories, Veenendaal, 
The Netherlands). 
Statistics 
Differences in cytokine production capacity between groups were analyzed using 
the Mann-Whitney U test. Differences were considered statistically significant 
at P<0.05. 
Results 
Cytokine produdion capacity of PBMCs induced 
by potentially probiotic strains 
To study the immunostimulatory capacity of the bacterial strains B. breve, 
L rhamnosus and L. case~ PBMCs were stimulated with bacterial cells at a ratio 
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of 20:1,. and cytokines were measured at different time points. Important differences 
were observed between induction of cytokine production by the bacterial 
strains. Most importantly, while all monocyte-derived cytokines can be induced 
by all probiotic strains studied, only Lactobacilli, but not 8. breve, stimulated 
production of IFNy (Figure 1). 
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To study the role of particular PRRs in the cytokine responses induced by the 
bacterial strains, several PRR specific blocking agents were applied to the PBMCs 
before administration of the bacterial strains. Surprisingly, blocking of TLR2 resulted 
in increased production of IL-l~, TNFa and IFNy when cells were stimulated with 
B. breve (Figure 2). However; no differences were observed when TLR2 was blocked 
either in production ofll-6, IL-10 and IL-17 (data not shown) or after stimulation with 
L rhamnosus or L casei (Figure 2). Stimulation of mouse BMDCs with Pam3Cys 
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or either Lactobacillus strain also demonstrated a minor role for TLR2 in recognition 
of these strains (Figure 3A). Accordingly, additional experiments in TLR2 transfected 
HEK293 cells revealed that B. breve but not L rhamnosus or L casei induces TLR2 
signalling (Figure 3B). Blocking of TLR4 had no effect on cytokine production. 
These experiments were also performed with mouse splenocytes, either 
wild-type, TLR2 KO or TLR4 KO. Consistent with the human data, IFNy 
responses in TLR2 KO cells but not in TLR4 KO cells were different compared 
to wild-type cells after stimulation with B. breve (Figure 3C). As compared to 
the human data, the TLR2 KO splenocytes also exhibited a further increase in 
the production of IFNy relative to wild-type splenocytes after stimulation with 
L rhamnosus and L. case~ whereas the TLR4 KO cells did not. Blocking the C-type 
lectin receptors dectin-, mannose receptor and DC-SIGN did not significantly 
influence probiotics induced cytokine production (data not shown). 
Role of intracellular receptors 
Microbial recognition at the level of the cell membrane is complemented 
by pattern recognition in the intracellular compartment, by TLRs (e.g. TLR9) or NLRs 
(e.g. NOD2). Therefore, the role of phagocytosis was studied by using the 
phagocytosis inhibitor cytochalasin B. Cytochalasin B decreased cytokine 
responses for virtually all cytokines, suggesting an important role for intracellular 
recognition receptors (Figure 4). Therefore, the role of intracellular PRRs for 
recognition of these bacterial strains, such as TLR9 and NOD2 were studied. Blocking 
of the TLR9 receptor resulted in a profound decrease in IL-10 and IFNy responses 
after stimulation of cells with either bacterial strain (Figure 5). For the other cytokines 
measured; TNFa.. Il-l~ and IL-6 concentrations revealed no differences between 
the conditions (data not shown). To assess the role of the intracellular PRR NOD2, 
cells from healthy subjects with functional NOD2 were compared with cells obtained 
from Crohn's disease (CD) patients that are homozygous for the 1007fsinsC 
frameshift mutation in NOD2 leading to a loss-of-function of the protein. These 
analyses revealed no apparent differences between the two groups after stimulation 
of these cells with the bacterial strains (Figure 6). 
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capacity to deviate immune responses towards Thl and/or Th17 immune responses 
that are associated with intestinal pathology [32,37,39]. Hence, the potential 
of probiotics as a therapeutic moiety in diseases involving the gastrointestinal tract 
(e.g. infections, inflammatory bowel disease and colon cancer) has been suggested 
[12,33,47]. The rational use of probiotics in health and disease needs however 
a detailed understanding of the recognition pathways that can activate host defence 
by probiotics. 
The potential of probiotics to modulate immune responses may represent 
an important factor for their therapeutic application. In fact, it is known that 
the release of TNFa by inflamed Crohn's disease mucosa can be significantly 
reduced by coculture with L. casei DN-114 001 [5]. More specifically, L. casei can 
counteract the pro-inflammatory effects of E. coli on Crohn's disease inflamed 
mucosa by specific downregulation of key pro-inflammatory mediators [19]. 
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In the present study, we compared the inflammatory properties of three different 
bacterial strains, B. breve NumRes204, L. rhamnosus NumRes1 and L. casei DN-114 
001, that belong to genera that are all widely used strains in dietary products, in their 
capacity to evoke and thereby skew immune responses towards distinct T helper 
mediated responses (i.e. immune deviation}. When compared with Lactobacilli, 
B. breve was less capable of inducing IFNy responses in human primary immune 
cells. The differential stimulation of cytokine production by B. breve and Lactobacilli 
was mediated by differences in recognition by PRRs with either stimulatory 
or inhibitory effects on cytokine responses. 
Specific blocking of particular PRRs enabled us to elucidate what receptors 
are involved in the activation of cytokine production. The first important observation 
was that cytokine induction by both B. breve and Lactobacilli is strongly dependent 
on TLR9. Blocking of TLR9 resulted in severely decreased production of Il-10 
and IFNy, indicating that these bacterial strains contain immune stimulatory 
ds-DNA containing unmethylated CpG sequences. In contrast, no differences 
were observed when the action of other PRRs was inhibited, such as TLR4, dectin-1, 
mannose receptor, DC-SIGN and NOD2, indicating that these receptors have 
a minor role in recognition of the bacterial strains. The role of TLR9 for recognition 
of bacterial [3,14] and fungal [26,34] DNA is well known, however its role in the 
induction of innate immune responses by probiotics in primary human cells has not 
been demonstrated until now. 
In contrast to TLR9, recognition of B. breve by TLR2 had an opposite effect. Blocking 
TLR2 with a specific antibody stimulated cytokine responses induced by B. breve, 
i ncl udi ng TN Fa, IL -1~ and IFNy. Interestingly, no role for TLR2 cou Id be demonstrated 
in L. rhamnosus and L. casei induced cytokine responses, indicating that these 
bacteria either lack TLR2 ligands in their cell wall or, perhaps more likely, that 
potential TLR2 ligands are masked. Of note, also bone marrow derived murine 
dendritic cells, which are highly susceptible to TLR2 agonists, failed to elicit 
noteworthy cytokine responses after exposure to these bacterial strains. 
In addition, data from TLR2 overexpressing human embryonic kidney (HEK293) cells 
containing a NF-KB reporter construct showed NF-KB induction upon incubation 
with B. breve whereas L. rhamnosus and L. casei were unable to do so. To complement 
and support the human data, additional experiments were performed with mouse 
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splenocytes either wild-type or deficient in TLR2 or TLR4. In these experiments, 
IFNy production was increased in TLR2 KO cells but was similar in TLR4 KO cells 
compared to wild-type, which is consistent with the human data. These findings 
suggest that TLR2 induces an intracellular inhibitory signal to downstream 
pathways that elicit cytokine production, such as the TLR9 pathway. Indeed, this 
anti-inflammatory role of TLR2 has been demonstrated before, both in vitro and 
in vivo [1,9,35,36]. Moreover, TLR2 has also been implicated in the induction 
of regulatory T cell responses, further emphasizing the immunosuppressive 
potential of TLR2 signalling [27,28,41]. Also, a Bi{idobaderium strain has been 
shown to be able to induce T regulatory cells [23]. However, it remains to be 
elucidated whether TLR2 is involved in this process, although previously indeed a 
immunoregulatory role ofTLR2 in recognition of pro biotic strains has been described 
[15,17,48]. 
When considering the potential therapeutic applications of these probiotic 
strains, one could draw useful information from the in vitro features of these 
strains. The data presented here suggest that B. breve may be more suitable than 
Lactobacilli in the context of inflammatory bowel diseases (and especially Crohn's 
disease), based on its lower inflammatory potential. Th1 responses, as reflected by 
IFNy production, are poorly induced by B. breve, while they are known to be crucial 
for the pathogenesis of Crohn's disease [24,29] . Beneficial effects of the inhibition 
of IFNy production by B. breve, as compared to e.g. anti-TNFa treatment, 
may result in a tolerant state with decreased Thl immune responses in the gut, 
whereas other (e.g. IL-l~ and TNFa driven) immune pathways remain intact, 
thereby sustaining immunocompetence of the host. However, further in vivo 
studies need to be performed to confirm these findings and to assess its effect 
on relevant animal models, such as experimental colitis. 
In conclusion, the observed differences in the capacity to induce cytokine secretion 
in human primary immune cells between the Bi{idobacterium and Lactobacillus 
strains is most likely due to the differential recognition by TLRs. TLR9 mediates 
proinflammatory signals induced by both B. breve, L. rhamnosus and L. casei. 
In contrast, TLR2 exerts inhibitory effects upon recognition of B. breve, but not 
Lactobacilli. It is to be hoped that these data would contribute to the decision 
for a deliberate choice on what probiotic to use in a given application. 
94 Chapter 4 
Acknowledgements 
This study was performed within the framework of the Dutch Top Institute Pharma 
# Dl-101. 
M.G.N. was supported by a Vici grant of the Netherlands Organization for Scientific 
Research (NWO). We thank Jan Knol and the microbiology team for their input and 
supply of probiotics. 
95Probiotics and immune regulation 
Reference List 
1. Agrawal, S., A. Agrawal, B. Doughty, A. Gerwitz, J. Blenis, Dyke, T. van, and 
B. Pulendran. Cutting edge: different Toll-like receptor agonists 
instruct dendritic cells to induce distinct Th responses via differential 
modulation of extracellular signal-regulated kinase-mitogen-activated 
protein kinase and c-Fos. J. lmmunoL (2003), 171: 4984-4989. 
2. Barton, G. M. and J. C. Kagan. A cell biological view of Toll-like receptor 
function: regulation through compartmentalization. Not. Rev. lmmunol. 
(2009), 9: 535-542. 
3. Bauer, S., C. J. Kirschning, H. Hacker; V. Redecke, S. Hausmann, S. Akira, 
H. Wagner; and G. B. Lipford. Human TLR9 confers responsiveness to 
bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. 
Sci. U. S. A (2001), 98: 9237-9242. 
4. Boge, T., M. Remigy, S. Vaudaine, J. Tanguy, R. Bourdet-Sicard, and Werf, 
S. van der. A probiotic fermented dairy drink improves antibody 
response to influenza vaccination in the elderly in two randomised 
controlled trials. Vaccine (2009), 27: 5677-5684. 
5. Borruel, N., F. Casellas, M. Antolin, M. llopis, M. Carol, E. Espiin, J. Naval, 
F. Guarner, and J. R. Malagelada. Effects of nonpathogenic bacteria on 
cytokine secretion by human intestinal mucosa. Am. J. GostroenteroL (2003), 
98: 865-870. 
6. Braat H., Brande, J. van den, Tol, E. van, D. Hommes, 
M. Peppelenbosch, and Deventer, S. van. Lactobacillus rhamnosus 
induces peripheral hyporesponsiveness in stimulated CD4+ T cells via 
modulation of dendritic cell function. Am. J. Clin. Nutr. (2004), 80: 1618-1625. 
7. Carol, M., N. Borruel, M. Antolin, M. Llopis, F. Casellas, F. Guarner, and J. R. 
Malagelada. Modulation of apoptosis in intestinallymphocytes by a 
probiotic bacteria in Crohn's disease. J. Leukoc. BioL {2006), 79: 917-922. 
8. Christensen, H. R., H. Frokiaer, and J. J. Pestka. Lactobacilli differentially 
modulate expression of cytokines and maturation surface markers in murine 
dendritic cells.J.Immunol. (2002), 168: 171-178. 
96 Chapter 4 
9. Dillon, S., A. Agrawal, Dyke, T. van, G. Landreth, L. McCauley, A. Koh, 
C. Maliszewski, S. Akira, and B. Pulendran. A Toll-like receptor 2 ligand 
stimulates Th2 responses in vivo, via induction of extracellular signal-
regulated kinase mitogen-activated protein kinase and c-Fos in dendritic 
cells. J. lmmunoL (2004), 172: 4733-4743. 
10. Foligne, B., G. Zoumpopoulou, J. Dewulf, V. A. Ben, F. Chareyre, J. C. Sirard, 
B. Pot, and C. Grangette. A key role of dendritic cells in probiotic 
functionality. PLoS. One. (2007), 2: e313. 
11. Gorbach, S. L. Probiotics and gastrointestinal health. Am. 
J. Gastroenterol. (2000), 95: S2-S4. 
12. Hailer, D., J. M. Antoine, S. Bengmark, P. Enck, G. T. Rijkers, and 
I. Lenoir-Wijnkoop. Guidance for substantiating the evidence 
for beneficial effects of probiotics: probiotics in chronic inflammatory 
bowel disease and the functional disorder irritable bowel syndrome. J. Nutr. 
(2010), 140: 6905-6975. 
13. Helwig, U., K. M. Lammers, F. Rizzello, P. Brigidi, V. Rohleder, E. Caramelli, 
P. Gionchetti, J. Schrezenmeir, U. R. Foelsch, S. Schreiber, and M. Campieri. 
Lactobacilli, bifidobacteria and E. coli nissle induce pro- and 
anti-inflammatory cytokines in peripheral blood mononuclear cells. World J. 
Gastroenterol. (2006), 12: 5978-5986. 
14. Hemmi, H., 0. Takeuchi, T. Kawai, T. Kaisho, S. Sate, H. Sanjo, M. Matsumoto, 
K. Hoshino, H. Wagner, K. Takeda, and S. Akira. A Toll-like receptor 
recognizes bacterial DNA. Nature (2000), 408: 740-745. 
15. Hoarau, C., C. Lagaraine, L. Martin, F. Velge-Roussel, and V. Lebranchu. 
Supernatant of Bifidobacterium breve induces dendritic cell maturation, 
activation, and survival through a Toll-like receptor 2 pathway. J. Allergy Clin. 
lmmunoL (2006), 117: 696-702. 
16. Imaoka, A., T. Shima, K. Kato, S. Mizuno, T. Uehara, S. Matsumoto, H. Setoyama, 
T. Hara, and V. Umesaki. Anti-inflammatory activity of probiotic 
Bifidobacterium: enhancement of IL-10 production in peripheral blood 
mononuclear cells from ulcerative colitis patients and inhibition of IL-8 
secretion in HT-29 cells. World J. Gastroenterol. (2008), 14: 2511-2516. 
97Probiotics and immune regulation 
17. Kaji, R., J. Kiyoshima-Shibata, M. Nagaoka, M. Nanno, and K. Shida. Bacterial 
teichoic acids reverse predominant IL-12 production induced by certain 
lactobacillus strains into predominant IL-10 production via TLR2-dependent 
ERK activation in macrophages. J. lmmunoL (2010), 184: 3505-3513. 
18. Kawase, M., F. He, A. Kubota, G. Harata, and M. Hiramatsu. 
Oral administration of lactobacilli from human intestinal tract protects mice 
against influenza virus infection. Lett. AppL Microbial. (2010) 
19. Llopis, M., M. Antolin, M. Carol, N. Borruel, F. Casellas, C. Martinez, E. Espin-
Basany, F. Guarner, and J. R. Malagelada. Lactobacillus casei 
down regulates commensals' inflammatory signals in Crohn's disease 
mucosa./nflamm. BoweL Dis. (2009), 15: 275-283. 
20. Lorea, B. M., P. V. Kirjavainen, S. Hekmat, and G. Reid. Anti-inflammatory 
effects of probiotic yogurt in inflammatory bowel disease patients. Clin. Exp. 
lmmunol. (2007), 149: 470-479. 
21. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, and G. 
Schuler. 1999. An advanced culture method for generating large quantities 
of highly pure dendritic cells from mouse bone marrow. J. lmmunol. Methods 
223:77-92. 
22. Lutz, M. B., R. M. Suri, M. Niimi, A. L. Ogilvie, N. A. Kukutsch, S. Rossner, G. 
Schuler, and J. M. Austyn.lmmature dendritic cells generated with low 
doses of GM-CSF in the absence of IL-4 are maturation resistant and 
prolong allograft survival in vivo. Eur. J. lmmunoL (2000), 30: 1813-1822. 
23. Lyons, A, D. O'Mahony, F. O'Brien, J. MacSharry, B. Sheil, M. Ceddia, W. M. 
Russell, P. Forsythe, J. Bienenstock, B. Kiely, F. Shanahan, and L. O'Mahony. 
Bacterial strain-specific induction of Foxp3+ T regulatory cells is 
protective in murine allergy models. Clin. Exp. Allergy (2010) 40: 811-819. 
24. Matsuoka, K., N. Inoue, T. Sate, S. Okamoto, T. Hisamatsu, V. Kishi, A Sakuraba, 
0. Hitotsumatsu, H. Ogata, K. Koganei, T. Fukushima, T. Kanai, M. Watanabe, 
H. Ishii, and T. Hibi. T -bet upregulation and subsequent interleukin 12 
stimulation are essential for induction of Th1 mediated immunopathology 
in Crohn's disease. Gut (2004), 53: 1303-1308. 
25. Medina, M., E. Izquierdo, S. Ennahar, and Y. Sanz. Differential 
immunomodulatory properties of Bifidobacterium logum strains: relevance 
98 Chapter 4 
to probiotic selection and clinical applications. Clin. Exp. lmmunoL (2007), 
150: 531-538. 
26. Miyazato, A, K. Nakamura, N. Yamamoto, H. M. Mora-Mentes, M. Tanaka, 
Y. Abe, D. Tanno, K. lnden, X. Gang, K. lshii, K. Takeda, S. Akira, S. Saijo, 
Y. lwakura, Y. Adachi, N. Ohno, K. Mitsutake, N. A Gow, M. Kaku, and 
K. Kawakami. Toll-like receptor 9-dependent activation of myeloid 
dendritic cells by Deoxynucleic acids from Candida albicans. Infect. lmmun. 
(2009), 77: 3056-3064. 
27. Netea, M. G., R. Sutmuller, C. Hermann, C. A. van der Graaf, J. W. van der Meer, 
J. H. van Krieken, T. Hartung, G. Adema, and B. J. Kullberg. Toll-like 
receptor 2 suppresses immunity against Candida albicans through induction 
of IL-10 and regulatory T cells. J. lmmunoL (2004), 172: 3712-3718. 
28. Netea, M. G., J. W. van der Meer, R. P. Sutmuller, G. J. Adema, and B. J. Kullberg. 
From the Thl/Th2 paradigm towards a Toll-like receptor/T -helper 
bias. Antimicrob. Agents Chemother. (2005), 49: 3991-3996. 
29. Neurath, M. F., B. Weigmann, S. Finotto, J. Glickman, E. Nieuwenhuis, H. Iijima, 
A. Mizoguchi, E. Mizoguchi, J. Mudter, P. R. Galle, A. Bhan, F. Autschbach, 
B. M. Sullivan, S. J. Szabo, L. H. Glimcher, and R. S. Blumberg. The transcription 
factor T -bet regulates mucosal T cell activation in experimental colitis and 
Crohn's disease.}. Exp. Med. (2002), 195: 1129-1143. 
30. O'Neill, L. A and A. G. Bowie. The family of five: TIR-domain-containing 
adaptors in Toll-like receptor signalling. Nat. Rev. lmmunol. (2007) 7: 353-364. 
31. Popa, C., S. Abdollahi-Roodsaz, L. A. Joosten, N. Takahashi, T. Sprong, 
G. Matera, M. C. Liberto, A. Foca, Deuren, M. van, B. J. Kullberg, 
W. B. van den Berg, J. W. van der Meer, and M. G. Netea. Bartonella 
quintana lipopolysaccharide is a natural antagonist of Toll-like receptor 4. 
Infect. lmmun. (2007), 75:4831-4837. 
32. Powrie, F., M. W. Leach, S. Mauze, S. Menon, L. B. Caddie, and R. L. Coffman. 
Inhibition of Th1 responses prevents inflammatory bowel disease in scid 
mice reconstituted with CD4SRBhi CD4• T cells. Immunity. (1994) 1: 553-562. 
33. Rabot, S., J. Rafter, G. T. Rijkers, B. Watzl, and J. M. Antoine. Guidance 
for substantiating the evidence for beneficial effects of probiotics: impact of 
probiotics on digestive system metabolism. J. Nutr. (2010), 140:6775-6895. 
99Probiotics and immune regulation 
34. Ramirez-Orti:z, Z. G., C. A Specht, J. P. Wang, C. K. Lee, D. C. Bartholomeu, 
R. T. Gazzinelli, and S. M. Levitz. Toll-like receptor 9-dependent immune 
activation by unmethylated CpG motifs in Aspergillus fumigatus DNA. Infect. 
lmmun. (2008), 76: 2123-2129. 
35. Re, F. and J. L. Strominger. Toll-like receptor 2 (TLR2) and TLR4 differentially 
activate human dendritic cells. J. BioL Chem. (2001), 276: 37692-37699. 
36. Redecke, V., H. Hacker. S. K. Datta, A Fermin, P. M. Pitha, D. H. Broide, and 
E. Raz. Cutting edge: activation of Toll-like receptor 2 induces a Th2 
immune response and promotes experimental asthma. J. lmmunol. (2004), 
172: 2739-2743. 
37. Rovedatti, L., T. Kudo, P. Biancheri, M. Sarra, C. H. Knowles, D. S. Rampton, 
G. R. Corazza, G. Monteleone, S. A. Di, and T. T. Macdonald. Differential 
regulation of interleukin 17 and interferon gamma production in 
inflammatory bowel disease. Gut (2009), 58: 1629-1636. 
38. Schultz, M., H. J. Linde, N. Lehn, K. Zimmermann, J. Grossmann, W. Falk, and 
J. Scholmerich. Immunomodulatory consequences of oral 
administration of Lactobacillus rhamnosus strain GG in healthy volunteers. 
J. Dairy Res. (2003), 70: 165-173. 
39. Seiderer, J., I. Elben, J. Diegelmann, J. Glas, J. Stallhofer, C. Tillack, S. pfennig, 
M. Jurgens, S. Schmechel, A. Konrad, B. Goke, T. Ochsenkuhn, 
B. Muller-Myhsok, P. Lohse, and S. Brand. Role of the novel Th17 
cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic 
IL-17F expression in active Crohn's disease and analysis of the IL17F 
p.His161Arg polymorphism in IBD.Inflamm. Bowel. Dis. (2008), 14: 437-445. 
40. Shida, K., J. Kiyoshima-Shibata, M. Nagaoka, K. Watanabe, and M. Nanno. 
Induction of interleukin-12 by Lactobacillus strains having a rigid cell 
wall resistant to intracellular digestion. J. Dairy Sci (2006), 89: 3306-3317. 
41. Sutmuller, R. P., M. H. den Brok, M. Kramer, E. J. Bennink, L. W. Toonen, B. J. 
Kullberg, L. A. Joosten, S. Akira, M. G. Netea, and G. J. Adema. Toll-like 
receptor 2 controls expansion and function of regulatory T cells. J. Clin. 
Invest (2006) 116: 485-494. 
42. Takeuchi, 0., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, 
and S. Akira. Differential roles of TLR2 and TLR4 in recognition of 
100 Chapter 4 
gram-negative and gram-positive bacterial cell wall components. Immunity. 
(1999), 11: 443-451. 
43. Vidal, M., C. Forestier, N. Charbonnel, S. Henard, C. Rabaud, and 0. Lesens. 
Probiotics and intestinal colonization by vancomycin-resistant enterococci 
in mice and humans. J. Clin. Microbiol. (2010), 48: 2595-2598. 
44. Wada, M., S. Nagata, M. Saito, T. Shimizu, Y. Yamashiro, T. Matsuki, T. Asahara, 
and K. Nomoto. Effects of the enteral administration of 
Bifidobacterium breve on patients undergoing chemotherapy for pediatric 
malignancies. Support. Care Cancer (2010), 18:751-759. 
45. Wang, H. B., F. D. Shi, H. Li, B. J. Chambers, H. Link, and H. G. Ljunggren. 
Anti-CTLA-4 antibody treatment triggers determinant spreading and 
enhances murine myasthenia gravis. J. lmmunoL (2001), 166: 6430-6436. 
46. Weiss, G., S. Rasmussen, F. L. Nielsen, H. Jarmer, N. B. Nohr, and H. Frokiaer. 
Bifidobacterium bifidum actively changes the gene expression profile 
induced by Lactobacillus acidophilus in murine dendritic cells. PLoS. One. 
(2010), 5: e11065. 
47. Waivers, D., J. M. Antoine, E. Myllyluoma, J. 5chrezenmeir, H. Szajewska, and 
G. T. Rijkers. Guidance for substantiating the evidence for beneficial 
effects of probiotics: prevention and management of infections by 
probiotics. J. Nutr. (2010), 140: 6985-7125. 
48. Zeuthen, L. H., L. N. Fink, and H. Frokiaer. Toll-like receptor 2 and 
nucleotide-binding oligomerization domain-2 play divergent roles in the 
recognition of gut-derived lactobacilli and bifidobacteria in dendritic cells. 
Immunology (2008), 124: 489-502. 
101Probiotics and immune regulation 

Multifaceted effects of synthetic TLR2 ligand 
and Legionella pneumophilia on Treg-mediated 
suppression ofT cell activation 
Wendy W.C. van Maren1 
Stefan Nierkens1 
Liza W. Toonen1 
Judith M. Bolscher-2 
Roger P.M. Sutmuller12* 
and Gosse J. Adema'* 
1 Department of Tumor Immunology, N~megen Centre for Molecular Life Sciences, Radboud University N~megen Medical Centre, 
Nijmegen, the Netherlands 
' Schering-Piough Research Institute, Target Discovery Oss, Molenstraat 110, 5340 BH Oss, The Netherlands 
* shared last author 
BMC Immunology (2011), 12:23-35 
104 Chapter 5 
Abstract 
Background: Regulatory T cells (Treg) play a crucial role in maintaining immune 
homeostasis and self-tolerance. The immune suppressive effects of Tregs should 
however be limited in case effective immunity is required against pathogens 
or cancer cells. We previously found that the Toll-like receptor 2 (TLR2) agonist, 
Pam3CysSK4, directly stimulated Tregs to expand and temporarily abrogate their 
suppressive capabilities. In this study, we evaluate the effect of Pam3CysSK4 
and Legionella pneumophila, a natural TLR2 containing infectious agent, on effector 
T (Teff) cells and dendritic cells (DCs) individually and in eo-cultures with Tregs. 
Results: TLR2 agonists can directly provide a eo-stimulatory signal inducing 
enhanced proliferation and cytokine production of naive CD4+ Teff cells. 
With respect to cytokine production, DCs appear to be most sensitive to low 
amounts ofTLRagonists. Using wild type and TLR2-deficient cells in Treg suppression 
assays, we accordingly show that all cells (e.g. Treg, Teff cells and DCs) contributed 
to overcome Treg-mediated suppression of Teff cell proliferation. Furthermore, while 
TLR2-stimulated Tregs readily lost their ability to suppress Teff cell proliferation, 
cytokine production by Teff cells was still suppressed. Similar results were obtained 
upon stimulation with TLR21igand containing bacteria, Legionella pneumophila. 
Conclusions: These findings indicate that both synthetic and natural TLR2 agonists 
affect DCs, Teff cells and Treg directly, resulting in multi-modal modulation 
of Treg-mediated suppression of Teff cells. Moreover, Treg-mediated suppression 
of Teff cell proliferation is functionally distinct from suppression of cytokine 
secretion. 
105Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophifia 
Background 
The immune system is of crucial importance to our health and survival. Faced with 
pathogenic threats from outside as well as the rise of cancer cells from within, 
our immune defense must be able to cope with very diverse opponents. Mammals 
have developed a diverse set of receptors that sense components derived from 
pathogens and damaged cells. Amongst the best studied receptors are the so called 
pattern recognition receptors (PRR) like the Toll-like receptor (TLR) family, RIG-1-
Iike receptor (RLR) family and the NOD-like receptor (NLR) family of proteins [1]. 
In general, engagement of these receptors on immune cells results in their activation, 
like enhanced antigen presentation, inflammatory cytokine production and the 
acquisition of immune effector function [2]. 
Pathogen recognition through specific TLRs can be of crucial importance 
for the induction of protective immunity. For instance, TLR4-deficient mice 
are more susceptible for infections with Neisseria meningitidis, E. coli, Haemophilus 
influenzae, Salmonella enteritidis, and Klebsiella pneumonia [3]. In this regard, 
the immunological effects of TLR2 ligation are remarkably different compared to 
the other TLRs (reviewed by Netea et al [3]). Firstly, TLR2 has been reported to direct 
the broadest repertoire of danger-associated molecular patterns from a large variety 
of pathogens, including gram-positive and gram-negative bacteria, fungi, viruses, 
and parasites, but also endogenous proteins like Heat Shock Protein 60 (HSP60} 
[4]. This broad range of recognition may be explained by the heterodimerization 
of TLR2 with either TLRl or TLR6. However; the recent publication of the TLRl/2 
receptor-ligand crystal structure [5], in combination with the extremely high affinity 
of TLR2 for its lipoprotein ligands [6], increases the possibility that a number 
of putative TLR2-Iigands have no intrinsic TLR2-activating capacities but were 
actually contaminated by lipoproteins [6]. Secondly, TLR2-deficient mice are less 
susceptible to lethal infections with Aspergillus fumigatus, Yersinia enterocolitica 
or Candida albicans, which is in contrast with e.g. TLR4-deficient mice [7]. In TLR2-
deficient mice, resistance to C. albicans is mediated by a stronger Thl response due 
to diminished production of IL-10 during the infectious challenge [8]. The distinct 
roles of TLR2 and TLR4 in immunomodulation was further emphasized by findings 
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that TLR2-deficient mice experienced increased joint inflammation in preclinical 
rheumatoid arthritis (RA) models, while TLR4-deficient mice were more resistant 
[9]. Interestingly, the enhanced immunological responses in TLR2-deficient mice 
correlate with decreased numbers of Tregs in these mice [8]. Moreover, C. albicans 
induced proliferation and survival of Tregs in a TLR2-dependent manner [8]. 
Different types of Tregs have been characterized and these Tregs are indispensable 
for the maintenance of immunologic self-tolerance and immune homeostasis 
[10]. The naturally occurring CD25+CD4+FoxP3+ Tregs are generated in the thymus 
and constitute about 5-15% of the peripheral CD4+ T cells in healthy animals and 
humans [11-13]. Once naturally occurring Tregs are activated via TCR-triggering, 
they are able to actively suppress the function of multiple immune cells, such as 
CD4+CD25- effector T cells (Teffs) and antigen presenting cells (APCs). Although 
these activities are essential for maintaining tolerance and preventing autoimmunity, 
their suppressive capacity may interfere with the development of a potential 
anti-tumor/anti-pathogen immune response, implicating the need for a mechanism 
that regulates Tregs. We recently demonstrated that TLR2 triggering on Tregs 
by Pam3Cys in combination with T -cell receptor (TCR) activation resulted 
in proliferation of the otherwise non-proliferating Tregs and, importantly, 
the temporal abrogation of their suppressive capabilities [14]. After a resting period, 
the Tregs regain their suppressive, non-proliferative phenotype, indicating this 
is a reversible process. 
Since TLR2 is widely expressed in immune cells, we now investigated 
the consequences ofTLR2-signaling on different immune subsets involved in adaptive 
immune responses; APCs, Teffs and Tregs. We found increased TLR2 expression 
on activated immune cells. Interestingly, although TLR2 triggering abrogated 
Treg-mediated suppression of Teff cell proliferation, TLR2 triggering was unable 
to restore effector cytokine secretion. In addition, we show that Pam3Cys acts 
on Tregs, Teffs and APCs to reverse the suppressive effects of Tregs. Similar results 
were found with the pathogen Legionella pneumophila (HKLP) containing potent 
TLR2 ligands [15-17], emphasizing the crucial role of TLR2 in immunomodulation 
in infections. 
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Methods 
Mice 
The wildtype C57BL/6 mice were obtained from Charles River WIGA (Sulzfeld, 
Germany) Gmbh. TLR2 knockout on CS7BLJ6 background mice were kindly obtained 
from S. Akira (Osaka University, Osaka, Japan). All animal experiments were approved 
by the Animal Experimental Committee of Radboud University Nijmegen Medical 
Centre and were performed in accordance with institutional and (inter)national 
guidelines. 
Antibodies and flow cytometry 
Directly labeled monoclonal antibodies used for staining by anti-CD4-APC 
or -FITC (clone L3T4), anti-CD25-FITC or -PE (clone 7D4), anti-CDllc-FITC (HL3), 
anti-Streptavidin-PerCp, and their isotype controls were obtained from 
BD Biosciences - Pharmingen. Anti-mTLR2-biotine (clone T2.5), anti-mFoxP3-biotine 
(clone FJK-165) and the isotype control were obtained from eBioscience. Analysis 
of cell surface markers on lymphocytes was performed using FACScalibur (BD) 
and CELLQuest software (version 3.3; BD Biosciences - Pharmingen). 
T cell purification and analysis 
Spleens from wildtype or TLR2 knockout mice were mashed and filtered, and CD4+ 
T cells were purified using anti-mouse-CD4 Microbeads (MACS, Miltenyi Biotec), 
resulting in a enriched CD3+CD4+ T cell population. Naive CD4+CD251ow Teff cells and 
naive CD4+CD2Shigh Treg cell subsets were obtained by flow cytometry purification 
of the pre-sorted CD4+ T cells; CD4 cells were stained with me-conjugated CD4 
mAb (BD bioscience, clone L3T4) and PE-conjugated CD25 (BD biosciences, clone 
7D4). Cell sorting was performed on a Coulter Altra HyPerSort cell sorter. Both 
naive CD4+CD2Siow T cells and naive CD4+CD2Shigh T cells were 98% pure, based 
on CD25 expression pattern. Determining the purity by using biotinilated-FoxP3 
Ab (eBiosciences, done FJK-165) and streptavidine-PerCp Ab (BD bioscience) showed 
that from the CD25high FACSsorted cells, 67% of the cells were FoxP3+, therefore 
Tregs. Sorted cells were used directly in several assays or kept in culture as described 
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below. After several weeks of culture the purity of the Treg cell line as well as the Teff 
cell line (referred in this paper to the cultured Tregs or cultured Teff cells) was 96% 
or higher (see Additional file 2). 
Treg and Teff cell culture and suppression assay 
FACS-sorted purified CD4+CD25+ T cells and CD4+CD2S- T cells are kept in culture for 
several weeks. Each cell-line is cultured in 104 cells per well of a 96-well plate, and 
were stimulated weekly with 5*1()4 irradiated CD4-MACS bead depleted splenocytes 
per well, in 2 IJg/ml Pam3Cys (EMC microcollections, Germany), 1 IJg/ml anti-CD3 
(145-2Cll; BD Biosciences - Pharmingen), and 120 IU (international units) IL-2/ 
ml complete medium. The cells were washed 3 days after each stimulation and 
maintained in culture medium supplemented with 120 IU IL-2/ml. When necessary, 
dead cells were removed by ficoll density gradient. Cultured Tregs or Teff cells were 
used in assays at least 6 days after stimulation, in this case the Tregs and Teff cells 
are in a resting state when used in all assays. 
Suppression assays were performed as follows; freshly sorted (wildtype or TLR2 
knockout) CD4+CD2S- naive T cells (20*103 per well) and either cultured or freshly 
isolated (wildtype or TLR2 knockout) Tregs (20*103 per well) were mixed and 
cocultured for 3 days with 20*103 irradiated (wildtype or TLR2 knockout) APCs 
per well. If indicated, the T cells were stimulated with TLR ligand Pam3Cys (SiJg/ 
ml, EMC microcollections GmbH) or HKLP (106-109CFU/ml of heat-killed Legionella 
pneumophila; InvivoGen) with or without soluble anti-CD3 (1 IJg/ml, 145-2Cll; 
BD Biosciences - Pharmingen) in complete medium. After 3 days of coculture, 
supernatant was collected for cytokine analysis. In addition, the suppression 
of proliferation was monitored by analyzing the CFSE-Iabeled (11JM) freshly sorted 
(wildtype or TLR2 knockout) CD4+CD2S- naive T cells. CFSE fluorescence intensity 
was measured by flow cytometry. 
Calculation of suppression 
The amount of suppression is calculated by the amount of proliferation or cytokine 
production. In each assay we include 5 conditions (see Additional file 3) by which we 
calculate the suppression, using the mean fluorescent intensity of the CFSE-Iabeled 
Teff cells. The first condition (background) is a coculture of CFSE-Iabeled Teff cells, 
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APCs and anti-CD3 stimulation (lj.Lg/ml). This condition indicates the level of Teff 
cell proliferation induced by anti-CD3 in the presence of APC. The second condition 
(0% suppression) is a coculture of CFSE-Iabeled Teff cells, APCs, anti-CD3 stimulation 
(lj.Lg/ml) and Pam3Cys (concentration used between 10 to 0.01j.Lg/ml). This condition 
represents maximum of Teff cell proliferation. The next condition consists of 
a coculture of CFSE-Iabeled Teff cells, APCs, Tregs and anti-CD3 stimulation (lj.Lg/ 
ml), which is used to achieve maximal suppression (set to 100% as a reference). 
The last condition consists of a coculture of CFSE-Iabeled Teff cells, APCs, Tregs, anti-
CD3 stimulation (lj.Lg/ml) and Pam3Cys (concentration used between 10 to O.Olj.Lg/ 
ml), indicated as 'x% suppression'. This x% suppression is calculated by the following 
formula; ((MFI x% - MFI 0%)*100)/(MFI max - MFI 0%). For all data presented the 
difference between the 0% suppression and max suppression was at least 150 
in MFI. In the case of cytokine production, we used the same formula with amount 
of cytokines produced as principle parameter. 
Cytokine measurements 
For the detection of cytokines in culture supernatant we used the Mouse Thl/Th2 
Bio-Piex Cytokine Assay (#171-F11081, Bio-Rad, Hercules, CA). All procedures were 
performed according to the manufacturer's instructions. 
Proliferation assay 
Freshly FACS-sorted or cultured CD4+CD25+Treg and CD4+Tconv cells were cultured 
for 4 days with a range of Pam3Cys concentrations (between Oj.Lg/mi-Sj.Lg/ml) 
or HKLP (l06-l09CFU/ml of heat-killed Legionella pneumophila; InvivoGen) with 
or without soluble CD3 stimulation (l!Jg/ml). After 4 days the proliferation 
was measured by overnight (20 hours) thymidine incorporation. 
Statistical analysis 
The data are analysed using a one-way ANOVA test to test the differences between 
groups (PRISM software version 4.0; GraphPad, San Diego, CA, USA). Statistical 
significance is inferred at P<O.OS. Significant differences are indicated with 
an asterisks (*). 
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Results 
TLR2 expression and effects on Treg, Teffs and DCs 
To decipher the role of TLR2 in immune responses in more detail, the expression 
and function of TLR2 on CD4•CD25•Foxp3... Tregs, CD4• Teffs and DCs 
were studied. Expression ofTLR2 is readily detected on the cell surface offreshly isolated 
DCs (Figure lA), while expression on freshly isolated CD4+ Teffs and Tregs is low 
or absent (Figure lA). In line with the data from Liu et al. [18], TLR2 expression 
is up-regulated upon activation of these T cells (data not shown), and both CD4 ... 
T cell populations continue to express TLR2 when cultured for several weeks 
with CD3 and Pam3Cys (Figure lB). 
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Since the expression of TLR2 on these 
T cell subsets seems to be affected by their 
activation state, we investigated how TLR2 
expression correlated to the functional 
responsiveness of DCs, Teffs and Tregs to the 
TLR2 ligand Pam3Cys. As shown in Figure 2, 
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Figure 1. TLR2 expression profile 
on fresh and cultured immune 
cells. (A) Dendritic cells (CDllc•), 
CD4•CD2S•Foxp3• Treg and CD4•effector 
T cells (Foxp3·) were isolated from 
spleens of naive mice and immediately 
analyzed for TLR2 surface expression 
by flow cytometry (grey line, isotype 
control; black line, TLR2 antibody). TLR2 
is expressed on freshly isolated DCs, while 
expression on Teff and Treg is absent or 
low. (B) Treg and Teff were cultured in 
the presence of Pam3Cys, anti-CD3 and 
irradiated splenocytes as APCs for several 
weeks (see materials and methods). 
Activation induced TLR2 expression 
on both Treg and Teff which remained 
high when cultured for several weeks. 
Representative results of 3 independent 
experiments are shown, all experiments 
were performed in duplicate. 
both freshly isolated Tregs and naive Teffs showed enhanced proliferation after 
CD3 stimulation in the presence of increasing amounts of TLR2-Iigand, indicating 
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Pam3Cys eo-stimulated these T cells. In the absence 
of CD3 stimulation, no proliferation was observed on 
either Teffs or Tregs (data not shown), which is in line with 
the absence of TLR2 up-regulation on these cells. Analysis 
of the cultured CD4+ T cell subsets revealed that only 
the cultured Tregs, not the cultured Teff cells, remained 
responsive towards TLR2 stimulation. This finding 
Figure 2. Eft'ectofPam3Cys 
titration on proliferation 
of fresh versus cultured 
TregsandTeffcells. Teffand 
Treg were freshly isolated 
from spleen or cultured for 
weeks and stimulated with 
different concentrations of 
Pam3Cys in the presence 
of 11lflfml anti-CD3. After 
4 days proliferation was 
determined using thymidine 
incorporation (relative 
expression compared to anti-
CD3 alone). The condition 
without Pam3Cys is set to 
1 and the conditions with 
Pam3Cys are related to this 
condition. The absolute cpm 
levels of the cells with (Sugf 
ml) and without Pam3Cys 
are for cultured Teffs 
13383cpm vs 7456cpm, 
for fresh Teffs 31076cpm 
vs 6693cpm, for fresh Treg 
15590cpm vs 3776cpm, and 
cultured Treg 16642cpm vs 
4936cpm. Freshly isolated 
Tregs and Teff cells showed 
increased proliferation upon 
TLR2 stimulation, while 
only cultured Tregs (not 
cultured Teff) remained 
sensitive to TLR2 triggering. 
Representative results of 3 
independent experiments 
are shown. The error 
bars represent standard 
deviations of triplicate 
measurements. 
is consistent with our current understanding that primed Teff cells become less 
dependent on eo-stimulatory signals, as has been described for CD28 stimulation. 
TLR2-triggering was also highly effective in eo-stimulating cytokine secretion 
in CD3-activated, freshly isolated Teff cells (Figure 3). They predominantly produced 
IL-2, IL-10, IL-4 and IFNy, and cytokine production was gradually increased with 
increasing Pam3Cys concentrations. As expected, freshly isolated Tregs did not 
produce any detectable levels of these cytokines (data not shown). Also the in vitro 
expanded Tregs did not produce any cytokines while the in vitro cultured Teff cells 
{Figure 3) already produced high amounts of cytokines in the absence of Pam3Cys 
(i.e. only in the presence of anti-CD3). Adding increasing amounts of Pam3Cys 
to these Teff cells did not significantly affect cytokine production. 
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Figure 3. Cytokine production of Tetfs upon TLRZ-triggering. Freshly isolated and cultured Teff were 
stimulated with anti-CD3 and increasing concentrations of Pam3Cys. Fresh Teff were additionally cultured 
in the presence of irradiated APCs that did not produce these cytokines upon stimulation (data not shown). 
Freshly isolated Teff showed a clear dose dependent increase in IL-2, IL-4, IL·lO and IFNy. Cultured Teff cells 
produced high amounts of cytokines in the absence of Pam3Cys and failed to show a clear effect ofPam3Cys. 
All cytokine profiles were determined by Luminex analyses. Representative results of 2 independent 
experiments are shown, all experiments were performed in duplicate. 
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Figure 4. Cytokine production ofDCs upon TLR2-triggering. 
Production of IL-6, IL-12, IL-10 and IL-8 by DCs after stimulation with Pam3Cys. 
All cytokine profiles were determined by Luminex analyses. Representative results 
of 2 independent experiments are shown, all experiments were performed 
in duplicate. 
Analysis of Pam3Cys-stimulated DCs indicated that they readily produce 
multiple cytokines, including high amounts of Il-6 and Il-12p40 (Figure 4). 
Maximal cytokine production by DCs already reaches a plateau at relatively 
low amounts of Pam3Cys (0.1 ~g/ml). Overall, the TLR2-induced cytokine 
profiles of the freshly isolated Teff cells and the DCs nicely correlate with 
a cytokine profile needed for the induction of an immune response 
[19, 20-22]. Collectively, these results show that Tregs, DCs as well as Teffs can express 
functional TLR2. DCs are most capable of sensing low amounts of TLR2 ligand. 
In agreement with the current understanding that activated Teff cells are 
less dependent of (co-)stimulation, we show that they are less sensitive 
to TLR2 eo-stimulation than naive Teff. In contrast, Treg remain relatively 
unresponsive to TCR stimulation and rely on eo-stimulation in order 
to enter a proliferative state. 
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Effect of TLR2 triggering on Treg function 
Recently, we as well as others reported that triggering of TLR2 on murine Tregs 
with a relatively high dose of Pam3Cys in combination with TCR signaling induced 
significant proliferation in the otherwise non-proliferative Treg subset [14,18]. 
Strikingly, Treg proliferation was accompanied by a temporal loss of the ability 
of the Tregs to suppress the proliferation of the Teff cells. To analyze the effects 
of TLR2 on Treg function in more detail, we titrated increasing concentrations 
of the TLR2-Iigand Pam3Cys in a suppression assay and determined its impact 
on Teff cell proliferation and on cytokine production, using CFSE-Iabeled TLR2-
deficient Teff cells eo-cultured with wildtype Tregs. In contrast to 3H-tritium-
Thymidine incorporation assay, the use of CFSE-Iabeled Teff cells allows to 
distinguish between Treg and Teff proliferation. As shown in figure SA (representative 
raw data are shown in Additional file 1}, very low TLR2-Iigand concentrations 
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FigureS. TLRZ triggeriDgeffeas Tregsuppression. (A) Suppression 
assays were performed with wild type Treg and TLR2·deficient Teff 
in the absence or presence of Pam3Cys, in which the read-out is Teff 
cell proliferation. Pam3Cys inhibited Treg-mediated suppression in a 
dose-dependent manner. (B) Analysis of the effect ofPam3Cys on IL-2, 
IL-4, IL-10 and IFNy cytokine production. Increasing concentrations 
of Pam3Cys did not restore cytokine production (nd, not detectable). 
Data representative of 2 experiments are shown. The error bars 
represent standard deviations of duplicate measurements. 
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( <0.21Jg/ml) hardly affected the Treg mediated suppression of Teff proliferation. 
In line with our previous results, a higher dose of TLR2-Iigands (>21Jg ml) induced 
a clear loss of Treg suppressive activity as reflected by increased Teff proliferation. 
The addition of Tregs to the Teff cell cultures blocked proliferation as well as 
cytokine production. In contrast to its effect on proliferative capacity, the addition 
of Pam3Cys to these cultures failed to restore cytokine production by Teffs 
(Figure 5B). These results indicate that with respect to Treg mediated suppression 
of Teff cells, suppression of proliferation and suppression of cytokine production 
should be regarded as two separate events. 
Effect of TLR2 triggering on immune cell subsets 
on Treg mediated immune suppression. 
To determine the contribution of TLR2 triggering on the different cell types 
present in a suppression assay (Tregs, Teffs and APCs), we performed suppression 
assays combining cells isolated from TLR2-deficient mice and wildtype mice. 
This setup ensures that any of the observed effect of the TLR2-Iigands is mediated 
through TLR2 triggering on the cells purified from the wildtype mice. We focused 
on Treg-mediated suppression of Teff proliferation as the read out system. 
TLR2 triggering on wildtype Tregs in the presence of TLR2-deficient Teff and 
APC resulted in a 57% reduction in the suppression of Teff cell proliferation 
(Figure 6A). Similarly, TLR2-signaling on Teffs (TLR2-deficient Tregs and DCs) 
or DC (TLR2-deficient Teff and Treg) inhibited Treg-mediated suppression to 55% 
and 65% respectively. A similar level of reduction in suppression was also 
observed when all cells were derived from wildtype origin Control suppression 
assays performed with only TLR2-deficient cells demonstrated the specificity 
of the TLR2-effect (Figure 6B). These data thus demonstrate that TLR2 is important 
in controlling activation of immune cells and that TLR2 acts on each of the three cell 
types present in the suppression assay; Tregs, Teffs and APCs. 
Effect of Legionella pneumophila on immune cell 
proliferation, cytokine production and Treg suppression 
So far, the experiments were performed with the synthetic TLR2 ligand Pam3Cys. 
We repeated these experiments with the natural pathogen Legionella pneumophila, 
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Figure 6. Tree suppressloo assay usiDg wUdtype and TLR·Z knockout 
cell types. (A) Suppression assays were performed with different 
combinations of wilcltype and TLR2· deficient Treg. Teff or APCs. In eac:h 
experiment only one of the three cell types was derM!dfrom wtld typemfce 
and thus able tD respond to Pam3Cys. Data sbow that Pam3Cys released 
Treg·mediated suppression In every condition and hence affected all cell 
types direc:tly. (B) Suppression assays with all cells being either TLR2 
lmockout or wlldtype show maximal suppresston and mmmaJ. release 
&om Treg media~d suppression, respectively. Represemative results 
of2 experiments are showu. The error bars represent standard devl.atfons 
of duplicate measurements. 
Chapter 5 
which is known to contain high amounts of TLR2 ligands [23]. As shown in Figure 
7, the proliferative capacity of the cultured Teff cells and Tregs were similar to the 
data found with Pam3Cys. The cultured Teff cells were hardly responsive to the HKLP, 
and this did not change upon increasing pathogen concentration. The naive CD4• 
Teff cells were highly responsive to HKLP in a dose-dependent manner. Both freshly-
isolated and cultured Teff produced IFN-y upon HKLP stimulation (Figure 8). 
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Figure 7. Effect of HKLP titnltion on proliferation of fresh versus 
cultured Tell cells and cultured Tregs. Cells were stimulated with 
different concentrations of HKLP in the absence or presence of anti-
COl. After 4 days proliferation was detennined by analyses of thymidine 
incorporation (A) or CFSE dilution, displayed as MFI values (B). Cultured 
Treg proliferated in response to HKLP in a dose-dependent manner. 
Freshly isolated Teff also slightly responded to HKLP, while no effects 
were observed In cultured Te!'f. Representative results of 3 Independent 
experiments are shown. The error bars represent standard deviations of 
duplicate measurements. 
Fresh Teffs 
To further investigate the effect of HKLP on Treg, suppression assays 
were performed. The results shown in Figure 9 indicate that HKLP abrogated 
the Treg-mediated suppressive capacity even in conditions where Tregs are the 
only TLR2 expressing cells. These data imply that the immune modulatory effect 
of Pam3Cys can be mimicked by a natural pathogen containing high amounts of 
TLR2 ligand. It is likely that during normal infections of Legionella pneumophila 
the suppressive capacity of the Tregs can at least in part be abrogated by directly 
acting on the Tregs themselves. 
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Figure 8. IFNy 
cytokine production 
by HKLP sdmuladon. 
Cultured Teff cells and 
freshly isolated Teff 
cells were stimulated 
with 109 CFUfml HKLP 
in the absence or 
presence of anti-CD3. 
Representative results 
of 2 independent 
experiments are 
shown. The error bars 
represent strndard 
deviations of duplicate 
measurements. 
Figure9. Tregsuppressionwith 
HKLP sdmuladon. Suppression 
assays were perfonned with 
two combinations of wildtype 
and TLR2-deficient cells. When 
all cells were from wildtype 
mice both Pam3cys and HKLP 
inhibited Treg-mediated 
suppression (left panel). Similar 
results were obtained when 
TLR2-deficient Teff and APC 
were cultured in the presence 
of wildtype Treg. indicating 
that HKLP acted on the Treg 
themselves. Representative 
results of 2 experiments are 
shown. The error bars represent 
standard deviations of duplicate 
measurements. 
The complexity of signals received and produced by our immune system 
has puzzled immunologist for many years. The re-discovery of the suppressor T cells 
mostly indicated as Tregs has increased our comprehension of immunity in health 
and disease. In immune homeostasis, immune activation events are kept in balance 
by many regulatory mechanisms like suppressors of cytokine signaling (SOCS), 
CTLA-4, suppressive cytokines like IL-10 and TGF-~, and importantly Tregs. However 
during infections, strong immune activation signals are released, including a set 
of pathogen-associated molecular patterns. These pathogen derived determinants 
are able to induce the activation of amongst others TLRs, one of the main 
families of receptors involved in pattern recognition. This will result in a strong 
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inflammatory immune response capable of dealing with the pathogenic challenge. 
More recently, TLR agonists have been shown to also act directly on Treg and 'lift' the 
suppressive pressure on other immune cells. We demonstrated that TLR2 triggering 
on Tregs in combination with TCR signaling induces proliferation of the Tregs and 
reduces their suppressive capacity [14]. Similar data were later reported by Liu et al. 
[18]. Recently Oberg et al. [24], examined the influence of different TLR2 ligands 
on human Tregs. They show similar results for75% of the used human donors, namely 
direct abrogation of the Treg suppressive capacity. They also observed individual 
differences in efficacy between different TLR2 ligands. Above all, Zhang et al. [25] 
currently tested the abrogation of Treg-mediated suppression in an in vivo turner-
bearing mouse model. They report that injection of the mice in combination with 
pretreatment of the Treg cells with Pam3Cys, induces a marked reduction of Treg 
cells in the lymph nodes and a diminished suppressive activity of the remaining Tregs 
present in these mice. On the contrary, another researcher group has published that 
TLR2 does not abrogate the Treg suppressive function [26]. The different findings 
might be explained by the difference in model systems, cell sources, experimental 
setups and as described by Oberg et al. [24] the expression pattern of TLR1/TLR2. 
The loss of suppression by TLR2 triggering on Treg facilitates the induction ofadaptive 
immune responses. At the same time, TLR2-stimulated Tregs expand and have been 
suggested to limit excessive tissue pathology and to prevent potential autoimmune 
events once the pathogen is efficiently cleared. To further assess the role of TLR2, 
we investigated the effects of TLR2 stimulation on Treg and other immune cells 
known to be involved in the adaptive immune response; Teffcells and the professional 
antigen presenting DCs. Freshly isolated splenic DCs express TLR2, but the freshly 
isolated Tregs and Teffcells only express TLR2 upon activation. Interestingly, all freshly 
isolated cells respond to the TLR2-Iigand Pam3Cys, however after in vitro culturing, 
only the Tregs remained responsive to TLR2-stimulation in lower concentrations. 
TLR2 on naive Teff cells enhanced Teff cell proliferation indicating that TLR2 acts 
as a eo-stimulatory signal, similar to CD28. Cultured Teff cells did not seem 
to respond to TLR2 triggering. These data are in line with the idea that primed 
Teff cells are less dependent on eo-stimulation by TLR2, similar to eo-stimulation 
by CD28, though the anergic Treg subset requires more than TCR triggering alone 
in order to enter a state of proliferation. 
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When analyzing the effects ofTLR2-stimulation ofTregs in more detail, we observed 
a difference between suppression of proliferation and suppression of cytokine 
production by the Treg. Interestingly, TLR2-treated Treg still suppressed cytokine 
secretion, but lost their ability to suppress the proliferation of Teff cells. Apparently, 
the process of suppression of cytokine secretion is different from that of suppression 
of proliferation. This is in line with data of Shevach et al. showing that mature DCs 
abrogated Treg-mediated suppression of left cell proliferation, while cytokine 
secretion was still suppressed [10]. Moreover; DCs stimulated the proliferation 
of Treg, similar as observed after TLR2 stimulation. It remains intriguing why such 
highly different signals (TLR2 versus mature DCs) would yield similar phenotypes 
in the Tregs. One possibility would be that the Tregs require a certain threshold 
of eo-stimulatory signals. Indeed, it has been shown that TLR2 can substitute 
for CD28 with respect to eo-stimulatory signals required forT cell stimulation [21]. 
Once the combination of eo-stimulatory signals and TCR triggering is sufficient, 
the Treg will suppress only cytokine secretion by Teff and will start to proliferate 
themselves. Why would Treg allow Teff proliferation whilst inhibiting Teff cytokine 
production? Possibly cytokine secretion is a far more dangerous effector mechanism 
as compared to Teff proliferation. 
Since TLR2 effected suppression of proliferation, we addressed the effects of TLR2 
on each of the cellular subsets present during the suppression assay. Our results 
show that TLR2 can abrogate the suppression of proliferation by acting on each 
subset being Treg, Teff or DC. TLR2 triggering on Treg induces their proliferation 
and temporal inhibition of their suppressive capacity, while on Teff cells TLR2 
has a co-sti mu latory role. TLR2 triggering on DCs resu Its in the production of cytokines 
like IL-6 that have been shown to release Teff from Treg mediated suppression 
[27]. We examined IL-6 production in our eo-culture experiments combining Teffs, 
Tregs and DCs for wild type and TLR2-knock out origin (data not shown). Although 
the presence of IL-6 coincides with the abrogation of Treg-mediated suppression 
of Teff proliferation in the wild type conditions, Teffs also start to proliferate when 
Teffs/DCs are TLR2-deficient. We therefore conclude that IL-6 is able to stimulate 
the proliferation of Teffs but is not absolutely required for abrogation of Treg-
mediated suppression of Teff proliferation. By acting on all multiple immune cell 
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subsets involved in adaptive immunity, TLR2 stimulation launches an effective 
immune response. A potent increase of regulatory mechanisms will have to occur 
to suppress any potential autoimmune events. The observed expansion of Tregs 
following immune activation shown here and in our previous work represents one 
of these feed-back mechanisms. The increased expansion of Treg may prevent 
immune pathology and help to dampen the immune response once the cause of 
the immune challenge has been eliminated. 
The question arose whether the effect of synthetic TLR2 ligand could also 
be observed during natural infections. The gram-negative micro-organism Legionella 
pneumophila is the causing agent of a severe pneumonia. Immune recognition 
of this microorganism has been reported to be dependent on TLR2 signaling and not 
on TLR4 signaling [15,16]. Therefore we repeated the experiments with heat-killed 
Legionella pneumophila (HKLP) to confirm our Pam3Cys findings. Indeed the effect 
of TLR2 triggering on all different immune cells could be confirmed when using 
HKLP in our assays. Most importantly the suppressive capacity of the Tregs could be 
abrogated in the presence of HKLP. These data indicate that TLR2 triggering potently 
modulates immune function during bacterial infections. However, it should be 
considered that besides effects on TLR2, stimulation of other pathogen recognition 
receptors could drastically influence the outcome of induced immune responses 
against specific pathogens. Recognition of Legionella pneumophila is mainly relying 
on TLR2 triggering. Other pathogens likely trigger other receptors that could possibly 
effect Treg suppression. 
Conclusions 
Our findings indicate that Treg-mediated suppression ofT helper cell proliferation 
is functionally distinct from suppression of cytokine secretion. TLR2 acts on multiple 
cells of the adaptive and innate immune system thereby providing direct immune 
stimulation of Teffs and DCs while simultaneously inhibiting the suppressive 
abilities of Tregs. These effects are not only observed for a synthetic TLR2 ligand, 
but could be confirmed with the natural TLR2 ligand containing bacteria Legionella 
pneumophilia. Further understanding of the precise mechanisms involved, will most 
likely contribute to new strategies for immune-based intervention strategies. 
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List of abbreviations 
APC: antigen presenting cell; DC: dendritic cell; FoxP3: fork-head box protein 
3; HKLP: heat-killed Legionella pneumophila; HSP60: heat-shock protein 60; 
IFNy: interferon gamma; IL-... : interleukin ... ; MFI: mean fluorescent intensity; 
NLR: NOD like receptor; Pam3Cys: Pam3CysSK4; PAMPs: pathogen associated 
molecular patterns; RA: rheumatoid arthritis; RLR: RIG-I like receptor; 
Teff(s): effector T cell(s); TGFP: transforming growth factor beta; 
TLR ... : toll like receptor ... ; Treg(s): regulatory T cell(s). 
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Additional file 2. Purity of isolated Tregs and Teffs. 
The Teff cells and Tregs were MACS-sorted from total splenocytes 
based on CD4 expression and thereafter FACS-sorted into CD25 
high or low expressing cells. After several weeks in culture, 
the purity of Teff and Treg was 98% and 96% respectively. 
Condit io n s 
R10 
96.43% 
1 Background Teff, APCs, aCD3 
2 0% suppression Teff, APCs, aCD3, PAM 
3 max. suppression Teff, APCs, Treg, aCD3 
4 X% suppression Teff, APCs, Treg, aCD3, PAM 
5 Contro l Teff, APCs, Treg, PAM 
Additional file 3. Conditions used in suppression assay. 
This list shows all conditions always used in suppression assays, 
and which cellsjstimulations are in each condition. 
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Abstract 
Regulatory T cells (Tregs) are a specific subset of T cells that play an important role 
in immune homeostasis. They help to maintain tolerance to 'self' antigens 
and control the protective immune responses against pathogens. We have previously 
described that triggering of the T cell receptor (TCR) in combination with stimulation 
ofToll-like receptor 2 (TLR2) influences the proliferation and the suppressive capacity 
of Tregs. When stimulated with anti-CD3 (aCD3) in combination with the TLR2 
ligand Pam3CysSK4 (PAM3Cys), Tregs temporarily lost their suppressive capacity 
on effector T (Teff) cell proliferation. The exact mechanisms underlying this finding 
are unclear. In this study we set out to identify genes of which the expression 
is affected by TLR2/TCR triggering in Tregs and Teff cells. The results show that 
many genes involved in the suppressive function of Tregs are down-regulated upon 
TLR2/TCR triggering. This decrease in Treg suppressive capacity also coincided with 
a strong decrease in the expression of the Crispl gene. We are the first to describe 
that Crispl is selectively expressed in previously activated but resting Tregs 
and is rapidly downregulated following activation with PAM3Cys/aCD3. 
131Gene expression analysis of Toll-like receptor 2 ligand stimulated regulatory T cells 
Introduction 
Regulatory T cells (Tregs) are key players in the control of immune responses 
by maintaining tolerance to self antigens and regulating responses to pathogens 
and microbial flora [1,2]. They are best characterized by a stable expression of the 
transcription factor Foxp3 and have been described in primary and secondary 
lymphoid organs, blood, and in non-lymphoid, tissues such as skin, lungs and 
intestine. In recent years it has become dear that the migration and function 
of Tregs are extensively controlled by signals from the local microenvironment. 
They are recruited to sites of (pathogenic) inflammation to prevent overexertion 
of immune effector cell activities and associated damage, and are found abundantly 
within tumors [3,4] where they actively suppress anti-tumor immune responses 
and have detrimental effects on immunotherapy. The regulation ofTregs themselves 
is therefore of utmost importance to allow proper immune responses against 
pathogens and cancer, while maintaining tolerance to healthy tissue of the host. 
Like all T cells, Tregs receive signals through their T cell receptor (TCR), eo-stimulatory 
molecules and cytokine receptors. These can be provided by dendritic cells (DCs) 
that not only instruct Tregs but also modulate the resistance of effector T cells 
to Treg-mediated suppression [5,6]. The immune program that DCs convey to Tregs 
is determined by the encounter with danger-associated molecular patterns that 
bind to a specialized set of recognition receptors. An important group of receptors 
are Toll-like receptors (TLRs) that have been identified as innate immune sensors 
of conserved patterns on microbes and endogenous ligands. TLRs are expressed 
on monocytes, macrophages, DCs and T cells [7] and drive the initiation of adaptive 
immune responses. Caramalho et al. revealed that Tregs express TLR1, TLR2, TLR4, 
TLRS, TLRG, TLR7 and TLR8 and may thus be directly responsive to pathogenic 
material [8]. The effects of TLR ligation on Tregs are however not fully elucidated 
yet. Triggering of TLR4 was reported to enhance Treg -mediated suppression 
[8], but this could not be confirmed by other groups [9-11]. TLRS stimulation 
on Tregs seemed to increase their suppressive function, while TLRS triggering on Teff 
cells increased the proliferation and production of IL-2 [12]. In contrast, triggering 
TLR8 resulted in inhibition of Treg-mediated suppression without affecting Treg 
proliferation [13]. 
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Compared to the other TLRs, TLR2 is remarkably different in respect to ligand 
binding and ensuing immunological effects. TLR2 forms homodimers and 
heterodimers with TLR1 and TLR6 resulting in the recognition of a broad range 
of ligands [7,14]. In comparison with TLR4-deficient mice, mice lacking TLR2 
are less susceptible to lethal infections with Aspergillus fumigatus, Yersinia 
enterocolitica or Candida albicans [15,16]. These enhanced immunological 
responses correlate with decreased numbers of Tregs in TLR2-deficient mice. 
In addition, C. albicans induced proliferation and survival of Tregs 
in a TLR2-dependent manner [16]. We and others have indeed confirmed 
that TCR stimulation in the presence of either synthetic [11,17] (Pam3CysSK4; 
Pam3Cys) or natural (Legionella pneumophila) [18] TLR2 agonists directly 
induced Treg proliferation in vitro and in vivo. Although TLR2-stimulated 
Tregs still suppressed Teff cell cytokine production [18], they failed 
to inhibit the proliferation of Teff cells [11,17-20]. The abrogation of the Treg 
suppressive function is a temporary and reversible effect, as a resting period 
and removal of the TLR2 ligands caused the Tregs to regain their suppressive 
and non-proliferating phenotype. Effector T cells also directly respond to TLR2 
stimulation resulting in proliferation and production of IFNy and IL-2, making them 
more resistant to Treg-mediated suppression [18]. 
The proliferative responses of both Treg and Teff cells and the recovery 
of suppressive function ofTregs after removal of the TLR21igand enabled us generate 
ex vivo functional cell lines that could be maintained for several months. These 
lines were used to investigate the differences in gene expression profiles in Tregs 
and Teff cells after stimulation with aCD3 and the synthetic TLR2 agonist Pam3Cys. 
Gene ontology analysis of the differentially expressed genes show that different 
processes are active within Tregs compared to Teff cells in both the naive and 
activated state. Furthermore a Treg-specific gene was identified, Crisp1, that shows 
characteristic expression patterns upon TLR2 triggering. Preliminary data suggest 
a potential role for Crisp1 in the suppressive function of Treg by influencing 
Ca2+ fluxes in Teff cells. 
133Gene expression analysis of Toll-like receptor 2 ligand stimulated regulatory T cells 
Methods 
Mice 
C57BI/6 mice were obtained from Charles River WIGA (Sulzfeld, Germany) Gmbh. 
All animal experiments were approved by the Animal Experimental Committee 
of Radboud University Nijmegen Medical Centre and were performed in accordance 
with institutional and (inter)national guidelines. 
Antibodies and flow cytometry 
Directly labeled monoclonal antibodies (anti-CD4-APC (clone l3T4), anti-CD25-FITC 
(clone 7D4), anti-CD3-PE {clone 145-2Cll)) and their isotype controls were obtained 
from BD Biosciences. Anti-mFoxP3-PE (clone FJK-16S) and the isotype control 
were obtained from eBioscience. Analysis of cell surface markers on lymphocytes 
was performed using a FACScalibur {BD) and CELLQuest software (version 3.3; 
BD Biosciences). 
T cell purification and analysis 
A single cell suspension was prepared from spleens of C57BI/6 mice. 
CD4•Tcellswereenriched using anti-mouse-CD4 Microbeads (MACS, Miltenyi Biotec). 
Naive CD4•CD2s- Teff and naive CD4•CD2Shi Treg subsets were obtained by flow 
cytometry purification of the pre-sorted CD4•T cells. Cell sorting was performed on a 
Coulter Altra HyPerSort cell sorter. Both naive CD4•CD2S-T cells and naive CD4+CD2Shi 
T cells were 98% pure, based on CD25 expression pattern. Of the CD25hi 
FACS-sorted cells, 67% expressed FoxP3. Sorted cells were kept in culture 
as described below. After several weeks of culture, the purity of both the Treg cell 
line and the Teff cell line (referred to in this paper as the cultured Tregs or cultured 
Teff cells) was 96% or higher. 
Treg and Teff cell culture and suppression assay 
Purified CD4•CD2S• T cells and CD4•CD2S- T cells were cultured in 2-5*104 cells 
per well in a 96-well plate, and were stimulated weekly with 5*104 irradiated 
CD4-MACS bead depleted splenocytes, in the presence of 2 IJg/ml Pam3Cys 
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(EMC microcollections, Germany), 0.1 or 11J.g/ml aCD3 (145-2C11; BD Biosciences), 
and IL-2 (120 IU/ml for Tregs and 60 IU/ml for Teff cells) in complete medium. 
The cells were washed 3 days after addition of the stimulation and maintained in the 
culture medium, supplemented with 120 or 60 IU/ml IL-2. Dead cells were removed 
by ficoll density gradient (Lymphoprep, Axis Shield Oslo, Norway). Cultured Tregs 
or Teff cells were used in assays at least 6 days after stimulation and are referred 
to as 'resting' cells. 
Suppression assays were performed as follows; freshly sorted CFSE-Iabeled 
(1 IJ.M, Invitrogen) CD4+CD2s- naive T cells (2*104 per well) and expanded Tregs 
(2*104 per well) were eo-cultured for 3 days with 2*1Q4 irradiated (wildtype) antigen 
presenting cells per well. The cells were stimulated with TLR2 ligand Pam3Cys (SIJ.g/ 
ml) with or without soluble aCD3 (0.1 IJ.g/ml or 1 IJ.g/ml) in complete medium. 
After 3 days of culture, suppression was monitored by analyzing CFSE fluorescence 
intensity in Teff cells by flow cytometry. In addition, supernatant was collected 
for cytokine analysis. 
RNA isolation, quality control, and microarray hybridization 
Total RNA was isolated from Teff cells and Tregs using the RNeasy Mini kit (Qiagen) 
according to the manufacturer's protocol. The quality of RNA was tested using 
the Agilent2100 Bioanalyzer following the manufacturer's protocol. All samples 
had a 28S:18S ratio > 1.5, thus passing quality standards for further processing. 
Two micrograms of total RNA was labeled according to the GeneChip Whole 
Transcript <Wn Sense Target Labeling Assay as provided by the manufacturer 
(Affymetrix, Santa Clara, CA), and hybridized to Mouse Exon 1.0 ST Arrays overnight 
before scanning in an Affymetrix GCS 3000 7G scanner. The Mouse Exon 1.0 ST 
Array contains -1,200,000 probe sets with an average of 4 probes per exon 
and an average of about 40 probes per gene. All hybridizations were carried out 
at the Microarray Facility of the Department of Human Genetics, Nijmegen Centre 
of Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands. 
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Analysis of microarrays 
The Affymetrix CEL files were imported into Affymetrix Expression Console version 
1.1 where control probes were extracted using the default RMA algorithm for quality 
analysis checks. The area under the curve (AUC) of the receiver operator characteristic 
was calculated using the positive and negative control probes. All arrays had an AUC 
score above the empirically defined threshold of 0.85, indicating a good separation 
of the positive controls from the negative controls. Subsequently, CEL files were 
imported into Partek (Partek Genomic Suite software, version 6.4; Partek Inc., 
St. Louise, MO) where only core exons were extracted and normalized using the RMA 
algorithm with GC background correction. Core transcript summaries were calculated 
using the mean intensities of the corresponding probe sets. The correspondence 
of the replicate samples was confirmed using principal component analysis (PCA) 
and Pearson correlation analysis. The Venn diagram was also generated in Partek. 
Gene ontology analysis of differentially expressed genes 
Lists generated in the pair-wise comparisons between the different cell types 
or stimulations were used as input for the online Functional Annotation Tool 
at the DAVID bioinformatics Resources (National Institute of Allergy and Infectious 
Diseases (NIAID), NIH, Bethesda, MD; http://david.abcc.ncifcrf.gov/). Only genes 
that were significantly differentially (P<O.OS) expressed (>4-fold) were included 
in the analysis. Affymetrix Exon Gene IDs were used as Gene List input and all the 
genes in the mouse genome served as the background. Furthermore, only GO terms 
that accurately describe biological processes (GO_BP) were further analyzed. 
Real-time quantitative PCR 
For conventional RT-QPCR, cDNA was synthesized from 2 ~g total RNA using 
the High Capacity cDNA Synthesis kit (Applied Biosystems, Foster City, CA), 
using the PowerSYBR Green Master Mix, following the manufacturer's directions. 
The cDNA samples were tested in a conventional quantitative PCR dilution assay 
on PBGD expression (CT value of -25), to determine the amount cDNA needed 
in the QPCR with the primer sets of interest. The gene-specific primers are listed 
in Supplementary Table 1. The reactions for Crisps were run on a MyiQ Single colour 
RT-PCR (BioRad), and data were collected using MyiQ Software (BioRad). flCT values 
for each gene were normalized against PBGD as a reference. 
136 Chapter 6 
Cell stimulations 
For the stimulation assay the cells were plated in 5*10" cells per well in 100 ~1. 
Stimulations were added in 100 ~I per well. The concentrations of the stimulations 
were4 ng/ml LPSpure (Sigma), 0.2 ~g/ml CpG 1668 (Invitrogen) or4 ~g/ml Pam3Cys, 
all with or without 0.1 ~g/ml aCD3 (BD Biosciences). The cells were stimulated 
for 24 hrs and washed before RNA was isolated. 
Transfection, protein production and concentration 
HEK293 cells were cultured in DMEM supplemented with 4.5 g/1 glucose, antibiotics/ 
antimycotics, non essential amino acids (Invitrogen) and 10% fetal calf serum (FCS, 
Greiner Bio-One). Cells were cultured in a 10 cm culture plate (Coming), harvested 
with trypsin/EDTA and split every 3-4 days. When the cells were used for transfection, 
they were harvested and plated in a 15 cm culture plate in a concentration 
of 12*106 cells per plate. The next day cells were transfected with Crisp-HA or HA 
DNA using metafectene® (Pro Biontex), which was added drop-wise. Cells were 
incubated at 37°C for 24 hrs, washed and new medium was added without FCS. 
Again the cells were incubated at 37°C for 24 hrs for production of Crisp-HA or HA 
protein. The supernatant was gently harvested, centrifuged and concentrated using 
the AmiconUitra (Millipore). 
Ca2+ flux assays 
CD4+CD2S- na"ive Teff cells were isolated from splenocytes using the MACS 
protocol. Cells were resuspended in HBSS+1mM CaCI2 + 1% BSA in a concentration 
of 1-2*106 cells/ml. To 1 ml of cells 4 ~I Fura-2-AM1 (Invitrogen) and 10% Pluronic 
was added and incubated for 30 min to load the cells with Fura-label. Cells were 
washed twice and resuspended in HBSS+1mM CaCI2 + 0.1% BSA. Measurements 
were done on Shimadzu RF-5301, and during the measurements different 
stimuli were added. After 100 sec PBS/Crisp-HNHA was added and incubated 
for 240 sec. After incubation 7.5 ~I aCD3 (clone 145-2Cll, 0.5 mg/ml stock) was added 
as stimulus. The ratio of Ca2+ flux of the sample without supernatant was set to 1. 
All other samples are related to the sample without supernatant, and the graph 
shows the relative change in Ca2+ flux. 
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Results 
Exon array gene profiling 
Tregs and Teff cells were isolated from spleens of C57BI/6 mice using magnetic 
bead separation and expanded with Pam3Cys/aCD3 stimulation at weekly intervals 
(see method section). Resting expanded Tregs showed high CD25 expression, 
whereas the Teff cells showed low or moderate CD25 expression levels (Suppl. Figure 
1). More than 95% of these CD4+ Tregs expressed FoxP3, compared to less than 3% 
of the CD4+ Teff cells (Figure 1). Teff cell functionality was confirmed by proliferation 
and cytokine production (data not shown), and the Tregs were highly efficient 
in suppressing Teff cell proliferation. To identify differences in gene expression 
profiles between antigen-experienced Pam3Cys-expanded Tregs and Teff cells, RNA 
was isolated from resting cells (t=O), and after 30 min, 24 hrs, and 48 hrs of stimulation 
with aCD3 stimulating antibody in the presence of Pam3Cys. As a control, both cell 
types were incubated for 48 hrs with aCD3 alone. 
Teff cells Treg cells Figure 1. Characterization of 
650 250 Trep and Teff cells. The cultured 
Tregs and Teff cells were analyzed 
for their FoxP3 expression profile 
487 187 by flow cytometry. The purity 
of Treg samples and Teff cells was 
3~ 1~ always higher than 95%. 
97.91% 
162 62 
0 
10' 10' 10' 10' 10 0 10' 10' 10' 10' 
FoxP3Pe FoxP3Pe 
Gene expression analyses were performed using Affymetrix Mouse Exon Arrays. 
The relationship between the different samples was analyzed using Principal 
Component Analysis (PCA), a mathematical procedure that reduces data 
dimensionality by transforming multiple correlated variables into a number 
of principle components. Figure 2A reveals a high correlation between resting 
and activated cells for both Teff cells and Tregs. Anti-CD3 increased the divergence 
between the gene expression profiles of Tregs compared to Teff cells, which 
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was even more pronounced upon Pam3Cys/aCD3 stimulation. This divergence 
is also shown in Venn diagrams displaying an overlap of 10096 genes at t=O (Figure 
28) compared to 9700 genes at t=48 hrs (Figure 2C). 
' 
B Venn Diagram 
Resting Tregs 
(10890) 
t=O 
Resting Teffs 
(10855) 
PCAMapping 
C Venn Diagram 
Stimulated 
Tregs(10275) 
Stimulated 
Teffs (10989) 
t=48hrs 
• Tregt:O 
• Treg t:30min Pam3Cys/aC03 
• Treg t:24hrs Pam3Cys/ aC03 
• Treg t:48hrs Pam3Cys/ aC03 
• Treg t:48hrs aC03 
• Tefft:O 
• Tefft:48hrs Pam3Cys/ aC03 
Tefft:48hrs aC03 
Figure 2. Principal 
Component Analysis 
(PCA). (A) Global expression 
profiles from the Exon 
arrays including resting Treg 
(t=O), aCD3 Tregs (t=48 
hrs), Pam3CysfaCD3 Tregs 
(t--30 min, 24 hrs, 48 hrs), 
and Teff cells without (t=O) 
or with (t=48 hrs) aCD3 or 
Pam3CysfaCD3 stimulation. 
Closely related samples are 
connected through planes: 
yellow for Teff cells and 
pink for Tregs. (B/C) Venn 
diagrams show the overlap 
in gene expression between 
Tregs versus Teff cells for 
t=O (B) and t=48 hrs (C). 
Genes expressed above 
a normalized value of 4 are 
represented. 
Next, gene ontology (GO) analysis was performed using the online functional 
annotation tool DAVID (http://david.abcc.ncifcrf.gov/) to identify the different 
pathways/genes that were activated in resting and stimulated Tregs versus 
Teff cells. Genes were considered differentially expressed when they complied with 
the following criteria; 1) at least one expression value >4.0, 2) >2 fold expression 
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difference, and 3) statistical significance (P<O.OS). In a resting state (t=O) the Teff cell 
gene expression profile included processes of organelle and cellular organization 
as well as metabolic processes. After 48 hrs of Pam3Cys/aCD3 stimulation 
Teff cells up-regulated genes associated with their effector function, such as cytokine 
production (Table 1 lower part). In contrast, the active processes in resting Tregs 
related to negative cell regulation and immune responses (Table 1 upper part), 
while stimulation induced transcription of genes related to cellular and metabolic 
processes. These data are in line with the proliferative responses and decreased 
suppressive capacity of Tregs after stimulation under these circumstances [11,18]. 
Table 1. Gene Ontology Analysis of genes differentially expressed in Teffs vs Tregs. 
Gene ontology class No of Percentage of P value 
(Biological Process, including GO accession) genes in genes in class {P<O.OS) 
cla.s.s 
Up Teff vs Treg t=O {total 749 genes) 
G0:00482SS-organelle fission 54 10 .3% 9.2E-37 
G0:0006996-0rganelle organization 101 19.2% 9.2E-27 
G0:0016043- cellular component organization 121 22.9% 4.7E-18 
G0:0006259""DNA meta bolic process 43 8 .2% 2.1E-12 
G0:0002376-Immune sy st em process 58 11% 1.4 E-10 
Up Treg vs Tefft=O {total 722 genes) 
G0:0048519""'Negative regulation of biological process 76 13% 1.9E-7 
G0:0002376-Immune sy st em process 53 9% 2.2E-7 
G0:0010646-Regulation of cell communication 51 8 .7% 5.7E-7 
G0:00069SS- Immune response 37 6.3% 5.8E-7 
G0:0048523- Negative regulation of cellular process. 68 11.6% 1.2E-6 
Up Teff vs Treg t=48hrs {toto/1048 genes) 
G0:0002376-Immune sy st em process. 65 10.4% 3.4E-8 
G0:00069SS-Immune response 47 7.5% 3.6E-8 
G0:000181 ?-Regulation of cytokine production 21 3.3% l . lE-5 
G0:000268:2-Regulation of immune s.y s.t em process. 31 4 .9% 1.6E-4 
G0:0019835- Cytolysis 1.4% 1.9E-4 
Up Treg vs Tefft=48hrs{toto/984 genes) 
G0:000998?-Cellular process 490 58.2% 2.2E-14 
G0:004423?-Cellular m etabolic process 322 38.2% 4.4E-8 
G0:000815:2-Metabolic process. 365 43.3% 1.4E-6 
G0:0044238""'Pri mary m et abolic process 328 39% 2.7E-6 
G0:0044260""Cellular m acrom olecule meta bolic 251 29.8% 5.6E-6 
process. 
Source: Gene-li st generat ed by pairwise compa rison betw een Treg and Teff samples. Only g enes w ere t aken 
a long which m eet the criteria; one of the two log2 AU data >4.0, and >2fold difference. List generat ed on 
http :1/david.abcc. ncifc rf .gov/ 
Individual gene regulation in Pam3Cys/CICD3-stimulated cells 
Analysis of individual genes confirmed that the known Treg markers, FoxP3 [1,21], 
Ikzf2 (Helios) [22,23], NtSe (CD73) [24], Itgae (CD103) [25,26], and Ebi3 (subunit 
of IL35) [27], are highly expressed in resting Tregs compared with resting Teff cells 
(Table 2 and Figure 3A). In addition, Tregs expressed high levels of TGF-~. some CD39 
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and TRAIL, and very low or no levels of Pde3B and granzyme B, Perforin, Lag3 and 
IllO (Figure 3B). Forty-eight hours after Pam3Cys/aCD3 stimulation the expression 
levels of FoxP3, Helios, TGF-~. CD73, CD39 and TRAIL genes were decreased 
(Figure 3A-B). Stimulated Teff cells showed an increased expression of genes 
encoding for ILlO, granzyme B, LAG3, and perforin (Figure 38). In summary, TLR2 
triggering causes a reduction in the expression of genes involved in Treg-mediated 
suppression, which is in agreement with the reduced regulatory and suppressive 
function observed after TLR2 triggering in Tregs. 
A B 
Tregs specifically express Crispl mRNA 
Figure 3. Genomic 
profiles of Treg-
specificcbaracteristics. 
Expression values of 
both Tregs and Teff 
cells, un-stimulated 
(rested; t=O} and after 
48 hrs of Pam3Cys/ 
aCD3 stimulation. (A) 
Treg specific markers. 
(B) genes associated 
with Treg-mediated 
suppression. Red and 
blue represent high and 
low expression values, 
respectively. 
Interestingly, the expression of the Crispl gene was strongly down-regulated in Tregs 
treated with Pam3Cys/aCD3 for 48 hrs (Table 3). Moreover, subsequent analysis of 
the array data revealed that the Crispl gene was 97 times higher expressed in resting 
Tregs compared to resting Teff cells (Table 2). Crispl belongs to the CAP (Cysteine-
rich secretory proteins, Antigen 5 and Pathogenesis-related 1 proteins) superfamily 
[28]. These proteins are found in a remarkable large variety of organisms, ranging 
from Crisps in mammals/lizards, AgS proteins in insects and Pr-1 proteins in plants 
[28]. It has been hypothesized that the evolutionary diversity of the CAP proteins 
might represent a functional link between the plant and human immune system 
[29]. The Crisp-family in mice contains 4 Crisps; Crispl [30-32), Crisp2 [33], Crisp3 
[30,34] and Crisp4 [35). We confirmed the specific expression of Crispl in expanded 
resting Treg samples of the original micro-array as well as in independent Treg-lines 
141Gene expression analysis of Toll-like receptor 2 ligand stimulated regulatory T cells 
Table 2. First 25 genes up-regulated in Treg cells compared to Teff cells. 
Transcript Gene Gene Gene Fold 
ID assignment symbol description difference 
6939731 NM_009972 Csn2 casein beta 149.1 
6855317 NM_009638 Crisp1 cysteine-rich secretory protein 1 97.4 
7009771 NM_054039 Foxp3 forkhead box P3 58.6 
6845435 NM_019388 Cd86 C086 antigen 58.5 
6777309 NM_017372 Lyzs lysozyme 45.3 
6969693 NM_026384 Dgat2 di acyl glycerol 0-acyltransferase 2 40.6 
6800468 NM_144552 Stxbp6 syntaxin binding protein 6 (amisyn) 31.1 
6840753 NM_001082547 EG433016 predicted gene, EG433016 30.1 
6886947 AK220372 A330104H05R RIKEN cDNA A330104H05 gene 28.4 
ik 
6982918 NM_013494 Cpe carboxypeptidase E 28.3 
6808279 NM_013628 Pcsk1 proprotein convertase 27.6 
subtili si n/kexin type 1 
6782286 NM_008399 ltgae integrin, alpha E, epithelial- 24.7 
associated 
6932164 NM_007784 Csn1s1 casein alpha s1 22.4 
6932175 NM_007785 Csn1s2a casein alpha s2-like A 20.4 
6800229 NM_009132 Scin scinderin 19.7 
6921154 NM_007654 Cd72 con antigen 19.6 
6831775 BC020489 BC020489 cDNA sequence BC020489 19.2 
6880776 NM_172537 Sema6d sema domain, transmembrane 18.5 
domain (TM), and cytoplasmic d 
6759549 NM_011770 lkzf2 IKAROS family zincfinger 2 17.4 
6991192 NM_011851 Nt5e 5' nucleot idase, ecto 17.1 
6915843 NM_009647 Ak311 adenylate kinase 3 alpha-like 1 16.1 
6755494 NM_001012330 Zfp238 zinc finger protein 238 16.1 
6919320 NM_001002927 Penk1 preproenkephalin 1 15.2 
6949744 15.0 
6901084 NM_146140 Tram111 translocation associated membrane 14.6 
protein 1-like 1 
Source: Gene-li st generated by pairwise comparison between Treg and Teff t=O. Only genes were taken along 
which meet the criteria; one of the two log2 AU data >4.0, and >2 fold difference. 
Table 3. First 5 genes which ore down-regulated in Treg cells after 48hrs 
Pom3Cys/aCD3 stimulation compared to resting Tregs. 
Transcript Gene Gene Gene Fold 
ID assignment symbol description difference 
6855317 NM_009638 Crisp1 cysteine-rich secretory protein 1 14.9 
6922188 ENSMUSTOOOOO Krtap16-8 kerat in associated protein 16-8 7.1 
074637 
6852882 NM_008532 Tacstd1 turner-associ ated calcium signal 6.3 
transducer 1 
6805370 NM_023422 Hist1h2bc histone cluster 1, H2bc 5.9 
6777309 NM_017372 Lyzs lysozyme 5.8 
Source: Gene-li st generated by pairwise comparison between Treg t=O and Treg t=48hrs Pam3Cys/ aC03. Only 
genes were taken along which meet the criteria; one of the two log2 AU data >4.0, and >2 fold difference. 
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by quantitative PCR (Figure 4A). Little or no expression of the other Crisp family 
members was observed in either the Tregs or the Teff samples. The Teff cell samples 
(from micro-array and independent lines) were all negative for Crispl expression, 
confirming the preferential expression of Crispl in Tregs. Subsequent analysis of the 
expression of Crisp family members by other immune cell subsets (B220+ B cells, 
CD8+ T cells, CD3-depleted splenocytes, bone marrow, and bone marrow-derived 
Flt3-Ligand DCs) or cell lines (RMA, RAW, 3T3 and EL4) failed to show Crispl 
expression. Crisp3 expression was found within B220 .. cells freshly isolated from spleen 
(Figure 4B) as previously described by Pflsterer et al. Collectively, these data show 
that Crispl is preferentially expressed by Tregs and not by other immune cells. 
Next, Crispl expression was analyzed in freshly isolated naive Tregs and resting Tregs 
obtained after different cycles following TCR/TLR2 stimulation. Freshly isolated naive 
Tregs expressed Crispl at low levels. Following a single in vitro stimulation with 
~ El. 
1 ::r~o 
0.0 1 I I 
I 
t I 
Freshly isolated cells 
I ~ 
. 
I . IJI. 
- Treg t=O 
~Tefft=O 
- Crisp 1 
~Crisp3 
~FoxP3 
Figure 4. Expression profile of 
Crisp fanilly members. (A) The 
expression of all Crisp family 
members was tested by RT-PCR 
inexpandedbutresttngTregsand 
Teff cells at t=O. Representative 
results of 3 Independent 
experiments are shown. (B) 
Expression of Crisp genes ln 
freshly isolated splenocytes 
or bone marrow-derived cells. 
Representative results of 2 
independent experiments are 
shown. The error bars represent 
standard deviations of duplicate 
measurements. 
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Pam3Cys/aCD3, Crispl expression was immediately up-regulated (Figure 5) and 
continued to be expressed in rested cells after each consecutive culture passage. 
The micro-array data revealed a clear Crispl down-regulation at 48 hrs of Pam3Cys/ 
aCD3 stimulation. Therefore, we determined the kinetics of Crispl expression in 
Tregs at different time points during and after stimulation with Pam3Cys/aCD3. 
Crispl, Foxp3 and Crisp3 expression were analyzed in parallel. Crispl expression was 
strongly down-regulated (66-fold) after 24-48 hrs (Figure 6). After removal of the 
stimulus (at 96 hrs) the Tregs regained a stable expression of Crispl and expression of 
Crispl was still present at 14 days after removal of the stimulus (Figure 6). Strikingly, 
the kinetics of Crispl down regulation paralleled the decrease in expression of 
the Treg marker Foxp3. Although expressed at a much lower mRNA level, similar 
expression kinetics were also observed for Crisp3. 
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Figure S. Crtsp expression 
patterns In repeated culture 
passages. Expression levels of 
Crisp! and Crisp3 were analyzed in 
freshly isolated Treg {Passage{P)=O) 
and 96 hrs after each subsequent 
passage. Cells were stimulated with 
irradiated CD4-MACS bead depleted 
splenocytes and Pam3Cys faCD3 in 
the presence of IL-2. The cells were 
washed after 3 days and maintained 
in IL-2 supplemented medium. 
Expression of Crisp was evaluated in 
'rested' cells at day 6. Representative 
results of3 independent experiments 
are shown. The error bars represent 
standard deviations of triplicate 
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Figure 6. Crtsp expression 
patterns In time. The expression 
levels of Crispl, Crisp3 and Foxp3 
were analyzed in Tregs after 
stimulation with Pam3Cys/aCD3 
at the indicated time points. The 
stimulation was removed after 
96 hrs. Representative results of 
3 independent experiments are 
shown. The error bars represent 
standard deviations of triplicate 
measurements. 
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Further analysis revealed that the down-regulation of Crispl observed with Pam3Cys/ 
aCD3 can be obtained by either Pam3Cys or aCD3 alone (Figure 7) in a dose-
dependent manner (data not shown). As we previously showed that TLR2 ligands, 
but not TLR4 or TLR9 ligands, affect Treg proliferation and function, ligands for these 
TLRs were tested for their effect on Crispl down-regulation in Tregs. The data show 
that the ligands for TLR4 (LPS) and TLR9 (CpG) (TLR4/9 are both expressed by Tregs; 
Suppl. Figure 2) did not affect the expression of Crispl (Figure 7). 
200 - no ligand 
Cl 
- pureLPS C> 
Ill 
a. c:::::l CpG 
2 c:::::l Pa m3 Cy s , 
.fl 
.. 
100 ~ 
1: 
0 
-~ 
"' ii 
>< w 
0 
no aCD3 0.1119 CD3 
Crispl influences Ca2+ fluxes in effector T cells 
Figure 7. Modulation of Crilllp 
expression by agonists of TLR2, 4 and 
9. Resting Treg lines were stimulated 
with Pam3Cys (TLRl/2), LPS (TLR4) or 
CpG (TLR9) in the absence or presence 
of aCD3. The expression of Crispl, -3 and 
Foxp3 was analyzed after 24 hrs. Similar 
results were obtained with 10-times 
higher concentrations of TLR-ligands 
and 48 hrs of stimulation. Representative 
results of 2 independent experiments are 
shown.Theerrorbarsrepresentst!ndard 
deviations of duplicate measurements. 
Although most CAP proteins expressed in human and mouse tissues have been 
suggested to have significant roles in reproduction, development the immune 
system and in pathologies, specific functions and binding partners are still unknown. 
The Crisp proteins in venoms of some reptiles have been confirmed to interact 
with ion channels, e.g. helothermine from the Mexican beaded lizard can block 
Ca2+ channels [36,37]. Because of the strong conservation and homology between 
all Crisp proteins, we hypothesized that the expression of Crispl might play a role 
in the suppressive capacity of murine Tregs through the modulation of ion channels 
on other immune cells. 
As calcium-mediated signals are highly important for lymphocyte activation, 
differentiation and effector functions [38-40], we studied the effect of Crispl 
to modulate aCD3 induced Ca2+ influx in CD4+ T cells. Hereto, supernatants 
derived from HEK293 cells transfected with HA-tagged murine Crispl or control 
HA vector were collected and concentrated (Suppl. Figure 3). Freshly isolated CD4+ 
Teff cells were derived from mouse splenocytes by MACS purification and loaded 
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with Fura-2 to analyze bound and unbound intracellular Ca2+. Following pre-
incubation with Crispl-HA supernatant, control-HA supernatant or no supernatant, 
the Ca2+ response upon aCD3 triggering was determined. Interestingly, Crispl-
HA supernatant dose-dependently reduced the aCD3-induced intracellular 
Ca2+ flux (Figure 8) when compared to HA-treated supernatant. Although additional 
studies are required, the present results suggest that Crispl may indeed represent 
a mechanism for Tregs to modulate Ca2+ fluxes in Teff cells. 
Discussion 
Regulatory T cells constitute a distinct lineage within the T cell population 
that are engaged in the maintenance of tolerance to 'self' and the control of 
protective immune responses against pathogens. To perform this delicate balancing 
act Tregs themselves are highly regulated by environmental factors. We previously 
found that stimulation of Tregs with aCD3 and synthetic or natural ligands 
for TLR2 induced Treg proliferation and evoked a temporary loss of their capacity 
to suppress the proliferation ofTeffcells [41,42]. In the present study, we examined the 
influence of TLR2 triggering on the gene expression profiles of Tregs in comparison 
to Teff cells using micro-array analyses. 
Pathway analyses showed that the expression of genes involved in immune 
regulation/suppression in resting Tregs are quickly down-regulated upon Pam3Cys/ 
aCD3 stimulation. Among the identified genes were those encoding for the Treg-
specific markers, FoxP3 and Helios, as well as the genes known to play a role in 
suppressive mechanisms, like TGF~. CD73, CD39 and TRAIL. Remarkably, expression 
of Ebi3, a subunit of the inhibitory molecule IL-35, was up-regulated in activated 
Tregs suggesting an unrelated expression pathway. Overall, the down-regulation 
of these genes following aCD3/TLR2 triggering supports our previous data and 
suggests the importance of these genes in Treg-mediated suppression of Teff cell 
proliferation. 
Comparison of gene expression profiles ofTregs and Teff cells revealed that Crispl was 
specifically expressed in the Treg lines. The Crisp family proteins are found in a great 
variety of organisms, like insects, reptiles (lizards and snakes), and most mammals 
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[28]. Phylogenetic trees containing all known mammalian Crisp homologues, reveal 
that the mammalian Crisp proteins can be categorized into three groups; Crispl, 
Crisp2 and Crisp3 [28]. Only mice seem to have 4 Crisp proteins, Crispl to Crisp4. 
The mouse Crispl and Crisp3 genes might have arisen by gene duplication somewhere 
in evolution because they are about 75% identical and are located next to each other 
in the mouse genome [28]. Both mouse Crispl and Crisp3 are highly homologous 
to human Crisp3; mouse Crisp2 is homologous to human Crisp2; and mouse Crisp4 
is homologous to human Crispl [28]. We found that Crisp3 is also expressed 
in Tregs, albeit at much lower levels. Crisp 3 expression was much less restricted to 
Tregs than Crispl, which is in agreement with previous reports showing expression 
of human Crisp3 in neutrophils and eosinophils [43], and mouse Crisp3 in B cells 
[44]. Interestingly, expression of Crispl was rapidly down-regulated after Pam3Cys/ 
aCD3 stimulation (top-1 of down-regulated genes), which warranted further studies 
on the regulation of this gene. 
Expression of Crispl is very low or absent in freshly isolated 'naive' Tregs but is 
highly up-regulated after stimulation with Pam3Cys/aCD3. When these cells 
are rested, they maintain the high expression of Crispl. However, Crispl expression 
is strongly down-regulated within 1 hour after re-stimulation with Pam3Cys/aCD3, 
remains low for at least 48 hrs and subsequently increases again between 48 and 
96 hours. The expression levels continue to rise upon every passage/stimulation of 
the cells. These expression profiles foster the suggestion that Crispl is a specific 
marker for previously-activated Tregs. Either Pam3Cys and aCD3 alone, but not LPS 
or CpG, were able to modulate Crispl expression, suggesting a specific role for TLR2 
signaling in the modulation of Crispl expression. Unlike TLR2 stimulation, the TLR4 
and TLR91igands were also unable to induce Treg proliferation. So far. the data may 
suggest that Crispl expression identifies Tregs that have encountered lipoprotein-
containing microbes. 
Crisps have been found in several tissues like epididymis and several different glands 
and are described to be packed in granules for secretion [30,45]. Crisp proteins 
are known to consist of two distinct domains: the highly conserved CAP domain, 
and the cysteine-rich domain (CRD) at the (-terminus. This CRD possesses a hinge 
region and a Crisp-family specific domain, the ion channel regulatory region [28,32]. 
Little is known about the function of the Crisp family of proteins. Some have been 
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found in venoms of certain reptiles and have been confirmed to interact with 
ion channels, e.g. stecrisp from the Trimeresurus stejnegeri snake venom seems 
to have K+ channel inhibitory functions [46]; pseudecheroxin and pseudecin, 
both from snake-venom, target cyclic nucleotide-gated ion channels [47]. 
Because of the conserved sequences between all Crisp proteins, we hypothesised 
that mouse Treg-expressed Crispl might also have a function in blocking ion 
channels on other immune cells. As Crisp1 expression coincides with the suppressive 
capacity of Treg lines, we hypothesized that Crispl in secreted form may contribute 
to Treg-mediated suppression of Teff cell proliferation. Ion channels expressed by 
Teff cells are known to play important roles in the activation by antigenic challenges. 
Ca2+ signals are required for T cell activation and differentiation. It has been 
shown that upon triggering of the TCR, intracellular Ca2+ is released from storage 
compartments [38]. 
The presence of Crispl protein indeed slightly reduced aCD3-stimulated Ca2+ flux 
in CD4+ T cells. It is tempting to speculate that Crispl expression does correspond 
to the suppressive function of Tregs. Further studies should shed light on the ability 
of Tregs to store Crisp1 intracellularly, the significance of Crisp1 protein in Treg 
function and homeostasis, as well as its effects on other (immune) cells. It will also 
be important to evaluate the role of Crispl in functional models, like in chronically 
C. Albicans or Legionella pneumophilla-infected mice where the presence of 
pathogens are providing a continuous source of TLR2-binding lipoproteins [16,18]. 
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Summary 
Only a few decades ago Tregs were acknowledged as a separate cell type [1]. 
Their immunosuppressive functions were shown to be crucial for the maintenance 
of immunological homeostasis in healthy individuals and for controlling excessive 
immune responses during the elimination of pathogens. In addition, Tregs are major 
players in the onset and progression of autoimmune diseases and regulate immune 
responses in the tumor microenvironment. The studies described in this thesis were 
developed to improve our understanding of how Tregs themselves are regulated. 
Understanding the mechanisms of Treg activation and inhibition will provide 
insights into how immune responses can be modulated in pathological situations 
and immune-mediated diseases. 
Within tumor settings, Tregs have been shown to play an important role in 
eo-orchestrating an immunosuppressive microenvironment [2]. Recruitment of 
immune-suppressive cells, like Tregs, is a well known mechanism by which tumor 
cells escape immune responses [2]. Tumor infiltrated Tregs can inhibit the cytotoxic 
function of antigen-specific COS+ T cells and, thus the destruction of the tumor 
[3,4]. For effective cancer immunotherapy the ratio between Tregs and COS+ 
T cells is of crucial importance. Animal studies show that, directly or indirectly, 
the expression of immunogenic tumor-specific antigen on exosomes secreted 
by the tumor enhances anti-tumor immunity and results in a lower ratio of Treg 
versus COS+ T cell (Chapter 3). Preventing Treg accumulation or inhibiting Treg 
functions are of great interest for cancer immunotherapy. However, the application 
of Treg depleting strategies using cyclophosphamide or CD25-targeting strategies 
to deplete Tregs in patients has not led to the desired increase in anti-tumor 
immunity [5] Modulating the function of Tregs through triggering of eo-stimulatory/ 
inhibitory molecules (e.g. GITR) or Toll-like receptors (TLRs) may lead to better 
responses. 
Chapter 2 gives an overview on the expression pattern of TLRs on Tregs and the 
effects of TLR triggering on the function of Tregs. Modulation of immune responses 
by directly targeting the TLR pathway in Tregs may provide new opportunities 
for the treatment of immune-mediated disease. 
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In this thesis we focussed on gaining more insight into the effect of TLR2 stimuli 
on the balance between immune inhibition and immune activation in general, 
and forTregs in particular. Aside synthetic TLR21igands, we made use ofTLR21igands 
expressed on the surface of Gram-positive bacteria, but also on other pathogens. 
In Chapter 4 we focused on the potential probiotic strains Bi{idobacterium Breve 
and Lactobaccilus as they were suggested to have immunomodulatory properties. 
Both strains induced pro-inflammatory cytokines in a TLR9-dependent manner, 
but levels induced by the Bifidobacterium strain were much lower compared to the 
Lactobaccilus strains. Interestingly, the blockade of TLR2, but not TLR4, increased 
the production of cytokines by Bifidobacterium Breve, indicating that TLR2 triggering 
limited the production of pro-inflammatory mediators. 
Besides the probiotic bacteria, our immune system encounters pathogenic bacteria. 
In Chapter 5 we investigated the effects of TLR2 triggering in classical suppression 
assays containing purified Tregs, antigen presenting cells and Teff cells. All cells 
express TLR2 and respond to the synthetic ligand PAM3Cys as well as a natural TLR2 
containing bacterium Legionella pneumophila. In these cultures the presence ofTLR2 
ligands restores the proliferation of Teff cells. We found that TLR2-stimulated DCs 
and Teffcells became less susceptible to Treg suppression. In addition TLR2-stimulated 
Treg temporarily lost their suppressive activity of Teff cell proliferation. Remarkably, 
we found that the decrease in suppression of Teff cell proliferation is functionally 
distinct from suppression of cytokine production. These findings implicate that 
Treg-mediated suppression can act at different levels, and more insight is needed 
to understand Treg suppression. We therefore analysed the effects ofTLR2 triggering 
with Pam3Cys on Tregs on genetic level as described in Chapter 6. 
Micro-array analysis revealed that TLR2/TCR triggering on Treg down-regulated 
the genes held responsible for Treg-mediated suppression, while Teff cells became 
more activated. Furthermore we discovered a gene expressed specifically within 
TLR2/TCR-stimulated Tregs, Crispl. The expression pattern of Crispl coincides with 
the suppressive activity of Tregs. Preliminary analysis suggests that Crispl inhibits 
stimulation of Teff cells and might be a molecular marker for TCR-experienced 
Tregs. 
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Discussion and future perspectives 
Tregs can play decisive roles in the maintenance of homeostasis and the initiation, 
prolongation and termination of immune responses. It is therefore important that the 
function of Tregs themselves is tightly controlled by factors in the microenvironment 
to allow a balanced interplay of Tregs with other immune effector cells. 
In pathogenic infections, stimulation of PRR. such as TLRs, may directly modulate 
the inhibitory function of Tregs. It has been hypothesized that administration 
of agonists or antagonists for these TLRs may provide novel strategies to inhibit 
or stimulate Treg functions as a therapy in cancer patients or patients suffering 
from severe allergies or autoimmune diseases respectively. 
Tregs and TLR2 
Tregs express a divers set of TLRs (TLR2, -4, -5, -8 and -9) [6-8]. Individual 
stimulation of these receptors has a specific effect on the function of Tregs [9,10]. 
We and others showed that triggering of TLR2 on Tregs not only decreased 
Treg-mediated suppression, but also induced Treg proliferation [11,12]. This effect 
appeared specific for TLR2 signaling and was not observed after stimulation of 
other TLRs, which might relate to the unique features of the TLR2 molecule existing 
as a homodimer or heterodimer with TLR1 or TLR6. As a result, TLR2 recognizes 
the broadest array of ligands, including bacteria (gram-positive and -negative), 
fungi, viruses, parasites and also endogenous proteins. 
It has been suggested that pathogens expressing TLR2 ligands inhibit 
Treg suppression allowing the development of microbe destructive functions 
in effector cells. Upon removal of the pathogen, TLR2 ligands are less abundant, 
which causes the restoration of the suppressive capacity of Tregs. The increased 
numbers of Tregs (TLR2 induces Treg proliferation) accelerates the restoration of the 
immunological balance to prevent tissue damage. 
Interestingly, the results presented in this thesis revealed that stimulation 
of TLR2 prevented Treg-mediated suppression of Teff cell proliferation, but we were 
unable to detect effector cytokines in supernatants. It remains to be elucidated 
whether Teff cells indeed fail to produce cytokines or that proliferating Tregs 
massively consume the cytokines in these cultures. 
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It is of note that the reported TLR2 effect on Tregs is only present in combination 
with stimulation of the TCR and might thus be considered a eo-regulatory signal. 
This would imply that the TLR2 only shuts down Treg suppressive functions after 
antigen-specific activation of the Tregs thereby providing a safety mechanism 
preventing systemic loss of Treg function. In other words, stimulation of TLR2 only 
causes a temporary loss of function in Tregs that have encountered the antigenic 
stimulus in specific locations, i.e. at the site where pathogens are present and effector 
functions are desired. Whether the Tregs and Teff cells in these responses are specific 
for the same antigens is unknown. 
Tregs and microorganisms 
The effect of TLR2 triggering on Treg suppression was observed in studies using 
synthetically derived TLR2 ligands [11,13]. This enabled dissection of TLR2 specific 
responses in Tregs, but did not representthe modulation ofTreg function in pathogenic 
infection and in interactions with gut flora. These microbiotics obviously express 
an excess of pathogen-associated molecular patterns in addition to TLR2 ligands. 
To test the effects of TLR2 stimulation in a natural infection, we studied Legionella 
pneumophila [13], a gram-negative bacillus, which can cause severe pneumonia [14] 
and elicits an immune response that is mainly driven by stimulation of TLR2 [15,16]. 
Stimulation ofTregs with L. pneumophila resulted in comparable results as observed 
with synthetical TLR2 ligands in a dose-dependent manner. Preliminary data show 
that TLR2-dependent Treg proliferation could also be induced by other TLR2-Iigand 
containing pathogens (Acholeplasma laidlawii, Porphyromonas gingivalis, Listeria 
monocytogenes). It can thus be concluded that TLR2-induced phenomena are 
dominantly stimulating Treg proliferation and abrogating Treg suppressive functions 
upon encounter with these specific bacteria. 
We next set out to study the immunomodulating effects of TLR2-containing 
candidate probiotic bacteria from the genera Lactobacillus and Bifidobacterium. 
These bacteria are currently used in probiotic dietary products, but their functionality 
in vivo are still subject of vivid debates. We explored the immunomodulatory effects 
of several strains and showed that Bifidobacterium Breve induced lower levels of the 
pro-inflammatory cytokine IFNy than the tested L. rhamnosus in cells from both 
mouse and man [17]. Preliminary data show that cytokine production in response to 
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B. breve is more skewed to IL17 (data not shown). This specific cytokine expression 
pattern was dependent on TLR2, but not TLR4 or NOD2 [17]. Interestingly, 
the blockade of TLR2, but not TLR4, increased the production of cytokines by 
Blfidobacterium Breve, indicating that TLR2 triggering limited the production of 
pro-inflammatory mediators. These results may be favourable in diseases such as 
inflammatory bowel disease, where an over activated immune system leads to gut 
inflammation. However whether these effects were specifically regulated through 
the direct effects of probiotic strains on Tregs remains to be studied. 
The role of TLR2 in Treg function has also been shown for viruses, fungi, 
and parasites. However these pathogens might use the effect of TLR2 on Tregs 
in favour of the pathogen. In C. albicans infections stimulation of TLR2 mainly 
induces anti-inflammatory signals and promotes Treg survival [18], resulting 
in reduced pathogen clearance. HIV infection is another example of a pathogen 
that uses TLR2 on Tregs as one of the several mechanisms to escape the immune 
system. TLR2 triggering via HIV-1 Nef protein increased Treg numbers, which might 
decrease immune activation [19]. 
The studies presented in this thesis provide a model for Treg function in pathogenic 
bacterial infections that are mainly driven by TLR2. The temporal inability to suppress 
Teff cell proliferation allows productive immune response to clear the infection. 
The TLR2-induced proliferation of Tregs than results in increased numbers of Tregs 
that help to restore the immunological balance once the infection has been cleared. 
It remains to be seen whether this holds true for other bacteria containing other 
sets of PAMPs that might initiate distinct programs in Tregs and other immune 
cells, which may overrule the primary effects of the imprinted signatures of Tregs. 
With candidate probiotics we already show that these strains induce different 
skewing of immune responses but it is clearly too early to support health claims. 
With increased knowledge of the immunological programming by specific bacterial 
strains we might be able to modulate the balance between pro-inflammatory 
and regulatory responses in immune-mediated disorders. 
Modulation of Treg function in tumor immunotherapy 
Tumor immunotherapy stimulates or inhibits components of the immune system 
to fight tumors. The last few decades several new tumor immunotherapeutical 
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strategies have been developed, such as monoclonal antibody-based vaccines, 
in which the mAbs target either to immune cells or to the tumor cells [20,21]. 
Other strategies involve cell based immunotherapy, in which DCs or T cells 
are isolated, educated outside the body and injected back into the patient [22,23,24]. 
Alternatively, immune cells can be targeted in vivo to stimulate anti-tumor immune 
responses [25], for instance by administration of TLR-Iigands [26]. 
Turners make brilliant use of the immune system by shifting the balance between 
immune tolerance and activation in favor of tumor survival. It has been shown that 
Tregs are preferentially attracted to the tu m or microenvironment and increased levels 
of Tregs have been documented in the peripheral blood of cancer patients [2,27,28]. 
To create a potent anti-tumor immune response, it is important to understand 
the interaction of the tumor microenvironment with the immune system, 
in particularTregs. The TLR2-induced inhibition ofTreg suppression would suggestthat 
TLR2-Iigands may be considered for immunotherapeutic approaches. In addition, 
we show in this thesis that DCs are activated and Teff cells are more resistant 
to suppression after stimulation of TLR2 in these cells. However, TLR2 stimulation 
also induces Treg proliferation leading to increased numbers offunctional Tregs once 
TLR2-Iigands are cleared. In addition, although Teff cells proliferate in the presence 
ofTLR2-stimulated Tregs, they fail to produce pro-inflammatory cytokines. The reason 
for this has to be elucidated. Before using TLR2 in anti-tumor immunotherapeutic 
approaches we need to make sure that these Teff cells are able to regain full effector 
function and have not developed into a state of anergy. 
Some studies showed the presence of heat-shock protein 60 (HSP60) in the tumor 
micro-environment. HSP60 is an endogenous danger-associated molecule, which 
is secreted by the tumors upon necrosis, apoptosis and stress [29]. Interestingly, 
HSP60was identified as an endogenous ligand forTLR2. It mightthus be hypothesized 
that Tregs receive TCR signals by self-antigens and are additionally stimulated 
by endogenous TLR2-Iigands leading to proliferation and increased Treg numbers 
at the tumor site. This process must however be tightly regulated as proliferating 
Tregs lose their function to suppress, which would favor the induction of anti-tumor 
immunity. We showed clear dose-dependent effects ofTLR2-Iigands on Treg function. 
HSP60 levels in the tumor might thus be balanced to favor proliferation of Treg 
that rapidly regain their suppressive function when HSP60 levels drop or when they 
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move away from this gradient. In all, it is hard to predict whether TLR2 stimulation 
will provide new therapeutic options for the treatment of immune-mediated disease. 
Additional studies in cancer models as well as pre-clinical models for autoimmunity 
are of great interest and should provide further insight in the complex role of TLR2 
in diverse pathological conditions. 
Treg and Crispl 
Tregs are able to suppress all different kind of immune cells like NK cells, T cells, 
DCs, and NKT cells. Multiple different suppression mechanisms have been reported 
for Tregs. Many of these are thought to act in a cell-contact dependent manner; 
others may have a soluble component and may also suppress in the local vicinity 
of the Tregs (chapter 2). New Treg suppression mechanisms are still being discovered, 
however. It will be important to learn more on the relationship between these 
different mechanisms, and during which phases of the immune response Tregs 
use one or more of these mechanism. In this thesis we discovered that expression 
of the Crisp1 gene is specific for Tregs. Interestingly, Crisp1 expression was strongly 
downregulated by TLR2 triggering, which coincided with a sharp decrease in Treg 
mediated suppression. In literature little is known about the function of Crisp1 
in general and in the immune system in particular. Many Crisp proteins are 
found within snake and lizard venoms [30-33] where their main function 
is blocking ion channels [30,34-38]. Our preliminary data have shown that Crisp1 
is capable of interfering with the Ca2+ flux in CD4+ T lymphocytes. Therefore, 
we hypothesized that Crisp1 has a role in Treg mediated immune suppression. 
Crisp1 might involve a very efficient mechanism of Treg suppression, because 
many ion channels in lymphocytes <Kc.3.1, Kv1.3 potassium channel, STIMl/Orai1) 
are located at the cell surface and/or intracellular on the ER membrane [39-41]. 
Moreover, ion signalling and/or fluxes are extremely important for lymphocyte 
activation and differentiation [41], and it is known that they occur atthe immunological 
synapse [40,41]. Taking into account that Tregs suppress in a contact-dependent 
mechanism, blocking ion fluxes byCrisp1 could bean efficient suppressive mechanism 
in the first activation of na"ive T lymphocyte when encountering the DC. Following 
TCR triggering, normally CRAC channels, like Orai1, open and Ca2+ is able to enter 
the naTve T cell. If the Treg is present at the same moment a naTve T cell encounters 
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a DC, the Treg-secreted Crisp1 could potentially block the CRAC channel (Figure 1). 
In this case the improperly activated na"ive T cell might become anergic. 
In this model, an important question is how Crisp1 affects Tregs themselves, since 
also Treg need ion channels for their function. It is interesting to note that we found 
that Crisp1 expression is very low or absent in freshly isolated na"ive Tregs, and that 
only high amounts of Crisp1 can be detected in experienced Tregs. Experienced 
Tregs might be less sensitive to Crisp1, which should be examined by studying 
Ca2+fluxes in na"ive Tregs relative to activatedTregsfollowing Crisp1exposure. Similarly, 
the influence of Crispl and Ca2+ fluxes should also be compared between na"ive 
T cells, effector memory T cells and subsets of effector T cells (Thl, Th2, Th17). 
If the proposed model holds true, this would implicate that the function of Tregs 
themselves is not restricted by Crisp, suggesting additional mechanism preventing 
or limiting detrimental Crisp-1 effects on activated Tregs. Similarly, the influence of 
Crisp1 might be different on experienced effector cells, assuming Crispl is particularly 
important for suppression of na"ive T cells. In addition more research is needed 
to investigate whether Crispl is indeed produced and secreted in considerable 
amounts by the different Treg subsets in vivo. 
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It should be considered that the experiments in this thesis are done with Tregs, 
which have been cultured in the presence of TLR2 ligand. It can be speculated that 
the culturing protocol might select specifically for the Tregs that are highly sensitive 
for TLR2 triggering. Therefore it should be studied whether the findings in this thesis 
can be extrapolated to different Treg 'subsets' or Tregs in diverse differentiation 
or activation states. 
Concluding remarks 
Tregs are important in keeping the balance between immune activation 
and immune inhibition. The focus of this thesis has been on the effectofTLR2 triggering 
on Treg function. This influence has been shown to be very versatile, and determined 
in part by the presence and strength of other signals, levels of TLR2 ligands, 
and the source of the TLR2 ligand (endogenous or exogenous, pathogenic 
or beneficial for the host}. In summary, TLR2 is a highly important factor in 
Treg function, evolution, maintenance and survival. Tregs are very special and 
serve as communicators between immune cells and environmental signals. 
They constantly receive signals (TLR ligands, cytokines, hormones, etc.} and the 
combinations of these signals and intracellular processes determine the function 
of Tregs. In the context of cancer immunotherapy, one should not solely focus 
on improving activation of anti-tumor immune response, but also on eliminating 
tumor infiltrated Tregs and/or modulating Treg function. Because of its versatile 
roles, the use of TLR2 ligands as possible therapeutical agents should be 
approached with care. It will be important to further increase our understanding 
of the mechanisms by which Tregs carry out their function. New findings and 
understandings on how Tregs work by themselves and in combination with other 
immune cells will likely improve immune therapeutic strategies for immune related 
diseases in the future. 
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Nederlandse samenvatting voor niet-ingewijden 
Het menselijk lichaam worclt voortdurend uitgedaagd om bacterien, virussen 
en schimmels te weren. Het immuun systeem is geevolueerd tot een zeer effectief 
systeem, dat de schade die deze indringers kunnen veroorzaken, tot een minimum 
reduceert. Het immuun systeem vertegenwoordigt een zeer complex systeem om 
de grate diversiteit aan pathogenen te kunnen uitschakelen. Tegelijkertijd moeten 
eigen weefsels in het lichaam getolereerd warden. Over het algemeen bepalen een 
groat aantal signalen en verschillende cellen of er een immuunreactie optreedt 
of niet. Vooral de diverse combinaties van deze signalen zijn bepalend of er tolerantie 
of een immuunreactie optreedt. 
Twee belangrijke typen cellen die een rol spelen bij het reguleren van de balans 
in het immuun systeem, zijn de 'regulerende T cellen' (Tregs) en de dendritische 
cellen (DCs). Tregs staan bekend om hun rol in het remmen van immuun reacties. 
De DCs spelen een cruciale rol in het herkennen van pathogenen, het activeren van 
het immuun systeem, en het bewaken van de immuun balans. 
Het immuun systeem 
Het immuun systeem kan onderverdeeld warden in twee onderdelen; het innate 
(aangeboren) en het adaptieve (verworven) immuun systeem. Het innate systeem 
vormt de eerste barriere tegen besmettingen, zoals de huid en de slijmlagen in 
de darmen en longen, en zorgt daarnaast voor een snelle maximale mobilisatie 
van innate immuun cellen om binnengedrongen pathogenen te herkennen en op 
te ruimen. Binnen enkele minuten of enkele uren kan de pathogeen opgeruimd zijn, 
maar deze snelle reactie is onafhankelijk van het soort pathogeen. Tot slot zorgt 
het innate immuun systeem oak voor het aantrekken van immuun cellen naar de 
plaats van infectie, en zorgt voor het activeren van het adaptieve immuun systeem. 
Het adaptieve immuun systeem wordt actief na het innate immuun systeem en zorgt 
voor het 'immuun geheugen'. Cellen die in het adaptief immuun systeem een rol 
spelen, zijn B-en T-lymfocyten, waaronder 'killer' CD8+ T-cellen en CD4+ T-helper 
cellen. Een van de belangrijkste cellen die het adaptieve immuun systeem activeert, 
is de dendritische eel. DCs kunnen gezien word en als communicatoren tussen innate 
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immuun eellen en de adaptieve immuun cell en. Ze zwerven in een inaetieve staat door 
het lichaam op zoek naar pathogenen. Wanneer een DC een pathogeen tegenkomt, 
neemt hij dit onbekende materiaal op, en breekt het pathogeen af tot kleine deeltjes 
(z.g. antigenen) en presenteert dit aan de lymfoeyten in de lymfeklieren. Zodra een 
van de eellen zijn specifieke antigeen herkent, wordt de T -eel geactiveerd tot een 
antigeen speeifieke 'killer' eel en de B-cel tot een specifieke antistof produeerende 
eel. Bij een tweede ontmoeting met hun specifieke antigeen zijn de lymfoeyten 
in staat een snellere aetivatie te laten zien. 
De stimulatie van DCs vindt niet alleen plaats door de opname van pathogenen, maar 
ook door specifieke gevaren signalen, die pathogeen geassocieerde moleeulaire 
patronen (PAMPs) genoemd warden. Deze PAMPs warden herkend door diverse 
patroon-herkennende receptoren (PRRs). Tot deze familie van reeeptoren horen 
onder andere de NOD-like receptoren (NLRs), en de Toll-like Reeeptoren (TLRs). 
De TLRs zijn de best bestudeerde PRRs. TLRs komen voor op alle versehillende 
immuun cellen, zoals macrofagen, DCs, monoeyten, B- en T -eellen, en ook op 
enkele niet-immuun eellen. Welke strueturen (ofwelliganden) herkend warden door 
de versehillende TLRs, wordt uitgelegd in het begin van hoofdstuk 2. In totaal zijn 
er 13 TLRs bekend en in dit proefschrift is vooral TLR2 van belang. TLR2 is een speciale 
receptor omdat het een paar (ofwel een dimeer) kan vormen met andere TLRs, 
namelijk met TLRl en TLR6. De versehillende dimeren herkennen ook versehillende 
liganden van pathogenen. De TLR1/TLR2 dimeer herkent vet-achtige liganden 
die in de meeste baeterien aanwezig zijn in de eelwand. Inmiddels is bekend dat 
TLRs ook liganden kunnen herkennen afkomstig van liehaamseigen eellen die vrij 
komen uit dode cellen. Deze liganden warden daarom ookwel'schade geassocieerde 
moleeulaire patronen' (DAMPs) genoemd. 
lmmuun remming/regulatie 
Immunologische tolerantie kan omsehreven warden als het proees waarbij immuun 
cellen geen immuun reactie vertonen tegen specifieke antigenen, terwijl daar normaal 
gesproken wel een reaetie getriggerd zou kunnen warden. Dendritisehe eellen 
kunnen, zoals eerder beschreven, een immuun reaetie opwekken. DCs kunnen eehter 
ook, nadat ze in aanraking komen met bepaalde signalen, een meer regulerende 
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functie krijgen. Deze tolerogene DCs hebben minder activatie receptoren en meer 
remmende receptoren. De DCs zijn ook in staat regulerende T cellen te activeren die 
op hun beurt geactiveerde CD4+ en CD8+ T cellen remmen. DCs hebben dus niet 
alleen een rol in activatie van het immuun systeem, maar hebben oak een belangrijke 
rol in het activeren van tolerantie. 
Regulerende T cellen (Tregs) zijn de belangrijkste subset van T cellen die immuun 
tolerantie bewaken, en zorgen ervoor dat het immuun systeem geen excessieve 
immuun respons veroorzaakt. Zodra een Treg eel door een specifiek antigeen 
geactiveerd wordt, onderdrukt deze de T cellen die een immuun respons 
veroorzaken. Er bestaan verschillende soorten Tregs; de van nature voorkomende 
Tregs (nTregs) en de ge"induceerde Tregs (iTregs). Dit onderzoek heeft zich vooral 
gericht op de nTregs. nTregs ontwikkelen oak in de thymus, net als de and ere T cell en. 
Van de gehele populatie CD4+ T cellen is ongeveer 5-15% nTreg. nTregs kunnen 
herkend warden door de expressie van FoxP3 (gen-transcriptie factor), CTLA4, 
TGF~, CD25, etc. Alle kenmerken zijn genoemd in figuur 3 van hoofdstuk 1. 
Een Treg kan op verschillende manieren een immuun respons remmen. Ze kunnen 
direct stimulaties geven via receptoren op hun oppervlak, of indirect door activatie 
signalen weg te vangen of zelf remmende factoren uit te scheiden. Deze soorten 
en mechanismen van remming warden besproken in hoofdstuk 2. 
Het immuun systeem in gezondheid en ziekte 
Wanneer op het verkeerde moment tolerantie of een immuun activatie optreedt, 
zal dat resulteren in een pathologische conditie. Dit kan bijvoorbeeld optreden 
bij transplantaties, waar het immuun systeem ontstekingen veroorzaakt, 
die uiteindelijk zorgen voor afstoting van het getransplanteerde orgaan. 
Bij tuberculose bijvoorbeeld kan geconstateerd warden dat er hogere hoeveelheden 
Tregs bij de besmettingshaard aanwezig zijn. Deze Tregs voorkomen dat 
de tuberculose bacterie opgeruimd wordt. Het is van belang te begrijpen hoe het 
immuun systeem tolerantie reguleert, en hoe dit te be"invloeden is. 
Bij tumoren faalt het immuun systeem om succesvol een immuun response 
op te wekken die de tumor opruimt. Normaal gesproken presenteren tumor cellen 
antigenen die als lichaamsvreemd gezien warden, waardoor een immuun respons 
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opgewekt wordt. Toch lukt het de tumoren te ontsnappen aan het immuun systeem. 
Recente studies wijzen richting Tregs als belangrijke factoren die tumor tolerantie 
veroorzaken. Enkele studies tonen aan dat het verminderen van de hoeveelheid 
Tregs in de omgeving van een tumor ervoor zorgt dat de tumor in grootte afneemt. 
De hoeveelheid Tregs aanwezig in een tumor kan tegenwoordig een prognose zijn 
voor de overlevingskans van patienten voor sommige tumoren. Maar uiteindelijk 
zijn Tregs wel belangrijk om de immuun reactie te stoppen, om te voorkomen 
dat goede weefsels aangetast warden. 
Dit proefschrift 
Het verbreden van de kennis over hoe Tregs te beTnvloeden zijn zal ervoor zorgen 
dat er betere immuno-therapieen ontwikkeld kunnen warden. Het onderzoek 
dat in dit proefschrift beschreven wordt, is uitgevoerd om meer inzicht te krijgen 
in de effecten die verschillende stimulaties hebben op de balans tussen immuun 
activatie en immuun remming. Hierbij wordt gefocust op Treg cell en en TLR signalen 
in verschillende immunologische condities. 
In hoofdstuk 2 hebben we een samenvatting gegeven van water al bekend is hoe 
TLR signalen het functioneren van Tregs kunnen beTnvloeden. Oak is onderzocht 
welke rol Tregs hebben bij kanker. 
In hoofdstuk 3 analyseren we de invloed die de locatie van een tumor antigeen heeft 
binnen tumor cellen. De balans tussen immuun activatie en remming is vergeleken 
met de hoeveelheid en de maturatie van DCs, effector T cellen, en regulerende 
T cellen. Tumor Tregs kunnen de functie van CDS killer T cellen remmen, waardoor 
de tumor cellen niet warden opgeruimd. De balans tussen Tregs en CD8+ T cellen 
in de tumor is dus erg van belang. In dit hoofdstuk laten we zien dat de locatie van 
het tumor antigeen de balans tussen Tregs en COS+ T eel kan beTnvloeden. 
In de rest van dit proefschrift richten we ens op de effecten die TLR2 stimulatie 
kan hebben op de balans tussen immuun activatie en remming in het algemeen, 
en specifiek op Tregs. Daar gebruiken we niet alleen synthetische TLR2 liganden 
voor maar oak TLR2 liganden afkomstig van Gram-positieve bacterien en andere 
TLR2 bevattende bacterien waaronder ziekte-verwekkende bacterien en probiotica. 
Met probiotica wordt tegenwoordig bedoeld: "Levende micro-organismen die, 
na toediening van de optimale hoeveelheid, een voordelig effect kunnen hebben 
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op de gezondheid van de gastheer". Hoewel deze definitie suggereert dat ze een 
voordelig effect hebben, is dit nog niet officieel bewezen. In hoofdstuk 4 wordt 
gekeken welke typen T eel reacties optreden bij verschillende probiotica, specifiek 
de Bifidobacterium Breve en Lactobaccilus. Beide stammen induceren immuun eel 
activerende stoffen (cytokinen), waarbij de Bifido Breve vele lagere levels induceert 
dan de Lactobaccilus. Interessant is dat wanneer TLR2 specifiek geblokkeerd wordt 
bij Bifida Breve, de productie levels van deze cytokinen hoger warden. Dit betekent 
dat TLR2 stimulatie specifiek door Bifido Breve op de DCs zorgt voor een remming 
van immuun activerende signalen. 
Hoofdstuk 5 focust op het belang dat TLR2 stimulatie heeft op het functioneren van 
Treg cellen. De data toont aan dat de TLR2 door veel immuun cellen gepresenteerd 
wordt, en dat TLR2 liganden niet alleen Treg cellen be"lnvloeden, maar oak CD4 
T cellen en dendritische cellen. TLR2 stimulatie van CD4 T cellen en DCs zorgt ervoor 
dat ze minder gevoelig zijn voor de remmende functie van Tregs. Daarnaast zorgt 
TLR2 stimulatie van Tregs ervoor dat zij tijdelijk hun remmende functie verliezen. 
Het verlies van remming is specifiek voor de deling van de CD4 T cellen en geldt 
niet voor de remming op de productie van immuun activerende cytokinen. Verder 
laten we dit effect niet alleen zien voor het synthetische TLR2 ligand, maar ook voor 
het natuurlijke TLR2 ligand afkomstig van Legionella pneumophila. 
In hoofdstuk 6 gaan we de invloed van TLR2 op de Treg verder onderzoeken. 
In dit hoofdstuk wordt beschreven welk effect TLR2 stimulatie heeft op het 
genexpressie profiel van CD4 T cell en en Treg cellen. Duidelijk is dat er verschillende 
groepen genen warden aan en/of uit gezet in de Tregs in vergelijking tot de CD4 
T cellen. Dit hoofdstuk beschrijft oak de specifieke expressie van het CRISPl 
gen in Tregs, wat nog nooit eerder is beschreven. De expressie van CRISPl in 
Tregs lijkt overeen te komen met de remmende functie van de Treg. Als de Treg 
zijn remming verliest, is oak de expressie van CRISPllaag. Voorlopige experimenten 
laten zien dat CRISPl inderdaad een mogelijk functie kan hebben in de Treg als een 
nieuw ge"identificeerd mechanisme van remming. 
Tot slot warden in hoofdstuk 7 de resultaten uit dit proefschrift nog een keer 
samengevat en bediscussieerd. 
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